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Abstract 
 
This research examined the ability of virus-like particles (VLP) assembled from the coat proteins of 
Murine polyomavirus (MPyV) to carry cytotoxic T cell (Tc) epitopes. MPyV VLPs can be assembled 
in vitro from purified subunits composed of pentamers of the major coat protein VP1 called 
capsomeres; and this approach provides fine control over VLP composition and structure. Tc-epitopes 
are often highly hydrophobic, which poses a significant bioengineering challenge and two distinct 
approaches were pursued to determine the optimal delivery strategy of Influenza Tc-epitopes by 
MPyV VLP. Firstly, identified epitopes were externally presented using established sites for peptide 
insertion on the MPyV major coat protein, VP1. Secondly, polypeptides possessing multiple epitopes 
were encapsidated within VP1 VLP using precise elements of the minor coat protein VP2/3 that 
interact with the interior cavity of capsomeres. Hydrophobicity-related capsomere aggregation arising 
from single Tc epitope presentation was successfully circumvented by engineering charged amino 
acids (DD) flanking the epitope displayed on a surface-exposed loop of VP1 and by use of an 
optimised buffer condition. A multiparametric, high-throughput buffer screen was implemented to 
optimise pH and buffer additives during affinity tag removal. Stable modified capsomere recovered 
from this reaction were assembly competent in the presence of L-Arginine, and VLP yield was high 
when modular capsomeres were co-assembled with unmodified VP1 capsomeres forming stable 
mosaic VLPs. The ability of the MPyV VLP to encapsidate foreign protein was first evaluated and 
optimised with green fluorescent protein (GFP) as a model protein to enable monitoring and analysis. 
A minimal VP1-interacting sequence was defined from the carboxy-terminus of VP2/3 (VP2C) and 
fused to the amino-terminus of GFP, ensuring internalisation of the reporter protein. VP1:VP2C-GFP 
capsomere complexes were successfully recovered when VP1 was co-expressed with VP2C-GFP, 
whereas complex formation was not observed when VP1 and VP2C-GFP were mixed in vitro. 
Recovered capsomere complexes were assembly competent and amount of encapsidated GFP was 
controllable when VP1:VP2C-GFP capsomere complexes were co-assembled with unmodified VP1 
capsomeres in a defined molar ratio. The encapsidation approach was then applied to a subdomain of 
the Influenza matrix protein M1 by co-expressing VP1 with VP2C-M1-I. M1-I capsomere complexes 
were assembly competent as indicated by gel electrophoresis, dynamic light scattering, and 
transmission electron microscopy. To enable recovery of VLPs for analysis and characterisation as 
well as to confirm encapsidation and the formation of mosaic VLPs, a semi-preparative size exclusion 
chromatography method was developed. This research was able to address bioengineering challenges 
posed by hydrophobic epitope presentation and developed MPyV VLPs into effective carriers of 
hydrophobic peptides such as influenza Tc-epitopes which may have use as a broadly protective 
influenza vaccine.
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1 Project Overview 
 
The prevention of an influenza pandemic still faces many challenges (WHO 2011). Firstly, 
conventional antibody based influenza vaccines have to be updated frequently to match mutating 
influenza strains (Subbarao and Joseph 2007). Secondly, conventional influenza vaccines can only 
become available approximately six months after identification of the pandemic strain, while global 
spread can occur within two months (Broadbent and Subbarao 2011; WHO 2011), as observed in 
recent 2009 H1N1 pandemic (Figure 1.1). Thirdly, current vaccine production capacity can only 
cover doses for 12.8% of the global population (Broadbent and Subbarao 2011; PRB 2009). And last, 
but not least, vaccine production is still costly and requires technology transfer for developing 
countries  where pandemic strains are more likely to emerge (Fedson 2009; Pagliusi et al. 2013a; 
Pagliusi et al. 2013b). 
Influenza outbreaks can either be epidemic or pandemic. Epidemic influenza is seasonal, occurring 
during winter in temperate regions. While the majority of normal people can recover from it, it still 
poses a major health risk to the very young, the elderly, and the chronically ill. Epidemic influenza is 
estimated to cause 250 000 – 500 000 deaths per year (WHO 2009a). Pandemic influenza is caused 
by sometimes highly lethal, but mainly highly transmissible strain that can accelerate the global 
spread of the virus globally within a short time. A pandemic strain usually arises from zoonotic strains 
that jump into the human host by genetic drift, genetic shift, and genetic reassortment (Herfst et al. 
2014; Sriwilaijaroen and Suzuki 2014). As these strains are not usually circulating in humans, 
immunity against these strains is generally weak, which results in accelerated spread and higher 
pathogenicity of the virus (McAuley et al. 2015). The estimated death toll of the recent H1N1 strain 
of swine-origin influenza virus (H1N1-SOIV) 2009 pandemic is estimated to be nearly 300 000 
during the first year of virus circulation (Dawood et al. 2012). 
Current influenza vaccines are mostly made of whole-virus inactivated vaccines grown in 
embryonated chicken eggs (Lambert and Fauci 2010). Production of this type of vaccine is limited 
by chicken egg availability, and this becomes a major limiting factor in pandemics by strains 
originating from chicken (Milian and Kamen 2015; Singh et al. 2010). A further advancement of 
currently licensed influenza vaccine includes live-attenuated influenza vaccines also grown in eggs 
(Jin and Subbarao 2015), insect cell derived subunit vaccines  (FDA 2013), and cell derived 
inactivated vaccines (Dormitzer 2015; Kistner et al. 1998). The latter two do not rely on chicken  
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Figure 1.1. Lessons from recent 2009 H1N1 pandemic. Pandemic influenza was declared by the 
WHO two months after the first H1N1 case, but vaccination only started six months later when most 
countries globally have been affected and cases have risen to almost half a million. Based on WHO 
2009 Influenza Pandemic data (WHO 2009b). 
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egg production and may reduce production time (Vlecken et al. 2013). However, production cost is 
high due to employment of cell cultures with strict biosafety requirements (Pattenden et al. 2005; 
Perdue et al. 2011). Administered influenza vaccines usually contain antigens from two influenza A 
strains and one influenza B strain matching identified circulating strains in the environment (Lambert 
and Fauci 2010). Recently a quadrivalent vaccine consisting of an additional influenza B strain has 
been available in the market (Gorse et al. 2015; Pepin et al. 2013). As influenza virus mutates 
frequently, strain identification has to be done periodically to update the vaccines for each season. 
However, traditional vaccine production takes 4 to 6 months to complete and might not match the 
newly mutated circulating strain (Milian and Kamen 2015; Soema et al. 2015). 
In order to improve influenza pandemic and epidemic preparedness, as well as to reduce economic 
burden, new strategies have to be developed. A broadly cross-protective influenza vaccine could 
reduce updating frequency or provide some level of protection to slow initial stages of a pandemic 
(Brown and Kelso 2009). This may be achieved by targeting the more conserved internal proteins to 
stimulate cellular immunity (Houser and Subbarao 2015; Milian and Kamen 2015; Soema et al. 
2015), by delivering conserved Tc-epitopes into dendritic cells to be presented via the Major 
Histocompatibility Complex (MHC) Class I pathway (Brown and Kelso 2009; Sette et al. 2002; 
Woolard and Kumaraguru 2010). A versatile delivery system capable of performing this function 
needs to be developed while maintaining short production time, low production cost, as well as high 
production capacity.  
My research project used MPyV viral coat proteins VP1 and VP2 to deliver identified conserved 
influenza Tc-epitopes. Delivery of these epitopes was done by either external modular insertion onto 
surface-exposed loop, or internal encapsidation of M1 protein containing these epitopes. The aim is 
to develop a MPyV-based vaccine to stimulate cellular immunity against influenza. This type of 
vaccine would be broadly cross-protective, and potentially be used as prepandemic vaccine before 
antibody based conventional vaccine technology becomes available. Utilizing the MPyV VP1 
delivery platform is advantageous because the proteins can be grown in Escherichia coli which will 
reduce production cost, shorten production time, and optimise yield. This may, in turn, increase 
affordability in developing countries where pandemic strains are more likely to emerge, accelerate 
preventive response against seasonal and pandemic influenza outbreaks, and augment vaccine 
accessibility and coverage for the global population. If the delivery of Tc-epitopes with MPyV coat 
proteins to stimulate cellular immunity in influenza model is successful, it will open up the possibility 
to examine Tc-epitope delivery with this platform in other disease models that require cellular 
immunity for protection or therapy, such as human immunodeficiency virus (HIV) and cancer. 
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1.1 Influenza Tc-epitope-based vaccines  
A Tc-epitope-based vaccines usually consist of 8 to 10-mer peptides with sequence identical to 
known, conserved Tc-epitopes of a pathogen, conferring cross-reactive cellular immunity against, for 
example, different influenza strains (Brown and Kelso 2009). In cellular immunity, Tc are stimulated 
to kill cells infected with  a pathogen via Tc-epitope presentation. Tc recognize infected cells by the 
presentation of 8-10 mer pathogenic peptide (Tc-epitope) by the infected cells via the MHC Class I 
presentation pathway. These Tc can only recognize the pathogenic antigen if they have been primed 
before with the epitope via dendritic cells in peripheral lymphoid organs (Murphy et al. 2008). A Tc-
epitope-based vaccine aims to prime naïve Tc with the target pathogenic antigen artificially before 
the host encounters the real disease-causing pathogen (Woolard and Kumaraguru 2010). This 
mechanism and activity is explained in more detail in Section 2.3.2. Even though Tc-epitope-based 
vaccine cannot prevent infection due to a prerequisite of pathogen entry into the cell, this type of 
vaccine can reduce the severity of the disease and prevent further spread of the pathogen in the host  
(Brown and Kelso 2009). Moreover, Tc-epitope presentation via the MHC Class I and MHC Class II 
pathways allows targeting of conserved internal proteins of influenza virus, and thus may provide 
broad protection against heterologous strains,  possibly reducing vaccine updating frequency (Milian 
and Kamen 2015; Soema et al. 2015). Thus, it could be used as prepandemic vaccine before 
conventional vaccine specific to the pandemic strain becomes available (Woolard and Kumaraguru 
2010), or between influenza seasons by boosting pre-existing T cell immunity (Gilbert 2012). 
A number of bioinformatic studies have identified conserved Tc-epitopes derived from past pandemic 
and seasonal strains. Some of these have further been shown to be positive  Human Leukocyte 
Antigen (HLA, human MHC) binders and elicit Tc immune responses (Alexander et al. 2010; 
Assarsson et al. 2008; Bui et al. 2007; Heiny et al. 2007; Parida et al. 2007; Somvanshi et al. 2008; 
Tan et al. 2010; Wang et al. 2007; Wang et al. 2010a). The Tc-epitope commonly used to test a 
vaccine candidate is the matrix 1 (M1) protein M158-66 epitope (Table 1.1). This epitope is conserved 
and is a high HLA*0201 binder (Abidin 2010). The M1 protein consists of a soluble N-terminal 
domain (1-164 aa) and a C-terminal domain (165-252 aa) linked by a proteolytic loop (Zhang et al. 
2012). The N-terminal domain consists of two 4-helix bundles, which in this research are termed M1-
I (2-67 aa), and M1-II (1-164). M1-II consists of M1-I in addition to the rest of the downstream amino 
acids of the N-terminal domain. Beside M158-66 epitope (further termed IT1 in this thesis), other 
epitopes covering a number of HLAs (Alexander et al. 2010; Assarsson et al. 2008; Babon et al. 2009; 
Lee et al. 2008; Liu et al. 2013; Tan et al. 2010; Wang et al. 2007) have been identified in the M1 N-
terminal domain as depicted on Figure 1.2.  
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Table 1.1 Current developments in influenza Tc-epitope delivery system. 
Delivery system Antigen type Antigen 
source 
Expression system Development 
Phase 
Large-scale 
platform 
Reference 
Lipopeptide Peptides M1, PA, NS1 Peptide synthesis Proof of concept None (Day et al. 2007; Deliyannis et 
al. 2006; Tan et al. 2013) 
Liposomes Peptides PA, PB1, PB2, 
M2, M1 
Peptide synthesis Proof of concept None (Ichihashi et al. 2011; Matsui et 
al. 2010) 
Virosomes Peptide NP Peptide synthesis Proof of concept None (Arkema et al. 2000) 
Subunit protein        
     Flagellin Recombinant 
peptide 
HA, NP, M1 Salmonella Proof of concept Developing (Adar et al. 2009) 
VLP       
     PapMV Recombinant 
peptide 
M1 E.coli Proof of concept None (Babin et al. 2013) 
     AdDd Recombinant 
peptide 
M1 Insect cells Proof of concept Developing (Szurgot et al. 2013) 
     HbsAg Recombinant 
peptide 
M1 HEK cells Proof of concept Developed (Cheong et al. 2009) 
     SV40 Recombinant 
peptide 
M1 Insect cells Proof of concept Developing (Kawano et al. 2014) 
Viral vector       
     MVA Peptide or subunit 
protein 
M1, NP CEF cells Clinical trial Developed (Berthoud et al. 2011) 
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Figure 1.2 M1 protein soluble domain and epitope distribution. 3D structure of influenza M1 
soluble domain (PDB 1EA3SID) (A). In this thesis they are used in two forms, which are the M1-I 
subdomain (light blue) and the M1-II subdomain. M1-II consists of M1-I and additional M1-II 
domain (dark blue) downstream (Zhang et al. 2012). Distribution of identified Tc-epitopes based on 
IEDB database (www.iedb.org) along the soluble domain is depicted with epitopes shown as black 
and green lines (B). IT1 and IT2 epitopes are used for research in Chapter 3, and the M1 soluble 
domain for research in Chapter 5. 
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A number of delivery systems have been developed to deliver Tc-epitopes, either as a peptide or as a 
protein subunit to stimulate cellular immunity against heterologous strains (Table 1.1). Lipopetides 
(Day et al. 2007; Deliyannis et al. 2006; Tan et al. 2013), liposomes (Matsui et al. 2010; Uchida 
2011), and virosomes (Arkema et al. 2000; Moser et al. 2011)  are amongst the systems that deliver 
Tc-epitope in the form of synthetic peptides, and have shown immunogenicity as a proof of concept. 
Although peptide synthesis is scalable (Bray 2003), the necessary coupling with delivery platform 
post-synthesis complicates the production and may add to production cost (Soema et al. 2015)  
Another strategy is genetically inserting these peptide sequences into a recombinant carrier protein 
such as capsid proteins in the form of virus-like particles (VLP), or subunit proteins such as flagellin. 
A VLP is generally an assembly of viral coat proteins, which may be partially embedded within cell-
derived membranes in the case of VLPs derived from enveloped viruses, taking the shape of the virus 
but lacking all other viral components such as DNAs and RNAs (Lua et al. 2014). The VLPs that 
have been tested with inserted influenza Tc-epitopes for immunogenicity include VLPs of Papaya 
Mosaic Virus (PapMV) (Babin et al. 2013; Denis et al. 2008), adenoviral dodecahedron (AdDd) 
(Coughlan et al. 2015; Lambe et al. 2013; Szurgot et al. 2013), Hepatitis B surface antingen (HbsAg) 
(Cheong et al. 2009), and Simian Virus 40 (SV40) (Kawano et al. 2014) (Table 1.1). They all have 
shown some degree of immunogenicity and were broadly-crossprotective.  
Of these, HbsAg has a well-established scale-up platform in different hosts (Hardy et al. 2000; James 
et al. 2007; Shah et al. 2015; Valenzuela et al. 1982), while large scale platforms for AdDd in insect 
cells (Szurgot et al. 2015), and SV40 in insect cells (Kosukegawa et al. 1996) are still in development. 
The use of flagellin as a carrier protein has also shown some degree of protection (Adar et al. 2009), 
and large scale production is also in development (Mardanova et al. 2015; Simon et al. 2014). The 
use of cultured eukaryotic cells as host for expression however, may increase production cost of these 
candidate vaccines. 
A Tc-epitope delivery platform to induce broadly-crossprotective immunity against influenza that has 
reached clinical trial phase to date is the modified Vaccinia Ankara (MVA) based vaccine (Krammer 
and Palese 2015). Using an HIV model protein subunit fusion has shown to give better protection in 
comparison to multiple Tc-epitope presentation on the MVA platform (Gasteiger et al. 2007). 
Influenza M1 and NP subunit proteins have been inserted into the MVA viral protein and the resulting 
vaccine candidate was shown to be immunogenic (Berthoud et al. 2011) and elicit T cell specific 
response (Powell et al. 2013). Clinical trials have shown that the vaccine worked in the elderly 
(Antrobus et al. 2012), and gave better protection if combined as prime-boost with DNA vaccines 
(Degano et al. 1999), or co-administered with conventional seasonal vaccines (Antrobus et al. 2014). 
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A large scale production platform in chicken embryo fibroblast (CFE) cells has also been established, 
with an estimated production capacity of 60 million doses a year (Rimmelzwaan and Sutter 2009). 
However, MVA is a replicating attenuated live virus, which still poses some health risk. The use of 
mammalian cells as expression host means production cost is high, and even though production 
capacity is relatively high, it is still not enough to provide global supply especially during a pandemic.  
 
1.2 Murine polyoma viral coat proteins as a vaccine delivery system 
As described above, the development of next generation vaccines does not only have to take into 
account the immunogenicity of vaccine candidates, but also aspects of production such as technology, 
cost, and time.  
Virus-like particles are generally derived from the coat proteins of a virus, which self-assemble into 
a spherical structure mimicking the original virus (hence its name) yet lacking DNA or RNA, 
rendering them non-infectious (Rodriguez-Limas et al. 2013). They have been developed for various 
uses such as antigen carriers (Babin et al. 2013; Kawano et al. 2014; Wibowo et al. 2012) or as carriers 
of other cargos such as drugs (Glasgow and Tullman-Ercek 2014), proteins (Abbing et al. 2004), and 
both oligonucleotides and plasmid DNA (Braun et al. 1999). Depending on the VLP, they can be 
produced in different hosts such as mammalian cells, insect cells, plants, yeasts, and bacteria (Kushnir 
et al. 2012). 
The MPyV capsid consists of three structural proteins, which are VP1, VP2, and VP3. The VP1 
subunit forms a pentamer known as a capsomere, and 72 of these capsomeres form an icosahedral 
VLP (Schmidt et al. 2000). The VP1 subunit alone is sufficient to form a spherical VLP (Salunke et 
al. 1986), and several surface-exposed loops of VP1 have been identified as suitable for foreign 
sequence insertion (Gedvilaite et al. 2000). However, as has been demonstrated before in Hepatitis B 
core antigen (HbcAg) particles, insertion of a foreign sequence in these loops may influence capsid 
protein stability, therefore, their ability to assemble into VLPs. . Depending on the nature of the 
inserted foreign sequence, they could either maintain the stability of VLP subunits and their assembly 
competency (Billaud et al. 2005), or destabilize them rendering them assembly incompetent 
(Jegerlehner et al. 2002), or prone to severe aggregation (Tekewe et al. 2015). More details are 
explained in Section 2.2.3. 
VP2 and VP3, though not essential for VLP formation, have been shown to enable encapsidation of 
fusion proteins inside the VLP (Abbing et al. 2004; Boura et al. 2005). The C-terminus of the 
VP2/VP3 protein interacts with capsomeric VP1 to encapsidate protein fused to this domain. Fusion 
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proteins, when delivered by MPyV VLPs, have been shown to enter dendritic cells and to be presented 
by the cellular antigen presentation system (Boura et al. 2005). More details are explained in Section 
2.2.3.2. 
At the Center for Biomolecular Engineering (CBE) of the Australian Institute for Bioengineering and 
Nanotechonology (AIBN), a VLP platform consisting of MPyV VP1 subunits has been developed to 
deliver modular antigens to elicit a humoral immune response (Middelberg et al. 2011) (Figure 1.3). 
The VP1 subunit, derived from MPyV (Middelberg et al. 2011; Wibowo et al. 2013) forms 
capsomeres in vivo, inside the E.coli expression host cells. The purified capsomeres may then be 
directed to self-assemble under defined conditions into VLPs and either platform (capsomeres and 
VLPs) may be used to develop vaccine designs (Chuan et al. 2010). Multiple matrix 2 ectodomain 
(M2e) epitopes have been inserted to the VP1 protein to improve immunogenicity, and adjuvanted 
capsomeres presenting the  M2e epitopes at the external loop of the protein were able to stimulate 
humoral immunity in mice (Wibowo et al. 2013) . The helical subunit helix 190 (H190) from 
influenza protein hemagglutinin has also been presented on MPyV VP1 and assembled VLPs were 
able to elicit a strong antibody response dependent on the epitope design (Anggraeni et al. 2013).  
Both capsomere production in E. coli cells with a 4.38 g/L volumetric yield   and in vitro assembly 
of modular capsomeres into VLP have been shown to be scalable (Liew et al. 2010; Liew et al. 2012a). 
Process simulation has estimated production cost to be less than 1 cent (USD) per dose  if capsomeres 
and VLPs were grown in 500 L and 1500 L fed-batch cultures, respectively (Chuan et al. 2014). An 
estimation of 320 million doses of vaccine (at 50 µg per dose) can be produced with 10 kL batch in 
2.3 days or 4.7 days for capsomeres or VLPs, respectively (Chuan et al. 2014). Robustness in 
production and humoral immunogenicity of modular MPyV capsomeres renders the platform 
attractive to further develop into a broadly-crossprotective influenza vaccine for cellular immunity. 
The potential of the MPyV VLP platform to deliver Tc-epitopes and stimulate cellular immunity 
against influenza has not been tested. Virus-like particles are a versatile delivery system for Tc-
epitopes because they can enter dendritic cells and present antigen via the MHC Class I and MHC 
Class II pathways (Boura et al. 2005; Eriksson et al. 2011); they can act as adjuvants by presenting 
pathogen-associated molecular patterns (PAMP) (Raghunandan 2011) and thus may initiate 
costimulatory signal required for Tc expansion (Murphy et al. 2008); and they do not contain nucleic 
acid, thus minimizing the risk of contamination with infectious particles (Josefsberg and Buckland 
2012). It would be useful to explore the potential of the MPyV VLP platform to deliver Tc-epitopes 
and stimulate broadly cross-protective cellular immunity against influenza. If this approach is  
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Figure 1.3 The MPyV vaccine delivery platform. The MPyV vaccine delivery platform utilizes 
either the VLP (3D structure from VIPERdb) (a) or the pentameric capsomere (PDB 1SID) (b) form 
to present epitopes genetically inserted into the surface-exposed loop of the VP1 subunit. Homology 
model created by the SWISS model portal (www.swissmodel.expasy.org/ workspace), inserted 
epitope in red (c). 
 
 
 
 
 
 
 
 
 
a b c
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successful, it will aid in better prevention and management of epidemic and pandemic influenza 
complementary to antibody based vaccine 
 
1.3 Research Aim and Objectives 
The aim of my research in this thesis is to explore the potential of the MPyV VLP system to deliver 
identified influenza Tc-epitopes both externally on surface-exposed loop, and internally by 
encapsidation. To achieve this aim, the research is guided by the following research objectives: 
1) To evaluate the ability of MPyV VLP platform to carry identified influenza Tc-epitope via 
external presentation; 
2) To develop and optimise encapsidation of foreign protein using the prokaryotic production of 
the in vitro assembled MPyV VLP platform; 
3) To demonstrate the assembly of MPyV VLPs presenting external and internal influenza Tc-
epitopes, and to analyse and characterise developed VLP vaccines. 
These research objectives are supported by rationale explained in the following sections. 
1.3.1 Cytotoxic T cell epitope delivery by external presentation 
Tc-epitopes can be delivered either as a single epitope, a string of multiple epitopes, or as a subunit 
protein (Rimmelzwaan and Sutter 2009; Sette et al. 2002). There are two delivery strategies that can 
be approached with the MPyV VLP platform, which are either delivering these epitopes as an 
insertion at the surface-exposed loop of VP1 subunit, or encapsidating the epitopes inside the VLP 
by fusion with VP2/VP3 C-terminus.  
Surface-exposed loop insertion of B cell epitopes has been established and has been commonly used 
at the CBE (Middelberg et al. 2011) (Figure 1.2). Insertion sites identified in Hamster polyoma virus 
(HPyV) (Gedvilaite et al. 2000) have been adapted to the MPyV capsomere platform by insertion of 
B cell epitopes, which in turn have shown immunogenicity when tested in influenza models 
(Anggraeni 2014; Wibowo et al. 2013). Insertion of Tc-epitopes in this platform has not been tested. 
Further use of this loop to insert Tc-epitopes could be practical because loop insertion has been shown 
to be amenable to modification without VP1 structure disruption, so that capsomeres could be formed 
and VLPs could be assembled. 
A number of epitopes have been identified immuno-informatically and are accessible in the literature 
as well as on online databases. However, Tc-epitopes are usually hydrophobic (Mitic et al. 2014) and 
this poses some challenge as their exposure to the surface of the protein may lead to aggregation due 
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to hydrophobic protein-protein interactions (Chong and Ham 2014b; Cromwell et al. 2006), which in 
turn may interfere with the assembly competency of VLP subunits displaying them.  As insertion of 
hydrophobic entities into the existing surface-exposed loop had not been tested before, the extent to 
which aggregation would occur due to hydrophobicity was not known. Moreover, hydrophobicity-
related aggregation would depend on individual physico-chemical characteristics of each inserted Tc-
epitope. 
The possibility of aggregation has to be resolved accordingly, both by rational protein design and 
engineering, as well as providing conditions that enable recovery of soluble and assembly competent 
capsomeres. Rather than simply inserting an unmodified Tc-epitope on the surface-exposed loop, the 
inserted epitope may be modified by adding charged amino acid to reduce hydrophobicity (Perchiacca 
et al. 2012). The use of a linker sequence which have been shown to aid proteasomal degradation 
may also be applied (Livingston et al. 2001). Lastly, the assembly of mosaic particles may overcome 
hydrophobicity-related capsomere aggregation during VLP assembly (Brown et al. 2009). 
1.3.2 Optimization of fusion protein encapsidation within MPyV VLP 
Even though the literature provides evidence of successful encapsidation of proteins such as green 
fluorescent protein (GFP) when fused with VP2/VP3 (Abbing et al. 2004; Boura et al. 2005), there 
has been to my knowledge no report to apply this to deliver subunit proteins of pathogens to elicit 
cellular immunity. In addition, there has only been one report that utilizes in vitro assembly for GFP 
and methotrexate (Abbing et al. 2004), and the approach they took does not ensure encapsidation of 
the fusion protein. More details in Section 2.2.3.2. 
Epitope delivery by encapsidation may be done by fusing either a single epitope, a string of multiple 
epitopes, and a subunit protein with the VP2/VP3 protein. Encapsidation of subunit protein may be 
preferable due to several reasons. Firstly, information on the behaviour and solubility of subunit 
proteins of influenza are available in the literature, while the behaviour of a newly tested string of 
multiple epitopes is unpredictable depending on the physico-chemical properties of the peptide and 
may interfere with the engineering of the VLP. Secondly, a subunit protein contains multiple epitopes 
of different HLAs and thus enables the vaccine to cover a more diverse human population. 
The engineering of VP1-VP2/3 protein interaction to encapsidate fused protein is not well explored 
yet, and thus application to the existing MPyV VLP platform as well as troubleshooting should be 
carried out with a model protein such as GFP to facilitate monitoring and analysis.  
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1.3.3 Characterisation and analysis of MPyV VLP based influenza 
vaccines via external and internal presentation 
Hydrophobic epitopes presented on surface-exposed loop of capsomeres may interfere with efficient 
VLP assembly due to aggregation. This may be resolved by mixing the modular VP1 with wild type 
(wt)VP1 in a pre-determined ratio to form a mosaic VLP vaccine. This is aimed to reduce global 
surface hydrophobicity and enable more efficient VLP formation under optimised buffer conditions. 
Foreign protein encapsidation optimised with the existing MPyV VLP platform using the model 
protein GFP to be applied to the encapsidation of influenza subunit protein containing identified Tc-
epitopes. Encapsidated influenza protein is expected to still be able to stimulate cellular immunity as 
this kind of immunity does not depend on external presentation and conformation (Murphy et al. 
2008). 
The vaccine particles developed should be analysed and characterised. Also isolation of the particles 
from other components such as aggregates and capsomeres may be needed. A preparative size 
exclusion chromatography (SEC) purification method could be used to address both of these needs. 
At the time this research was conducted, such a method had not been reported elsewhere.  
 
1.4 Thesis organisation 
In addition to this introductory chapter, this PhD thesis consists of 5 other chapters. 
Chapter 2 provides a literature review of key topics in this research. It includes a review of the MPyV 
VLP vaccine technology and the basis of further development; a review on how the cellular immunity 
works; and a review about the fundamentals of size exclusion chromatography. 
Chapter 3 highlights limitations posed by external Tc-epitope presentation in harvesting soluble 
capsomeres and high-throughput buffer screen to resolve this problem. 
Chapter 4 investigates ways to encapsidate foreign antigen inside the VLP by application to and 
optimisation within the already established MPyV VLP platform.  
Chapter 5 explores the assembly of Tc-epitope-based MPyV VLP influenza vaccines, employing 
both external and internal presentation; and assesses methods to enable their analysis and 
characterisation. 
Chapter 6 summarises the findings of all the work above and suggests possible future research.
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2 Literature Review 
 
2.1 Overview 
This chapter will provide basic concept and extended knowledge on topics pertinent to the scope of 
my research. It contains three main sections. In the first main section (Section 2.2), the development 
of murine polyomavirus-like particles (MPyV VLP) as vaccine delivery technology will be explained. 
In the second main section (Section 2.3), the topics pertinent to the specific development of the 
platform into Tc-epitope-based influenza vaccine will be described. In the third main section (Section 
2.4), the principles and evaluation of SEC will be briefly explained. 
 
2.2 The murine polyomavirus-like particle vaccine delivery technology 
A VLP is generally an assembly of coat proteins, forming the capsid while maintaining protein shape 
and structure of the virus. It has an empty hollow, and does not contain other viral components such 
as pathogenic proteins and genetic materials, and is thus non-pathogenic and non-infectious (Lua et 
al. 2014; Rodriguez-Limas et al. 2013; Teunissen et al. 2013). VLPs can either be enveloped or non-
enveloped. The envelope consists of a lipid bilayer with protruding glycoproteins outside the viral 
coat proteins (Kushnir et al. 2012). 
The existence of naturally occurring VLPs was first reported in 1965 (Blumberg et al. 1965) and their 
ability to induce cellular and humoral immunity was subsequently elucidated in 1968 (Bayer et al. 
1968). The advancement in genetic engineering further allowed the expression and purification of 
synthetic VLPs (Hagensee et al. 1993; Kirnbauer et al. 1992; Li et al. 1997), which enabled further 
characterisation and enhanced our understanding of their assembly (Li et al. 1997; Salunke et al. 
1986). Over the course of more than four decades, 110 VLPs from 75 different viral families have 
been constructed and evaluated (Yan et al. 2015; Zeltins 2013). VLPs are deemed an ideal biological 
vehicle due to their biocompatibility, solubility, uptake efficiency, and their capability for targeted 
delivery and drug loading (Yan et al. 2015). Thus, they have been developed for vaccines, drug 
carrying, gene delivery, and in vivo imaging (Teunissen et al. 2013; Yan et al. 2015).  
In vaccine development, VLPs can be used in two ways. Firstly, native viral VLPs from pathogenic 
strains may be utilised by itself as vaccines. Secondly, chimeric VLPs carrying foreign antigens either 
by genetic engineering or chemical conjugation may be used as vaccines (Glasgow and Tullman-
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Ercek 2014; Kushnir et al. 2012; Lua et al. 2014; Rodriguez-Limas et al. 2013; Yan et al. 2015). VLPs 
are attractive for vaccine development not only because they are immunogenic, but also because they 
can be rapidly and efficiently produced (Yan et al. 2015). Different expression systems have been 
established for VLP production such as bacteria, yeast, insect cells, plant cells, mammalian cells, 
plant cells, and even cell-free systems (Kushnir et al. 2012).  
Currently different VLP-based candidate vaccines have been developed not only for diseases caused 
by infectious agents such as hepatitis, HIV, human papillomavirus (HPV), influenza, malaria, Nipah 
virus (NV), and respiratory syncytial virus (RSV); but also non-pathogen-associated cancers such as 
breast cancer and melanoma; as well as other non-pathogen-associated conditions such as allergy, 
asthma, Alzheimer's, type II diabetes mellitus, hypertension, and nicotine addiction (Kushnir et al. 
2012). Many of these VLP-based vaccine candidates have entered the clinical trial phase and to date, 
there are three VLP-based vaccines that have been officially approved for clinical use (Kushnir et al. 
2012). The first to be approved was the recombinant Hepatitis B (HB) VLP expressed in yeast 
(Recombivax HB, Merck), approved by Food and Drug Administration (FDA) for use as a vaccine 
in 1986. The second was recombinant HPV VLP vaccine produced either in yeast (Gardasil, Merck), 
approved by the FDA in 2006; or produced in insect cells (Cervarix, GlaxoSmithKline), approved by 
the FDA in 2009. The third was a recombinant hepatitis E (HE) VLP vaccine produced in E.coli 
(Hecolin, Xiamen Innovax Biotech), approved by Chinese FDA in 2011 (Rodriguez-Limas et al. 
2013). However, all of the approved VLP-based vaccines use native viral coat protein as vaccines 
and none of them are in the form of chimeric VLPs carrying foreign antigens. Recently, the WHO 
recommended the pilot implementation of a recombinant HbsAg VLP based candidate vaccine 
carrying foreign circumsporozoite protein fusion produced in yeast (RTS,S/AS01 Mosquirix, funded 
by GlaxoSmith Kline Biological SA and PATH Malaria Vaccine Initiative) (Gordon et al. 1995; 
Otieno et al. 2016). More research in the application of recombinant VLPs carrying foreign antigen 
could be beneficial for the prevention and treatment of pathogen and non-pathogen-associated 
diseases. 
My current research aims to explore the ability of a chimeric VLP to carry foreign antigen to elicit 
cellular immunity using the non-enveloped MPyV coat proteins. MPyV is a virus oncogenic in 
infected mice cells (Benjamin 2001). The virus infects multiple cell types due to its promiscuous 
surfaced-exposed loops able to bind to a variety of sialic acid receptors in the host (Buch et al. 2015). 
The virus is a double-stranded DNA virus belonging to Polyomaviridae family (ICTV 2012). The 
coat protein of MPyV consists of the major protein VP1 and the minor proteins VP2 and VP3 
(Liddington et al. 1991; Rayment et al. 1982). The icosahedral (T=7d) MPyV VLP and has a diameter 
of 45 nm and consists of 360 VP1 subunit proteins, arranged in 72 pentamers (these pentamers are 
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called capsomeres). As for other members of the polyomaviridae, sixty capsomeres are hexavalent 
and the other twelve are pentavalent (Liddington et al. 1991; Stehle and Harrison 1997). The VP1 
subunit (42.5 kDa) consists of three major parts which are: 1) N-terminal part, which extends to 
clockwise neighbouring VP1 subunit to form a capsomere; 2) the core anti-parallel β-sandwich part 
with jelly-roll topology, which is uniform across all VP1 subunits; and 3) the C-terminal extension 
into neighbouring capsomeres, the conformational variability of which plays a major role in shaping 
the pentavalent and hexavalent interaction between capsomeres to form the icosahedral VLP 
(Liddington et al. 1991; Rayment et al. 1982) (Figure 2.1). The VP1subunit self-assembles into 
capsomeres when expressed in E.coli (Leavitt et al. 1985; Salunke et al. 1986). The capsomere is 
cylindrical with a hollow conical interior, approximately 80 Å in diameter and 70 Å tall. The hollow 
conical interior has a diameter of 50 Å at its base and 12 Å at its upper neck and the top of the 
capsomere contains a dimple 20 Å wide and 12 Å deep (Liddington et al. 1991). The VP1 subunit 
alone can form VLPs both in vivo when expressed in insect cells (Montross et al. 1991), yeast 
(Salunke et al. 1986), or plants (Catrice and Sainsbury 2015), and in vitro when capsomeres are 
dialysed in optimised assembly buffer conditions (Salunke et al. 1986; Schmidt et al. 2000). In vitro 
dialysis experiments demonstrated that capsomere assembly into VLPs depends on calcium and 
disulphide bridges, and thus, capsomere form can be maintained in buffers containing 
ethylenediaminetetraacetic acid (EDTA) to chelate calcium, and dithiothreitol (DTT) to prevent the 
formation of disulphide bridges (Salunke et al. 1986; Schmidt et al. 2000). Salt concentration and pH 
play a role in assembly and disassembly of capsomeres into VLP and vice versa (Chuan et al. 2010; 
Salunke et al. 1986). The ability to manipulate assembly in vitro eliminates the need for disassembly 
and reassembly process usually applied to remove genetic material inside in vivo assembled VLPs 
(Pattenden et al. 2005). 
Besides the three major domains of the VP1 subunit, Liddington et al. (1991) also identified surface-
exposed loops that protrude into the outer part of the capsomere, connecting the antiparallel β-sheets 
with each other. These loops are named DE, EF, BC, and HI based on the β-sheets they are connecting 
(Figure 2.1A). Subsequently, Gedvilaite et al. (2000) identified insertion sites at these surface-
exposed loops of the VP1 subunit at HPyV and named them site 1 (80-89 aa), site 2 (221-224 aa), 
site 3 (243-247 aa), and site 4 (288-295 aa). Insertion at these sites, based on theoretical and structural 
considerations, would not interfere with the correct folding of the protein and would expose the 
inserted sequences, such as antigenic determinants, into the surface of the protein, a prerequisite to 
stimulate humoral immunity. This information is crucial in further attempts to insert foreign peptides 
into the VP1 subunit without interfering with the structure of both the carrier and the foreign entities. 
Even though the loops have been identified in Simian virus 40 (SV40) VP1 (Liddington et al. 1991)  
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Figure 2.1 Structure of MPyV VP1, capsomere, and VLP. A. Structure of VP1 subunit including 
intruding arms from neighbouring subunits. Loops and insertion sites identified in the literature are indicated 
(Adapted from Liddington et al. (1991)). B. VP1 monomer (without intruding arms from neighbouring 
subunits) forms a pentamer called a capsomere, and 72 capsomeres form the VLP (Adapted from Pattenden et 
al. (2005)). 
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and the insertion sites in HPyV VP1 (Gedvilaite et al. 2000), they can be adapted to MPyV as they 
are structurally similar. The adaptation will be explained further in the next subsections. 
MPyV VLPs can enter the MHC Class I and MHC Class II pathways as they can be processed by the 
lysosome and the proteasome, demonstrated by Abbing et al. (2004) and Boura et al. (2005). MPyV 
VLPs enter the cell by monopinocytosis (Richterova et al. 2001) followed by fusion of the 
monopinocytic vesicle with the endosome (Liebl et al. 2006) as can be observed 30 min after entry 
into the cell (Boura et al. 2005). After 90 minutes the MPyV VLP has migrated to the perinuclear 
space and fused to the lysosome, where it gets degraded (Boura et al. 2005). After 6 hours the 
degraded MPyV VLP translocate into the cell periphery and enter the cytoplasm, to be further 
degraded by the proteasome 2 hours later (Boura et al. 2005). This intracellular migratory pattern was 
also observed in antigen presenting cells (APC), and MPyV VLP cellular uptake by dendritic cells 
has been shown to stimulate interleukin (IL)-12 production (Boura et al. 2005). The MHC Class I 
pathway will be explained in more detail in Section 2.3.2 and the MHC Class II will also be explained 
briefly. The MPyV VLP can be taken up by antigen presenting cells of diverse host species via a 
groove on the VP1 protein promiscuous to different ganglioside and sialic acid receptors, especially 
those with [α-2,3], [α-2,6], and [α-2,8]-linked sialic acid (Buch et al. 2015). When injected in mice, 
MPyV VLPs could elicit a dose-dependent high titer humoral response and a T helper cell 1 (Th1) 
type cellular response (Caparros-Wanderley et al. 2004). The ability of MPyV VLPs to enter the 
MHC Class I and II pathways and their promiscuity to different types of eukaryotic cells are some of 
the advantages of the MPyV VLP platform that makes it attractive to develop into Tc-epitope-based 
vaccine.  
The AIBN-CBE Group, led by Professor Anton Middelberg, has developed the MPyV VLP platform 
as a commercially viable platform using E.coli as the expression host (Chuan et al. 2008b; Liew et 
al. 2010) (Figure 2.2). Briefly, at laboratory scale, capsomeres are produced within the bacterial cells 
with a single-batch culture under optimised conditions and isopropyl-β-D-thiogalactopyranoside 
(IPTG) induction (Chuan et al. 2008b; Middelberg et al. 2011). The cells are then harvested and lysed 
by sonication and the capsomeres purified by glutathione-S-transferase (GST) affinity 
chromatography. The GST-tag is removed by enzymatic cleavage and the free capsomeres are then 
isolated from aggregates and free GST by SEC (Lipin et al. 2009). The capsomeres can be maintained 
in capsomere form or assembled into VLP in vitro in optimised buffer conditions (Chuan et al. 2010). 
The laboratory scale production has subsequently been translated into a large-scale process, involving 
fed-batch E.coli expression with a volumetric protein yield of 4.38 g/l which is 15- fold laboratory 
scale production (Liew et al. 2010). Capsomere purification can also be achieved by ion exchange 
chromatography (IEX) (Chuan et al. 2014), and assembly into VLP can be performed by diafiltration  
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Figure 2.2 MPyV capsomere and VLP microbial platform established at AIBN-CBE. The 
established platform includes genetic engineering, microbial production, affinity chromatography, tag 
removal, SEC, and capsomere assembly into VLPs. The platform is scalable (Modified from unpublished 
collection of AIBN-CBE). 
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or dilution method (Liew et al. 2012a; (Liew et al. 2012a; Liew et al. 2012b). Optimised assembly 
buffer for the assembly via diafiltration increased yield by 42-56% in comparison to laboratory scale 
assembly (Liew et al. 2012b). Computational simulation with SuperPro Designer has been used to 
estimate production costs (Chuan et al. 2014). Optimised large scale production of capsomeres and 
VLPs at 500-L and 1500-L volumes respectively were calculated to have an 80% probability of 
manufacturing vaccine at less than 1 cent (USD) per dose (50 µg per dose). Moreover, the simulation 
also predicted that at a 10k-L production scale, 320 million capsomeres or VLP vaccine doses could 
be produced within 2.3 or 4.7 days, respectively.   
The wealth of information available as well as having established a microbial production platform for 
the MPyV capsomere and VLP platforms enabled the group to develop these platforms further into 
vaccine candidates. The initial approach was to insert influenza antibody epitopes into identified 
insertion sites, develop them into either capsomere or VLP vaccines, and test their immunogenicity 
and ability to protect against influenza strains in mice. 
2.2.1 Established MPyV Vaccine Platform 
Vaccine candidate development using the MPyV coat proteins as an antigen carrier has been 
established at the AIBN-CBE. The vaccines can come in either of two forms, capsomeres or VLPs. 
Epitopes which stimulate antibody production from a variety of pathogens, including influenza and 
group A staphylococcus (GAS) (Chuan et al. 2013; Middelberg et al. 2011; Rivera-Hernandez et al. 
2013; Wibowo et al. 2012), have been inserted into engineered sites of the VP1 subunit protein. 
Insertion of antigens of other pathogens, such as the rotavirus, are also in the pipeline (Tekewe et al. 
2015). 
Positions corresponding to site 1 and site 4 identified by Gedvilaite (2000) in HPyV are used in MPyV 
VP1 by inserting distinct restriction enzyme sequences at amino acids 85 and 293, respectively, to 
enable epitope insertion via homologous recombination (Middelberg et al. 2011; Wibowo et al. 2012). 
Capsomeres with successful foreign peptide insertion are then assembled into VLPs and their 
immunogenicity tested in mice (Anggraeni et al. 2013; Chuan et al. 2013; Middelberg et al. 2011; 
Rivera-Hernandez et al. 2013). In cases where epitope insertion interfered with the ability of the 
modular capsomeres to form VLPs, leading to incomplete VLPs or aggregation, the C-terminus can 
be truncated (Wibowo et al. 2012). The VP1 C-terminus plays a significant role in VLP formation by 
forming interpentamer interaction, and its truncation results in stable and assembly incompetent 
capsomeres. As it has previously been reported that capsomeres alone were able to stimulate humoral 
immunity (Fligge et al. 2001), and that stimulation of humoral immunity occurs extracellularly 
(Murphy et al. 2008), it was reasonable to engineer the capsomeres into stable and assembly 
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incompetent epitope presentation platforms. However, this strategy may not be applicable for cellular 
immunity stimulation as it requires Tc-epitopes to enter the cytoplasm of APCs and capsomeres alone 
are not able to enter cells. The following section will describe the current state of MPyV vaccine 
development, both in capsomere (Section 2.2.1.1) and VLP (Section 2.2.1.2) forms.  
2.2.1.1 Capsomere platform 
Stable and assembly incompetent capsomeres have been engineered to carry the M2e epitope 
(CapM2e) of influenza virus. Beside site 1 and site 4, restriction enzyme sequences were also inserted 
at truncated N-terminus (28 aa) and truncated C-terminus (63 aa) to enable epitope insertion 
(Middelberg et al. 2011; Wibowo et al. 2012). It was demonstrated that the number of epitopes 
inserted as well as insert position, influenced capsomere expression levels (Wibowo et al. 2012). Co-
formulation with adjuvants in combination with a higher number of epitopes have been shown to 
increase immunogenicity (Wibowo et al. 2012). Homologous influenza challenge in mice vaccinated 
with CapM2e showed significant protection, reflected by high antibody titer (>105), reduction in lung 
viral load (90.4%), and prevention of body weight loss in comparison to non-vaccinated mice 
(Wibowo et al. 2014). Non-chromatographic purification economically optimised production process, 
and purified and adjuvanted modular capsomeres using this process resulted in high immunogenicity 
when injected in chicken (Wibowo et al. 2015). 
2.2.1.2 VLP platform  
The ability to assemble MPyV capsomeres into VLPs in vitro is a major advantage in VLP-based 
engineering as it removes the disassembly and reassembly process that can be necessary to formulate 
in vivo assembled VLPs and results in loss of protein due to chemical denaturation. The in vitro 
assembly buffer is a solution of fine-tuned function and of simple components: desalting effect of 
ammonium sulphate; facilitation of disulphide and calcium bridge formation by the removal of DTT 
and EDTA, and the addition of CaCl2; and the manipulation of VLP-compatible pH and salt 
concentration (Chuan et al. 2010).  
Insertion of H190, an antigen from influenza hemagglutinin (HA), into site 4 of VP1 has been reported 
not to interfere with assembly (Anggraeni 2014). Two insertion approaches were applied; the use of 
linker sequences flanking the antigen, or a dual tandem repeat of the antigen. Modular capsomeres 
were assembly competent and results showed that the tandem repeat modularisation was better 
regarding structural preservation of the antigen and VLPs were immunogenic when injected into mice 
(Anggraeni 2014). A different antigen, the J8i peptide from GAS was also inserted into site 4 
(Middelberg et al. 2011; Rivera-Hernandez et al. 2013). In this case, and unlike the aforementioned 
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capsomeres, there was no difference in immunogenicity observed between adjuvanted and non-
adjuvanted VLPs (Middelberg et al. 2011). There was also no significant difference in 
immunogenicity when VLPs carry single or dual tandem epitopes, and they were both similarly 
protective for mice against challenge with GAS (Rivera-Hernandez et al. 2013). Chuan et al. (2013) 
also showed that pre-existing immunity against the carrier, a major concern for heterologous 
presentation platforms, did not hinder the production of antigen-specific antibodies, which is good in 
terms of vaccine development. 
Even though a variety of MPyV-based vaccine candidates in the form of capsomeres and VLPs have 
been developed (Table 2.1), they all are targeting antibody production to raise humoral immunity. 
The ability of the MPyV VLP to stimulate cellular immunity by carrying Tc-epitopes has not been 
tested. Cellular immunity stimulation may provide an alternative solution in influenza pre-pandemic 
and seasonal epidemic preparation as eliciting cellular immunity can exploit the more conserved 
internal influenza proteins, which are less prone to mutation in comparison to antibody targeted 
external proteins (Subbarao and Joseph 2007). Other diseases such as cancer and acquired 
immunodeficiency syndrome (AIDS) also may benefit from stimulation of cellular immunity as 
humoral immunity does not work in these conditions in general. Therefore, the ability of the MPyV 
platform to carry Tc-epitopes needs to be explored and challenges particular to the nature of Tc-
epitopes in combination with the nature of MPyV coat proteins need to be addressed. 
2.2.2 Further development for hydrophobic Tc-epitope presentation 
Influenza vaccine development to stimulate cellular immunity by delivering Tc-epitopes has several 
advantages over antibody-based vaccines. Firstly, unlike humoral immunity, stimulation of cellular 
immunity does not depend on the protein conformation of the antigen (Murphy et al. 2008). Secondly, 
stimulation of cellular immunity occurs inside the cell, where the antigenic protein is degraded into 
nonameric Tc-epitopes (Section 2.3.3), which does not require the antigen to be presented on the 
surface of the carrier. Thus, thirdly, the Tc-epitope-based vaccine can make use of the internal 
proteins of influenza virus which are more conserved and are less prone to mutation (Brown and 
Kelso 2009; Krammer and Palese 2015). However, cellular immunity stimulation presents several 
challenges which are: 1) the antigen is required to enter the APC's cytoplasm (Yewdell et al. 2003); 
2) the antigen needs to be processed into smaller peptides by the proteasome, which then enter the 
endoplasmic reticulum (ER) to couple with MHC molecules (Yewdell et al. 2003); and 3) the majority 
of Tc-epitopes are hydrophobic in nature, which may lead to aggregation (Mitic et al. 2014) (More 
on these mechanisms in Section 2.3.3). An MPyV VLP based system may address the first two 
challenges as the VLP has been shown to enter dendritic cells, and be processed by both the  
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Table 2.1 MPyV-based candidate vaccines. 
MPyV platforms Antigen Pathogen References 
Capsomere    
 M2e Influenza (Wibowo et al. 2012) 
VLP    
 J8i GAS (Rivera-Hernandez et al. 2013) 
 H190 Influenza (Anggraeni 2014) 
 VP8 Rotavirus (Tekewe et al. 2015) 
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proteasomal and lysosomal pathways (Abbing et al. 2004; Boura et al. 2005). The hydrophobicity of 
Tc-epitopes and its potential to cause aggregation, however, remains to be addressed and has been a 
major goal of my thesis research. The next subsections will outline problems associated with 
hydrophobic Tc-epitope presentation and ways to resolve aggregation related to hydrophobicity, and 
also discuss other potential approaches in Tc-epitope delivery with the MPyV VLP platform. 
2.2.3 Problems related to hydrophobic Tc-epitope delivery 
Insertion of foreign peptides into a viral coat protein can either maintain protein stability (Anggraeni 
2014; Billaud et al. 2005; Middelberg et al. 2011; Rivera-Hernandez et al. 2013); or interfere with 
protein stability, rendering the VLP components assembly incompetent as has been experienced with 
M2e insertion into MPyV VP1 (Wibowo et al. 2012), or prone to aggregation as has been 
demonstrated with hydrophobic rotavirus epitope insertion within MPyV VP1 (Tekewe et al. 2015). 
Normal protein aggregation is usually initiated by nucleation of partially unfolded protein 
intermediates which expose hydrophobic patches as well as extended unfolding arms (Wang et al. 
2010b). This phenomenon then leads to disordered self-assembly via hydrophobic and electrostatic 
protein-protein interaction (Fink 1998; Wang et al. 2010b). Initial disruption of conformational 
stability leads to the disruption of colloidal stability (Chi et al. 2003) as proteins interact with each 
other to form soluble aggregates. Gradual increase in aggregate size may extend beyond their 
solubility limit, leading to precipitated insoluble aggregates (Wang et al. 2010b). Simulation has 
shown aggregation of proteins with hydrophobic entities on the surface before (Zhang et al. 2008). 
Therefore, insertion of hydrophobic Tc-epitopes on the surface-exposed loop of VP1 protein may 
emulate hydrophobicity related protein aggregation. Aggregation of therapeutic proteins usually 
reduces or eliminates their biological activity or immunogenicity (Wang et al. 2010b), and this may 
also apply to an MPyV-based vaccine presenting hydrophobic Tc-epitope on the surface if they 
aggregate. In addition, aggregation in therapeutic protein formulation is undesirable as the presence 
of particles >10 µm renders the preparation unsuitable for administration (Cromwell et al. 2006). 
Aggregation is influenced by several environmental factors such as pH, temperature, ionic strength, 
sequence hydrophobicity, local surface charges, protein concentration, buffering agent, and the 
presence of chaperones and additives (Chong and Ham 2014b; Fink 1998; Wang et al. 2010b). Ionic 
strength and pH play a major role in influencing intramolecular and intermolecular interactions, both 
hydrophobic and electrostatic. To prevent protein aggregation, pH and ionic strength of the solvent 
is usually optimised, and a selection of additive, depending on the nature of the protein, is often added 
to the solvent (Wang 2005). For example, additives commonly used to prevent aggregation include 
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detergents, chaperones, osmolytes, and charged amino acids such as L-Arginine (L-Arg) (Arakawa 
et al. 2007; Lanckriet and Middelberg 2004; Leibly et al. 2012). 
2.2.3.1 Mosaic particles 
One way to reduce hydrophobicity on the surface of a VLP to prevent aggregation and to maintain 
VLP structure is by combining hydrophobic modified capsomeres with unmodified capsomeres, 
forming a mosaic particle. The bioengineering of mosaic particles has been demonstrated before with 
the Qβ bacteriophage and the plant virus cowpea chlorotic mottle virus (CCMV). The Qβ virus-like 
particle can self-assemble inside E.coli and co-expression of modified Qβ monomer subunit 
displaying foreign protein on the surface with unmodified Qβ monomer can result in stable VLP 
mosaic particles. This approach permitted insertion of either the Z protein (Brown et al. 2009) or the 
epidermal growth factor (EGF) protein (Pokorski et al. 2011) on the surface of Qβ. Expression of 
modified Qβ alone interfered with the assembly competency of the particles and co-expression with 
unmodified Qβ restored the assembly competency of the particles in vivo.  
Mosaic particle formation has also aided in the encapsidation of GFP inside the CCMV VLP (Minten 
et al. 2010). Modified subunit was co-assembled with unmodified subunit in vitro to control the 
amount of encapsidated GFP. Co-assembly resulted in stable mosaic particles encapsidating GFP in 
a controlled manner. Similar to MPyV VLP, the CCMV VLP can be assembled in vitro. Co-assembly 
of modified MPyV VP1 carrying antigens on the surface or in the internal cavity of capsomeres with 
unmodified wtVP1 capsomeres in vitro has not been reported before. Mosaic particle formation could 
be a good strategy in reducing hydrophobic effects on the surface of modified MPyV VLPs, and in 
controlling the number of encapsidated proteins. The protein encapsidation approach is explained in 
the next subsection.  
2.2.3.2 Protein Encapsidation by MPyV 
Another way to overcome hydrophobicity-related aggregation is by encapsidating the hydrophobic 
antigen inside the cavity of MPyV VLP rather than presenting it on the surface. The minor coat 
proteins VP2 or VP3 are not required for self-assembly, but they have been shown to enable foreign 
protein encapsidation inside the MPyV VLP (Abbing et al. 2004; Boura et al. 2005; Inoue et al. 2008). 
The VP2 differs from VP3 only by additional 115 aa at the N-terminus of VP2 (Barouch and Harrison 
1994). One VP2 (and VP3) protein binds to the hydrophobic inner cavity of one VP1-capsomere via 
a conserved hydrophobic region close to the C-terminal of VP2, forming a VP1:VP2 capsomere 
complex (Barouch and Harrison 1994; Chen et al. 1998) (Figure 2.3). While the hydrophobic binding  
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Figure 2.3 VP1:VP2 interaction. The diagram shows three VP1 subunits as members of a 
pentameric capsomere, with one VP2 inside the cavity of the capsomere. VP2 binds to the inner cavity 
of VP1 via a hydrophobic binding region at the C-terminus of VP2 (Adapted from Chen et al. (1998)). 
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region of VP2 is very conserved, amino acid sequences at the N-terminal and C-terminal arms of this 
binding region are not as conserved, underlining the important function of the binding region 
(Barouch and Harrison 1994; Sapp and Day 2009). The binding affinity of the capsomere:VP2 
interaction is quite high, with reported dissociation constant (Kd) of 5 µM (Barouch and Harrison 
1994) or 190 nM (Abbing et al. 2004). 
Foreign protein encapsidation with VP2 has been demonstrated by fusion of the foreign protein to 
either the N-terminus or C-terminus of VP2. VP2 and a variety of minimal sequences omitting some 
part of the N-terminal region but still retaining the hydrophobic binding site of VP2 (VP2C) have 
been engineered for this purpose (Abbing et al. 2004; Boura et al. 2005; Inoue et al. 2008). 
Encapsidation has been achieved by either co-expression of VP1 and foreign protein fused VP2/VP2C 
within insect cells (Boura et al. 2005; Inoue et al. 2008), or by separate expression in E.coli and 
separate chromatographic purification before co-assembly in vitro (Abbing et al. 2004). The GFP has 
been fused to VP2/VP2C in most cases to enable chromatographic detection at A488 nm (Abbing et 
al. 2004; Boura et al. 2005; Inoue et al. 2008) to validate the approach. Abbing et al. (2004) reported 
an encapsidation capacity of 64 GFP molecules when unmodified VP1 was co-assembled in vitro 
with VP2/VP2C-GFP. It was also demonstrated that GFP encapsidation did not interfere with the 
ability of MPyV VLPs to enter cells (Abbing et al. 2004; Boura et al. 2005). While Abbing et al. 
(2004) and Boura et al. (2005) fused GFP at the N-terminus arms of MPyV VP2, Inoue et al. (2008) 
fused GFP at either N-terminus or C-terminus of SV40-VP2C. Inoue et al. (2008) were able to show 
that C-terminal fusion was preferable as it resulted in regularly shaped VLPs while N-terminal fusion 
resulted in irregularly shaped VLPs. Furthermore, Pleckaityte et al. (2015) demonstrated that fusion 
of foreign proteins into truncated N-terminus of VP2 resulted in the foreign protein being exposed to 
the surface of the VLP and in antibody recognition of the foreign protein. Their results suggested that 
N-terminal fusion resulted in the protrusion of the fusion proteins through the upper opening of the 
capsomere into the external space of the VLPs. Thus, foreign protein fusion to the C-terminus of 
VP2C was more preferable for encapsidation. The encapsidation strategy enables carriage of a longer 
stretch of amino acids, even in the form of whole protein or soluble subdomains, without interfering 
with assembly competency and cell entry. Regarding MPyV VLP development as a Tc-epitope 
carrier, a longer stretch of amino acid would entail the ability to carry multiple numbers of epitopes 
with different HLA specificities. Encapsidation of soluble subdomains of conserved internal proteins 
of influenza could be an immunological advantage because proteins and longer peptides have been 
shown to be better processed by the MHC Class I pathway and are more likely to be presented by 
APCs than short peptides (Berthoud et al. 2011). 
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This section started by describing the existing MPyV vaccine platform and pointed out limitations 
associated with hydrophobic Tc-epitope carriage. Further, approaches to circumvent bioengineering 
challenges were explained, such as buffer optimisation, the engineering of mosaic particles, and 
antigen encapsidation strategies. The next section will further discuss the advantages and 
disadvantages of the MPyV platform as influenza Tc-epitope carrier, by first explaining the influenza 
phenomenon, as well as limitations in current influenza vaccines. 
 
2.3 MPyV VLP-based influenza Tc-epitope vaccines 
2.3.1 Influenza 
The influenza virus belongs to the Orthomyxoviridae family, characterised by an enveloped virus 
containing negative single-stranded ribonucleic acid (RNA). The family includes six different genera 
which are Influenza A, Influenza B, Influenza C, Thogovirus, Isavirus, and Quaranjavirus. Of these 
genera, Influenza A is the most relevant to humans (Subbarao and Joseph 2007; Szewczyk et al. 
2014). Different HA and neuraminidase (NA) types define serological features of an influenza strain. 
Currently, there are 18 HA and 11 NA serological types (Szewczyk et al. 2014). 
The HA and NA proteins are the external proteins of influenza, which mutate frequently (Subbarao 
and Joseph 2007). The HA protein comprises 80% of the external proteins protruding like a spike. 
The NA comprises the other group of major external proteins protruding like a mushroom (Norkin 
2010; Szewczyk et al. 2014) (Figure 2.4). HA plays a role in viral entry into the cell, and NA plays 
a role in viral exit from the cell (Norkin 2010; Szewczyk et al. 2014). Another minor external protein 
is the M2, which is embedded in the viral membrane and acts as an ion channel. The internal proteins 
are more conserved (Subbarao and Joseph 2007) and include the M1, nucleoprotein (NP), polymerase 
basic protein 1 (PB1), polymerase basic protein 2 (PB2), polymerase acidic protein (PA), and non-
structural protein 2 (NS2) (Norkin 2010; Szewczyk et al. 2014). The most abundant protein is the M1 
capsid protein, partly embedded along the inner part of the membrane, and binds to the 
ribonucleoproteins (RNP) in the cavity of the virus. The RNP complex consists of NP; and the 
ensemble of RNA-dependent RNA polymerases PB1, PB2, and PA. The NP protein encases each of 
the eight RNA segments separately (Norkin 2010; Szewczyk et al. 2014).  
Influenza pathogenicity is associated with mutations more frequently in the external and less 
frequently in the internal proteins, causing an elevation in RNA replication, cytokine and chemokine 
dysregulation, antiviral cytokine resistance, and interference with human signalling pathway  
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Figure 2.4 Schematic diagram of the influenza virus. A. The influenza virus consists of major 
external protein HA and NA and minor external protein M2. Internal proteins include M1, and 
NEP/NS1 and the RNP. B. RNP consists of viral RNA wrapped in NP protein which bind to 
polymerase proteins PA, PB1, and PB2 (Adapted from Norkin (2010)). 
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(Korteweg and Gu 2008; Neumann et al. 2010). In particular, HA cleavage plays an important role in 
influenza virus replication and pathogenic protein translation inside the host cell, including 
subsequent pathogenic viral protein translation and virus replication (Korteweg and Gu 2008; 
Neumann et al. 2010; Peiris et al. 2007).  
The influenza viral proteins, especially the external proteins, are prone to mutation by three 
mechanisms: 1) antigenic drift; 2) antigenic shift; and 3) recombination (Szewczyk et al. 2014). 
Antigenic drift is caused by the lack of proofreading ability of influenza RNA polymerases, 
introducing single or more amino acid mutations (Holland et al. 1982; Szewczyk et al. 2014). 
Mutation occurs continuously, accumulatively leading to new strains unrecognisable by humoral 
immunity. This, allows transmissibility and maintenance of the virus in the host population and results 
in seasonal influenza epidemic (Ryan et al. 2014). Antigenic shift can happen in two ways which are: 
reassortment; and viral jump into a different host. Reassortment occurs when two different strains 
infect the same host cells and exchange genetic material (Ryan et al. 2014; Stevens et al. 2006). An 
example of this is when influenza virus of avian and of human origin infect the same swine cell. 
Avian influenza viruses have different receptor specificities [α-2,3 sialic acid] than human influenza 
viruses [α- 2,6 sialic acid] and they usually do not cross-infect. However, the swine cell contains both 
avian and human receptors (Liu et al. 2009). Other intermediates such as ferrets, horses, and terrestrial 
avian species, and even human, have also been identified (Herfst et al. 2014; Matrosovich et al. 2004). 
When reassortment becomes phenotypic, it is called antigenic shift. An example of this is when host 
cell specificity changes from avian to human due to possible reassortment in swine or even human 
cells (Matrosovich et al. 2004; Wang and Jiang 2009). The H1N1-SOIV strain responsible for the 
2009 pandemic was a reassortant strain containing six RNA segments from North-American swine-
origin strains and 2 RNA segments originating from Eurasian strains (Mamun and Huda 2011). 
Influenza virus can also jump directly to a different host species with or without intermediates 
(Schnitzler and Schnitzler 2009; Wang and Jiang 2009). Both forms of antigenic shift, reassortment 
and host jump, can result in a pandemic as the new host does not have any herd immunity against the 
new strain (McAuley et al. 2015; Schnitzler and Schnitzler 2009; Wang and Jiang 2009). Especially 
when the new strain becomes highly transmissible among the new host population as experienced in 
the H1N1-S-OIV pandemic (Herfst et al. 2014). Homologous and non-homologous RNA 
recombination, may also occur at a rarer frequency, but may transform a low pathogenic strain into a 
high pathogenic strain (Suarez et al. 2004). 
An influenza epidemic is an increase, often suddenly, in the number of cases of influenza above what 
is usually expected in that population in that area (Dicker et al. 2012). Epidemic influenza usually 
affects a particular region and occurs seasonally, especially during winter. The estimated death rate 
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of epidemic influenza is about 250 000-500 000 per year and especially prevalent in the very young, 
elderly, and chronically ill (WHO 2009a).  
An influenza pandemic occurs when a new influenza subtype emerges against which there is minimal 
immunity in the population, resulting in concurrent epidemics with a high number of cases and 
fatalities worldwide (WHO 2005). The 1981 H1N1 Spanish flu and the 2009 H1N1 S-OIV pandemic 
were some of the examples in human history. The estimated fatal case of the recent H1N1 S-OIV 
2009 pandemic was estimated to be 300 000 (Dawood et al. 2012). International airline travel 
accelerated its global spread as the rate of transmission increased proportionally to the number of 
people travelling from affected countries (Davis et al. 2013; Neatherlin et al. 2013). The outbreak 
started in Mexico in April 2009 and spread to North America and Europe in May 2009, and World 
Health Organisation (WHO) declared a full-blown pandemic in June 2009 (WHO 2013). Vaccines 
were only available six months (October 2009) after the onset of the pandemic, when it had spread 
across the globe and reached Australia, with delays in certain countries where antivirals were 
distributed before the pandemic (WHO 2013). 
During the 2009 pandemic, school closures occured across affected countries and there were many 
absentia from the workplace due to treatment or avoidance of possible transmission (Keogh-Brown 
et al. 2010). These factors, along with the pathological effects of influenza were estimated to place a 
heavy economic burden on the individual level (Sander et al. 2009), and loss in gross domestic 
product (GDP) on the national level (Keogh-Brown et al. 2010). The use of antiviral drugs and 
vaccination were estimated to reduce these economic burdens significantly (Keogh-Brown et al. 
2010; Sander et al. 2009), which underlines the importance of vaccination in mitigating influenza 
pandemic and epidemic, both health wise and economy wise. 
2.3.2 Current influenza vaccines and their limitations 
The aim of vaccination is to activate the adaptive immunity of a patient against a target pathogen. 
Although the adaptive immunity lags in response during primary pathogen exposure, it acquires 
memory of the pathogenic antigen. When the same pathogen attacks a second time, the adaptive 
immunity via memorised antigen recognition, clears away the pathogen before the disease can 
progress (Murphy et al. 2008). There are two types of adaptive immunity, humoral immunity and 
cellular immunity. Humoral immunity plays a role in clearing extracellular pathogens by the 
production of antibody, leading to neutralisation, complement activation, and opsonisation. Cellular 
immunity plays a role in clearing intracellular pathogens by killing infected cells displaying pathogen-
derived antigens on their surface (Murphy et al. 2008). 
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Vaccination by administration of harmless antigen into the patient aims to mimic the first round of 
infection to activate the adaptive immunity of the patient. Administered influenza antigens may be in 
the form of killed or attenuated-live pathogens or their subunit proteins. Administration of harmless 
antigen would mimic the first infection without causing severe disease, to enable the adaptive immune 
system to acquire memory about the antigen. In turn, the next time the real pathogen attacks, the 
adaptive immune system would be able to clear it immediately without the pathogen causing the 
disease to the vaccinated individual (Murphy et al. 2008; Nolz and Harty 2011a). Section 2.3.3 will 
explain the mechanism of memory acquisition and subsequent selective cytotoxicity of the cellular 
immunity in more detail. 
Current influenza vaccines are usually trivalent or quadrivalent. A trivalent vaccine contains two 
Influenza A strains and one Influenza B strain according to WHO recommendation for that season. 
A quadrivalent influenza vaccine contains and additional Influenza B strain (Krammer and Palese 
2015). Licensed influenza vaccines to date come in the form of inactivated influenza vaccines (IIV), 
live-attenuated influenza vaccines (LAIV), and recombinant influenza protein vaccine (Cox and 
Hollister 2009; Del Giudice and Rappuoli 2015; Jin and Subbarao 2015; Krammer and Palese 2015) 
(Table 2.2). An IIV consists of killed whole virus that could further be disrupted into split vaccines 
and protein subunit vaccines. This method was first developed in 1937 and has been further optimised 
ever since and recent development includes the addition of adjuvants and high-dose administration 
(Del Giudice and Rappuoli 2015; Krammer and Palese 2015). An LAIV is an artificially reassortant 
virus with six backbone gene segments that introduce attenuation of viral replication in tissues >25°C. 
Two other gene segments are HA and NA from circulating strains. LAIV vaccines were the second 
influenza vaccine technology licensed after IIV and gave better protection than IIV (Jin and Subbarao 
2015). A new generation of licensed influenza vaccine, recently approved by FDA in 2013, is the 
trivalent Flublok vaccine containing recombinant HA proteins produced in insect cells, without the 
whole virus (Cox and Hollister 2009). Other vaccines based on more advanced technologies such as 
reverse genetic viruses are currently in the pipeline (Gomila et al. 2013; Suphaphiphat et al. 2010).  
There are several impediments in currently licensed vaccines, one of which is egg-dependent 
production, and in the case of an avian influenza outbreak, highly virulent avian influenza virus may 
not be grown in high titres in embryonated eggs, and therefore, conventional vaccine production 
would be delayed (Buckland 2015). Recent advancement in technology allows the use of mammalian 
or insect cells for production (Table 2.2), which, however, requires higher biosafety measures, adding 
significantly to production cost, rendering the vaccines less affordable in developing countries 
(Buckland 2015). Furthermore, global vaccine production capacity would not be able to satisfy global 
demand in the event of a pandemic. As an example, seasonal influenza vaccine production capacity 
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Table 2.2 Currently licensed influenza vaccine. 
Vaccine 
technology 
Expression 
system 
Biosafety 
Level Product 
Immunity 
Type Breadth 
IIV 
(Del Giudice 
and Rappuoli 
2015) 
Eggs. BSL-2 Inactivated 
virus, split 
virus, 
subunit 
vaccines. 
Humoral. Strain 
specific 
Mammalian 
cells. 
BLS-3 Inactivated 
virus, split 
virus, 
subunit 
vaccines. 
Humoral. Strain 
specific 
LAIV 
(Jin and 
Subbarao 
2015) 
Eggs. BSL-2 Attenuated 
virus. 
Humoral, 
cellular. 
Strain 
specific but 
broader than 
IIV 
Mammalian 
cells. 
BSL-3 Attenuated 
virus. 
Humoral, 
cellular. 
Strain 
specific, but 
broader than 
IIV 
Recombinant 
protein 
(Cox and 
Hollister 
2009) 
Insect cells. BSL-2 HA proteins. Humoral. Strain 
specific 
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was 876 million doses during the 2009 H1N1 S-OIV pandemic according to WHO report (Girard et 
al. 2010). Monovalent pandemic vaccine production six months after strain identification was 
estimated to be 4.9 billion doses according to a joint report by the International Federation of 
Pharmaceutical Manufacturers and Associations – Influenza Vaccine Supply task force (IFPMA IVS) 
and the European Vaccine Manufacturers (EVM) (Abelin et al. 2011; Collin et al. 2009). However, 
global population was estimated to be 6.8 billion people (PRB 2009) at that time. Global supply is 
still not able to satisfy global demand, exacerbated by logistic problems such as vaccine distribution 
and vaccine shelf-life. These problems necessitate new approaches in vaccine manufacture 
technology which preferably involves simpler and cost efficient procedures, shorter production time, 
high yield, and longer vaccine shelf-life.  
Moreover, all of the currently licensed vaccines aim to stimulate the humoral immunity for antibody 
production and are thus strain specific as the influenza virus external proteins frequently mutate due 
to antigenic drift, antigenic shift, and recombination (Broadbent and Subbarao 2011; Krammer and 
Palese 2015; Subbarao and Joseph 2007). Due to the highly mutative behaviour of the external 
proteins, influenza vaccines have to be updated from season to season and in the occasional pandemic 
outbreak to match mutated circulating strain (Broadbent and Subbarao 2011; Subbarao and Joseph 
2007). Current vaccine manufacturing technology requires six months, including lengthy regulatory 
process, to produce distributable vaccines (Buckland 2015). As circulating strains keep mutating, 
vaccine strains may not match the circulating strain resulting in reduced immunogenicity (Buckland 
2015; Singh et al. 2010). These drawbacks of the dominant existing technology necessitate the 
development of broadly cross-protective influenza vaccine able to raise immunity against 
heterologous strains to reduce vaccine update frequency and to facilitate better preventive measures 
for an emerging pandemic (Brown and Kelso 2009; Subbarao and Joseph 2007). There are several 
options to achieve this, for example by utilising conserved B cell epitopes of HA and M2e identified 
recently to increase heterologous humoral immunity (Krammer and Palese 2015). Moreover, a 
strategy to raise the cellular immunity may also be explored, and may have several advantages 
including the utilisation of more conserved internal proteins of influenza to enable the stimulation of 
broadly cross-protective immunity. To develop an MPyV VLP-based Tc-epitope carrier to enable 
cellular immunity stimulation against influenza is the main aim of my research. 
2.3.3 The mechanism of cytotoxic T cell activity 
The aim of Tc-epitope-based vaccination is to protect from severe infection by the generation of 
memory Tc specific to the pathogen in question. Memory Tc generated via Tc-epitope vaccination 
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are expected to recognise the antigen and exert its cytotoxic activity to eliminate the pathogen faster 
than the time it takes for the pathogen-related disease to progress (Nolz and Harty 2011b). 
APCs, especially dendritic cells, prime the Tc to initiate the acquisition of memory and subsequent 
selective cytotoxicity (Murphy et al. 2008; Yewdell et al. 2003) (Figure 2.5A). Dendritic cells have 
to internally process and externally present the antigens to Tc to prime them with the foreign 
pathogenic antigens. Dendritic cells process antigens by degrading intracellular viral or bacterial 
proteins into smaller peptides via cytoplasmic proteasomal activity. The degraded peptides are then 
transported into the ER via the transporter associated with antigen processing (TAP). In the ER, the 
peptides are further degraded into smaller 8-10 amino acid, usually 9-mer peptides by the ER 
aminopeptidase associated with antigen processing (ERAAP). These 8-10 amino acid long peptides 
are called Tc-epitopes. One Tc-epitope then bind to the Tc-epitope binding cleft of one MHC Class I 
and the combination of the MHC Class I binding cleft and the Tc-epitope is called the antigenic 
determinant. MHC Class I is partly embedded into the inner membrane layer of the ER cavity, 
anchored there by several other proteins, including tapasin, which binds to both MHC Class I and 
TAP, thus bringing the Tc-epitope and MHC Class I in proximity to each other. Once the Tc-epitope 
binds to MHC Class I, the MHC Class I becomes stabilised and travels from the ER to the surface of 
the dendritic cells (Murphy et al. 2008; Yewdell et al. 2003).  
Dendritic cells usually take up foreign pathogens at the periphery by several mechanisms, including 
macropinocytosis and phagocytosis. Proteins degraded in the phagolysosome can enter the cytoplasm 
and be further degraded by the proteasome and enter the MHC Class I pathway, and this event is 
called cross-presentation (Murphy et al. 2008). Upon foreign antigen uptake in the periphery, 
dendritic cells become activated and travel to peripheral lymphoid organs such as the lymphatic 
nodules or the spleen. Surface antigen presentation by dendritic cells activates the naïve Tc, which is 
a Tc that has not been primed with foreign antigen before (Murphy et al. 2008; Yewdell et al. 2003). 
The Tc recognises the surface presented peptide:MHC Class I complex (antigen determinant) by its 
T cell receptor (TCR).  Activated Tc (effector Tc) then exit the peripheral lymphoid organs and travel 
across the lymphatic system and circulate in the blood to scan for other host cells displaying the same 
peptide:MHC Class I complex that they have been primed before by the dendritic cells in the 
lymphoid organs. Host cells infected by the same pathogen as the dendritic cells display the same 
antigenic determinant. Thus, the Tc only select these cells to exert its cytotoxic activity. Upon 
antigenic determinant recognition via the TCR, effector Tc release their granules into the cytoplasm 
of the infected cells. These granules contain perforin, granzymes A and B, and granulysin. These 
cytokines stimulate apoptosis in the target cells by initiating the caspase pathway, leading to DNA 
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Figure 2.5 The mechanism of Tc activity. A. The MHC Class I pathway: 1) viral entry into host cell; 
2) viral protein synthesis; 3) proteasomal degradation; 4) entry into ER via TAP; 5) Tc-epitope binding to 
MHC Class I; 6) peptide:MHC complex migrate to the surface of the cell; 7) peptide:MHC complex 
recognition by TCR. B. Activation of Tc: 1) dendritic cell pathogen uptake; 2) dendritic cell migration to 
lymphoid organs; 3) Tc-epitope presentation by the MHC Class I pathway; 4) peptide:MHC complex 
recognition by TCR; 5) naïve Tc activation and proliferation; 6) Tc differentiation into effector and memory 
cells; 7) activated Tc migrate to periphery; 8) Tc selectively kills cells which present the same antigen they 
have been exposed to in the lymphoid organs (Adapted from Abidin (2010)). 
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damage of both pathogen and host cell and eventual cell death. By signalling the death of pathogen-
infected host cells, the Tc stops pathogen replication and also hinders pathogen spread by killing the 
cells the pathogens reside in (Murphy et al. 2008; Yewdell et al. 2003) (Figure 2.5B). After 12 days, 
90-95% Tc undergo apoptosis while 40 days after, the rest differentiate into central memory T cells 
(Tcm). The number of Tcm is about 500-1000 fold of its naïve precursor and they live for extended 
period of time. They can home to peripheral lymphoid organs and exert robust recall response upon 
secondary antigen exposure (Harty and Badovinac 2008). 
The MHC Class II pathway occurs with a slightly different mechanism where protein degradation 
and MHC binding takes place in the acidic endolysosomal compartment (Murphy et al. 2008). T cells 
corresponding to MHC Class II differentiate into a number of cell types: 1) T helper cells type 1 (Th1) 
which activate macrophages to kill intracellular pathogens;  2) T helper cells type 2 (Th2) which 
mature B cells into plasma cells to produce antibodies of immunoglobulin (Ig)E types, as well 
activating mast cells and eosinophils; 3) T follicular helper cells (TFH) which also matures B cells into 
plasma cells to produce antibody of IgG types; 4)T helper cells type 17 (Th17) which helps in 
recruiting neutrophils into site of infection; and 5) regulatory T cells (Treg) which prevent cytotoxic 
activity against self-antigens (Murphy et al. 2008).  
A Tc-epitope-based vaccine would target cellular immunity by delivering Tc-epitopes into dendritic 
cells to prime naïve Tc cells. However, this type of vaccine would have to take into account the 
extensive polymorphism of HLA (human version of MHC) molecules. As of April 2016, there are 
10 730 recorded HLA Class I and 3 743 HLA Class II alleles (Robinson et al. 2015). The analysis of 
nonameric Tc-epitopes revealed that amino acid 2 and amino acid 9 bind specifically to pocket B and 
F of HLA Class I binding pockets respectively, defining their specificity to different HLA Class I 
types (Sette and Sidney 1999; Sidney et al. 2008). HLAs bind specifically to Tc-epitopes, however, 
some HLAs may bind to the same Tc-epitopes due to similarity in the B and F pockets, and based on 
this most HLAs can be grouped into supertypes (Lund et al. 2004; Sette and Sidney 1999; Sidney et 
al. 2008). According to Sette and Sidney (1999), Tc-epitope-based vaccines targeting 9 supertypes 
(A2, A3, B7, B44, A1, B27, B62, and B58) may cover 99.8% of the global population. 
2.3.4 Advantages of Tc-epitope delivery with MPyV VLP platform 
The potential advantages of using the MPyV VLP platform as a vaccine carrier for influenza Tc-
epitope had been pointed out throughout this literature review and will be summarised again in this 
subsection. These advantages may be categorised based on the following aspects: 1) immunogenicity; 
2) process development; 3) production; 4) safety; and 5) stability (Table 2.3).  
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Table 2.3 Advantages of MPyV VLP platform for Tc-epitope-based vaccines. 
Advantage 
Implication for 
influenza vaccine 
production 
Disadvantage 
Implication for 
influenza vaccine 
production 
Immunogenicity 
 Enter different cell 
types. 
 Enter dendritic cells 
and the MHC Class I 
and II pathways. 
 Immunogenic 
repeated molecular 
patterns (PAMP). 
 Pre-existing immunity 
does not interfere with 
protection. 
 
 Can vaccinate hosts of 
different species. 
 Cellular immunity 
stimulation for broader 
cross-protection. 
 Less updating 
frequency. 
 Adjuvant not needed. 
 Allows booster 
vaccination. 
  
Process development 
 Encapsidation 
possible. 
 In vitro assembly. 
 Well established 
knowledge-base. 
 Multiple epitope 
delivery for broader 
population coverage. 
 Circumvent 
hydrophobicity related 
aggregation. 
 Easier manipulation. 
 
 Downstream 
processing may be 
less applicable in 
developing countries. 
 Need to develop 
simpler purification 
methods. 
Production 
 Bacterial production 
system. 
 Safe, BSL-1. 
 Scalable. 
 Flexible vaccine 
production. 
 Simple manufacturing 
process. 
 Cheap, fast, and high 
yield production. 
 
 Genetically modified 
product. 
 
 Stricter regulation. 
Safety 
 No genetic material.   Safe. 
 
  
Stability 
 Stable at RT for 9 
weeks. 
 Stable at -80°C for a 
couple of years. 
 Stockpiling and remote 
distribution possible. 
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Viral capsids have a distinct characteristic of repetitive molecular patterns commonly known in 
immunology as PAMP, recognised by the innate immunity and dendritic cells as a hallmark of a 
foreign entity. Upon recognition of the foreign entity by special receptors, the innate immune system 
and dendritic cells produce different signals which lead to dendritic cell maturation and activation to 
prime T cells (Jennings and Bachmann 2008; Melchjorsen 2013). The MPyV VLP has been shown 
to activate and maturate dendritic cells and is one of only two polyomaviral-like particles of the 
polyomaviridae family that do so effectively (Gedvilaite et al. 2006). MPyV VLPs are also able to 
enter dendritic cells and be processed by both the MHC Class I and MHC Class II pathways as has 
been demonstrated by Abbing et al. (2004) and Boura et al. (2005). Moreover, they are able to enter 
different type of cells via different sialic acid receptors (Section 2.2) and thus can be used as Tc-
epitope-based vaccine for a different host species. These are the immunological advantages of the 
MPyV VLP as a carrier for influenza Tc-epitopes. 
In addition to external epitope presentation by insertion at the surface-exposed loop, the MPyV VLP 
may also encapsidate foreign protein inside its cavity (Abbing et al. 2004; Boura et al. 2005), allowing 
the carriage of soluble domain proteins with multiple epitopes of different HLA Class I specificities. 
This strategy may circumvent hydrophobicity-related aggregation and possibly strengthen T cell 
response. Assembly of MPyV VLP could also be done in vitro, which eliminates disassembly and 
reassembly process usually needed to remove genetic material (Chuan et al. 2010). The process may 
potentially be manipulated for capsomere co-assembly to form either mosaic particles or to control 
the amount of encapsidated foreign protein. Recombinant technology and process development of the 
MPyV VLP platform has been well established at AIBN-CBE and thus may facilitate process 
development. These are the process developmental advantages of the MPyV VLP as a carrier for 
influenza Tc-epitopes. 
A scalable bacterial expression platform in a biosafety lever (BSL)-1 environment has been developed 
at the AIBN-CBE for the MPyV VLP, which allows simple manufacturing process, lower production 
cost, shorter production time, and higher production yield (Chuan et al. 2014). These are the 
production advantages of the MPyV VLP as a carrier for influenza Tc-epitopes. However, 
downstream processing involves relatively advanced purification apparatus, and thus adjustment may 
be needed if manufacturing is set in developing countries. Nevertheless, low production cost and high 
yield, as simulated for large scale production (Chuan et al. 2014), may minimise vaccine 
manufacturing plant localisation. Vaccine price would then only be limited by distribution cost and 
vaccine shelf-life. In addition, a precipitation method to harvest MPyV capsomeres is being 
developed at the AIBN (Wibowo et al. 2015). MPyV VLP for up to a couple of years of storage is 
stable at -80°C, and at room temperature (RT) for up to 9 weeks as previously mentioned (Caparros-
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Wanderley et al. 2004). The MPyV VLP is also safe as it does not contain genetic material (Chuan et 
al. 2010). However, MPyV VLP is a genetically modified product and could meet stricter regulation 
procedures (Kushnir et al. 2012). 
This main section has summed up the advantages and disadvantages of the MPyV VLP platform to 
develop into a Tc-epitope-based influenza vaccine. Even though the MPyV VLP platform is easily 
adjustable, a method to analyse and characterise modified VLPs to confirm successful VLP formation 
and modification was not available at the time I pursued my research. Thus, a new SEC method was 
developed alongside to analyse and characterise VLPs modified as Tc-epitope-based influenza 
vaccine. The next main section will describe briefly the basic principles of SEC and factors 
influencing an efficient SEC method. 
 
2.4 Size exclusion chromatography 
Limited availability of methods to isolate the VLPs for analysis and characterisation hinders the 
development of VLP-based vaccines. A few of these methods have been recently reported (Ladd Effio 
et al. 2016; Lagoutte et al. 2016), but were not readily available at the time I did my research. Thus, 
a new preparative SEC method to enable isolation and characterisation of VLPs was developed in my 
research. This section briefly describes the principles of SEC and gel filtration in process 
development.  
2.4.1 Principles of size exclusion chromatography 
SEC or gel filtration chromatography is a method to separate molecules based on their size. The 
sample is run through a liquid mobile phase and a solid stationary phase. The stationary phase consists 
of a porous matrix with a defined porosity, typically in the form of inert beads, made from a variety 
of materials such as agarose, dextran, or cross-linked polyacrylamide or the combination thereof 
(O'Fagain et al. 2011).  The liquid mobile phase consists of external volume and internal volume. The 
external volume is the volume outside the pores, and is also called the void volume. The internal 
volume is the volume inside the pores. Total liquid volume comprises both the external and the 
internal volumes (O'Fagain et al. 2011). 
Due to their sizes, particles have different abilities to travel inside the pores. Particles that are too 
large to travel through the pores will elute earlier, and molecules of smaller sizes travel through more 
pores and thus elute in decreasing particle size (Hagel 2011; Hagel and Janson 1992; O'Fagain et al. 
2011) (Figure 2.6). The volume of the peak when a particle of a certain size elutes from the column 
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Figure 2.6 Principles of size exclusion chromatography. A. Magnified diagram of a media bead 
and its pores. B. Illustration of selective pore entry based on sample particle size. C. SEC run: 1) 
sample application; 2) small molecules (yellow) travel slower through the column while large 
molecules (red) travel faster; 3) large molecules are eluted earlier from the colum. D. SEC 
chromatogram. Vo is void volume, Ve is elution volume, and Vt is total liquid volume (Adapted from 
GE-Healthcare (2010b).  
 
 
42 
 
is called retention volume, or elution volume. Besides particle size, elution volume is also dependent 
on the hydrodynamic diameter of the particles. Particles of asymmetrical shapes, such as fibrous 
proteins, travel faster than globular particles of the same molecular weight, appearing as if they have 
a larger particle size (Hagel 2011; Hagel and Janson 1992; O'Fagain et al. 2011). The size of the pores 
and the beads in the matrix depends on the composition of the media, and media with different particle 
size separation range are available commercially. Examples of commercially available media include: 
1) Superdex, composed of dextran and agarose, with 0.1 -102 kDa separation range; 2) Superose, 
composed of highly cross-linked porous agarose particles, with a  
1 - 103 kDa separation range; and 3) Sephacyrl, composed of covalently cross-linking allyl dextran 
with N,N’-methylene bisacrylamide, with a 1-105 kDa separation range. Each of these media are 
divided into types with a narrower separation range, for example, Sephacryl S100 HR has a 1-102 
kDa separation range while Sephacryl S500 HR has a 10-105 kDa separation range (GE Healthcare 
Lifesciences). SEC has several applications such as high-resolution protein or peptide fractionation, 
desalting, solvent removal, removal of inhibitors from enzymes, separation of cells and virus 
particles, molecular mass estimation, and removal of byproducts of chemical reactions such as 
PEGylation (GE-Healthcare 2010b; O'Fagain et al. 2011). A good media should have a reasonable 
pore volume to provide maximum separating volume, and a reasonable particle diameter to give 
optimum column efficiency (Hagel and Janson 1992). 
2.4.2 Column efficiency and influencing factors 
A good SEC separation is marked by a good resolution, which is the degree of separation between 
peaks in an elution profile chromatogram. Resolution is a function of selectivity and column 
efficiency. Selectivity relates to separation range of the pore sizes of the media beads discussed in the 
previous subsection. Column efficiency is the efficiency of the column to produce narrow peaks and 
to reduce zone broadening (GE-Healthcare 2010b; Hagel 2011). Column efficiency can be measured 
by determining the number of theoretical plates, height equivalent of a theoretical plate, reduced plate 
height, and asymmetry. The value of the number of theoretical plates, height equivalent of a 
theoretical plate, and reduced plate height are derived from relative peak width, while asymmetry is 
a measurement of deviation from ideal Gaussian peak shape (GE-Healthcare 2010a; GE-Healthcare 
2010b; Hagel 2011).  
A theoretical plate is a theoretical zone required for the mobile phase and the stationary phase to reach 
an equilibrium with each other (Braithwaite and Smith 1999; Hamilton and Sewell 1982). The number 
of theoretical plates is conversely related to elution volume, but inversely related to peak width at 
half peak height which correlates to zone broadening (Figure 2.7). The higher the number of  
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Figure 2.7 Zone broadening variables. Wh is peak width at half peak height. a is forward peak 
and b is rear peak length at 10% peak height. Ve is elution volume of the particle (Adapted from 
Hagel (2011)).  
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theoretical plates, the less the zone broadening, the better the column efficiency. This relationship is 
formulated in the following equation: 
ܰ ൌ 5.54	 ൬ ܸܹ݄݁൰
ଶ
ܧݍݑܽݐ݅݋݊	2.1 
where N is the number of theoretical plates, Ve is the elution volume, and Wh is peak width at half 
peak height.  
The theoretical plate can also be translated into its height, defined as height equivalent of a theoretical 
plate. Shorter plate height reflects better column efficiency (Braithwaite and Smith 1999; Hamilton 
and Sewell 1982). The height equivalent of a theoretical plate can be derived by dividing the length 
of the column with the calculated N of the column, formulated in the following equation: 
ܪܧܶܲ ൌ ܮܰ 	 ܧݍݑܽݐ݅݋݊	2.2 
where HETP is height equivalent of a theoretical plate and L is the length of the column.  
Further, the HETP can be translated into reduced plate height that denotes the number of vertical 
media beads within a theoretical zone by dividing HETP with the bead diameter. An excellent column 
efficiency would have a reduced plate height <3 (Hamilton and Sewell 1982), formulated in the 
following equation: 
݄ ൌ ܪܧܶܲ݀݌ ܧݍݑܽݐ݅݋݊	2.3 
where h is reduced plate height, and dp is bead diameter. 
Zone broadening and column efficiency may also be measured by calculating the asymmetry of the 
peak. Ideal solute distribution through the column should follow a Gaussian distribution, and 
deviation is visible as peak tailing. Peak tailing may indicate low column efficiency or solute 
interaction with the media (Braithwaite and Smith 1999). Asymmetry is the ratio between the rear 
peak part  and the forward peak part  at 10% peak height, both measurable as volume or time (Figure 
2.7). Good asymmetry may fall between 0.8-1.3 depending on the media, and formulated with the 
following equation: 
ܣݏ ൌ ܾܽ 	 ܧݍݑܽݐ݅݋݊	2.4 
where As is asymmetry, b is rear peak part width at 10% peak height, and a is forward peak part width 
at 10% peak height. 
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Total diffusion time and total diffusion distance influence column efficiency. Flow rate, column 
length, and solute viscosity affect total diffusion time while particle size and pore size distribution 
affect total diffusion distance (Hagel and Janson 1992). In addition, mixing chambers and external 
dead volumes in connectors, adaptors, and other parts may contribute to zone broadening and reduce 
column efficiency (Hagel 2011). Sample volume may also cause zone broadening, and a sample 
volume of 1-2% of total column volume is usually recommended (Hagel 2011).  
The information available in the literature as described in this main section would be helpful in the 
development of an SEC method to analyse and characterise modified VLPs developed in my research. 
The information will aid in media selection and overall evaluation of column performance and 
efficiency, which is required to confirm the validity of the column to analyse and characterise 
modified VLPs. The variables described in Section 2.4 will only be used in the context of semi-
preparative SEC column efficiency testing in this thesis. 
 
. 
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3 Insert engineering and solubility 
screening improves recovery of virus-like 
particle subunits displaying hydrophobic 
epitopes 
 
The entire Chapter 3 consists of the journal article submitted as: 
Abidin RS, Lua LH, Middelberg AP, Sainsbury F. 2015. Insert engineering and solubility screening 
improves recovery of virus-like particle subunits displaying hydrophobic epitopes. Protein Science 
24(11):1820-8. 
The following modifications were made to the original submitted article: 
- Page numbers of the original submitted article were changed into the numbers consistent with 
those on the remainder of the thesis page numbers. 
- Figure numbers were changed into the numbers consistent with those on the remainder of 
figure in the thesis. 
- Section and sub-section numbers were changed into the numbers consistent with those on the 
remainder of sections and sub-section numbers in all chapters of the thesis. 
- The reference style of the original submitted article was changed into the style consistently 
used in all chapters of the thesis. 
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3.1 Abstract 
The Polyomavirus coat protein, VP1 has been developed as an epitope presentation system able to 
provoke humoral immunity against a variety of pathogens such as Influenza and GAS. The ability of 
the system to carry Tc-epitopes on a surface-exposed loop and the impact on protein solubility has 
not been examined. Four variations of three selected epitopes were cloned into surface-exposed loops 
of VP1, and expressed in E. coli. VP1 pentamers, also known as capsomeres, were purified via a 
GST-tag. SEC indicated severe aggregation of the recombinant VP1 during enzymatic tag removal 
resulting from the introduction of the hydrophobic epitopes. Inserts were modified to possess double 
aspartic acid residues at each end of the hydrophobic epitopes and a high-throughput buffer condition 
screen was implemented with protein aggregation monitored during tag removal by 
spectrophotometry and dynamic light scattering (DLS). These analyses showed that the insertion of 
charged residues at the extremities of epitopes could improve solubility of capsomeres and revealed 
multiple windows of opportunity for further condition optimisation. A combination of epitope design, 
pH optimisation and the additive L-Arg permitted the recovery of soluble VP1 pentamers presenting 
hydrophobic epitopes and their subsequent assembly into virus-like particles. 
Keywords: aggregation, cytotoxic T cell epitope, high-throughput screening, hydrophobicity, 
hydrophobic epitopes, protein aggregation, protein engineering, virus-like particles. 
 
3.2 Introduction 
The coat protein subunits (VP1) of MPyV form a pentameric structure, called a capsomere. Purified 
capsomeres self-assemble to VLPs under defined conditions (Chuan et al. 2010; Garcea et al. 1987; 
Salunke et al. 1986)  and both capsomeres and VLPs have been developed into vaccine platforms 
(Middelberg et al. 2011; Wibowo et al. 2013). For example, MPyV VLPs presenting a helical epitope 
from influenza hemagglutinin via genetic insertion into surface-exposed loops of VP1 elicited a 
strong antibody response (Anggraeni et al. 2013). The capsomere platform allows for the presentation 
of antigens at the VP1 termini as well as internal loops and multiple influenza M2e epitopes presented 
in this way are able to stimulate protective humoral immunity in mice (Wibowo et al. 2013). As 
capsomeres can be produced in bacterial cultures, both platforms have the potential to reduce vaccine 
production cost in comparison to that of conventional vaccines (Chuan et al. 2014).  
In addition to stimulating humoral responses, MPyV VLPs are known to stimulate strong cellular 
immune responses (Caparros-Wanderley et al. 2004). MPyV VLPs have great potential as a delivery 
system for Tc-epitopes because they enter the cytoplasm during infection, thus escaping the 
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endosome (Sapp and Day 2009) and this ability has been observed using isolated dendritic cells in 
vitro (Boura et al. 2005). Processing by the immune-proteasome leads to MHC Class I presentation 
of epitopes and a cellular immune response (Schirmbeck et al. 1995). Furthermore, MPyV VLPs are 
able to activate dendritic cells (Boura et al. 2005) leading to antigen specific T cell proliferation and 
likely immune-proteasome processing (Fric et al. 2008). Therefore, MPyV VLPs displaying Tc-
epitopes could provide effective vaccines for the stimulation of cellular immune responses that are 
both relatively cheap and quick to manufacture.   
However, selection bias for MHC Class I presentation dictates that Tc-epitopes are commonly 
hydrophobic (Mitic et al. 2014). Aggregation is a limiting factor in every step of protein bioprocessing 
(Cromwell et al. 2006) and a major role of hydrophobicity in protein aggregation has been 
demonstrated in recent studies (Chong and Ham 2014a; Chong and Ham 2014b). The stability of a 
protein in aqueous solution is heavily dependent on the solvent environment and unfavourable 
interactions between the solvent environment and protein surfaces can de-stabilise colloidal and 
conformational stability (Chi et al. 2003). Protein colloidal stability is influenced by intermolecular 
protein-protein interaction, which depends on overall electrostatic and hydrophobicity of the protein 
(Chi et al. 2003; Chong and Ham 2014b)(15; 17). Conformational stability can be lost by unfolding, 
leading to intermediate and fully denatured species. Partial unfolding, either by natural or chemical 
denaturation, or by incomplete folding, usually exposes the hydrophobic region of the protein and 
thus increases attractive intermolecular interactions and initiates aggregation (Wang et al. 2010b). 
Insertion of hydrophobic entities into surface-exposed loop of a protein may emulate this, also leading 
to aggregation, due to artificial hydrophobic interactions not seen in the native protein. A promising 
strategy to counter this effect is to co-engineer charged amino acid residues alongside the inserted 
hydrophobic entities (Perchiacca et al. 2012). 
Our current research further examines the ability of MPyV VLPs to carry Tc-epitopes to potentially 
elicit cellular immune responses against influenza. To this end, we designed four variants of MPyV 
VP1 with single or multiple Tc influenza epitopes, with or without charged amino acid inserts, 
inserted into a surface-exposed loop. Severe aggregation in the standard buffer condition chosen for 
unmodified VP1 was observed upon enzymatic removal of the affinity purification tag. To help 
overcome this aggregation a buffer condition screen comprising six different additives across five 
different pH values was implemented and analysed by different methods. Our results showed that 
such high-throughput buffer screening for solubility identified windows of opportunity to improve 
capsomere recovery. Furthermore, in the presence of additives, insert engineering made a significant 
difference to modified capsomere solubility, resulting in improved recovery and permitting the 
assembly of VLP-like structures.  
49 
 
3.3 Results 
3.3.1 MPyV VP1 displaying Influenza cytotoxic T cell epitopes  
Four insertions were designed from three Tc-epitopes (Table 3.1), which were inserted into the HI 
loop of MPyV VP1 (Middelberg et al. 2011). For each of the four constructs the spacer amino acid K 
was added at the C-terminus of the epitopes for better cellular processing (Livingston et al. 2001). 
IT1 was inserted alone and a longer insert possessing all three epitopes was created (IT123). 
Additional designs for both the IT1 and triple epitopes were generated using double Aspartic acid 
(DD) inserts at the N- and C-terminus of IT1 (DDIT1) and at the N-terminus of each epitope in IT123 
(DDIT123).  The resulting constructs encoded glutathione S-transferase (GST)-VP1 fusion proteins 
linked by thrombin cleavage sites (Figure 3.1). 
3.3.2 Aggregation of modified VP1 during affinity tag removal  
Wild type VP1 and the modified variant IT1 were expressed in E. coli, purified by GST affinity 
chromatography and treated with thrombin for two hours to remove the GST tag. SEC of the digestion 
reaction showed that in contrast to wtVP1, no soluble capsomere could be detected for IT1 using 
standard buffer conditions, previously optimised for unmodified VP1 (Figure 3.2). Moreover, the 
apparent reduction in absorbance at A280 nm indicates that a significant portion of IT1 is lost as 
insoluble aggregates following centrifugal clarification prior to SEC. Spectrophotometric monitoring 
of the enzymatic digest showed that there was an increase in aggregates as the GST tag was released 
from IT1 (Figure 3.3). Initial values suggested that even before the tag removal there was a difference 
in the aggregation status of IT1 compared to wtVP1 capsomere. After an initial period of slight 
decrease, the Aggregation Index (AI) of the IT1 reaction increased steadily from 20 minutes 
indicating the formation of IT1 aggregates as the GST tag is removed. In contrast, wtVP1 also showed 
a slight decrease in AI during the early stages of the reaction, but this was not followed by an increase 
in AI, indicating no induction of aggregation. No change in solubility for both wtVP1 and IT1 was 
observed in the absence of thrombin (data not shown). Therefore, in these reaction conditions, 
optimised for wtVP1 capsomeres (Chuan et al. 2008b; Lipin et al. 2008b), IT1 tended to aggregate as 
the proportion of tag-free capsomere accumulated.   
3.3.3 High-throughput buffer screen 
A 40 buffer condition library was developed on 96 well plates by varying pH and additives during 
enzymatic GST removal. The additives used comprised detergents (Leibly et al. 2012), charged amino 
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Table 3.1 Influenza T cell epitopes used in this study. 
Epitope1 Name Protein Origin References 
GILGFVFTL IT1 Matrix 1 (Alexander et al. 2010) 
LLTEVETYV IT2 Matrix 1 (Adar et al. 2009) 
RLIQNSLTI IT3 Nucleoprotein (Ishizuka et al. 2009) 
1 The Tc-epitopes are presented by HLA A*0201. 
 
 
 
Figure 3.1 Schematic representation of designed and cloned MPyV VP1 constructs. 
Cytotoxic Tc-epitopes IT1, IT2, and IT3 were inserted into GST-tagged VP1 in 4 different 
configurations. K, lysine spacer; DD, double aspartic acid insert. The arrow indicates the location of 
the thrombin cleavage site.  
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Figure 3.2 Modified capsomere aggregation during GST removal. Following enzymatic tag 
removal wtVP1 can be separated by SEC into an aggregate peak, soluble capsomere peak and GST 
peak. The small peak eluting as a shoulder to the capsomere peak has been previously identified as a 
chaperone-VP1 complex (Liew et al. 2010). Tag removal from IT1 VP1, containing a hydrophobic 
epitope, results in only free GST and aggregated IT1 VP1. 
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Figure 3.3 Spectrophotometric analysis of the GST removal reaction. (A) SDS-PAGE 
analysis of wtVP1 digestion reaction with samples taken during the reaction. The position of the GST 
fusion protein and thrombin digestion products, VP1 and GST, are shown. (B) Change in the 
aggregation index of wtVP1 and IT1 VP1 digestion mixtures over the course of the reaction.  
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acids (Ho et al. 2003; Leibly et al. 2012; Tsumoto et al. 2004), osmolytes  (Leibly et al. 2012), and 
molecular chaperones (Lanckriet and Middelberg 2004; Prashar et al. 2011; Serno et al. 2011) as 
detailed in Table 3.2. Thrombin activity in the different buffer conditions was assessed and confirmed 
that complete digestion of the GST-VP1 fusion was achieved between pH 7.0 and pH 9.0, irrespective 
of the additive present. Below pH 7.0, there was reduced digestion efficiency in the presence of some 
additives and, therefore, we chose to proceed with pH values at or above neutral.   
The AI measurement proved to be a good means by which to detect aggregation in a buffer screening 
system. As samples showed considerable differences in their starting values, we compared conditions 
by calculating the difference in these values between the start and end of the thrombin digest. Plotted 
as heat maps, this parameter showed some differences in the aggregation status of wtVP1 across the 
buffer conditions tested (Figure 3.4). In general, VP1 capsomeres were more stable above neutral pH 
and additives had mixed effects on solubility. In order to compare the relative changes in AI to an 
absolute parameter in the measurement of aggregation status that would enable comparison between 
constructs and not just between conditions, we turned to DLS. Plotting a heat map of the endpoint Z-
average size revealed a similar distribution of aggregation status as those observed by 
spectrophotometric measurement (Figure 3.4). Thus, taken together, Z-average size and ΔAI can 
provide complementary parameters that can be measured in a high-throughput mode to assess the 
solubility of MPyV capsomeres in various buffer conditions.     
The high-throughput screen was then applied to the four modified capsomere constructs and heat 
maps were used to assess the impact of buffer conditions for each construct. The screening showed 
that optimal conditions varied considerably for each construct and that complementarity was again 
observed between the assessment parameters (Supplementary Figure 3.2). As was observed for 
wtVP1, alkaline conditions (pH 8.5 to 9.0) were better for solubility of the modified constructs. The 
Z-average size was then used to normalise the heat maps across constructs (Figure 3.5) to determine 
the effect of construct design on capsomere solubility. This analysis showed that the inclusion of 
charged residues (DD) could, to some extent, overcome the hydrophobicity of the IT1 epitope, 
resulting in a solubility profile similar to wtVP1. This was not the case for the larger, though less 
hydrophobic IT123 epitope. This result could also be confirmed by normalising final AI 
measurements across the constructs (Supplementary Figure 3.3). However, the resolution of this 
parameter does not appear to be as good as Z-average size, which may be explained by the fact that 
the coefficient of variation across all constructs and conditions is 1.7 times higher for the final AI 
than for Z-average measurements. 
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Table 3.2 Additives used in buffer screening. 
Class Additive Conc. References 
 
Detergent 
 
CHAPS 
 
10 mM 
 
(Leibly et al. 2012) 
  Triton X-100 0.05% (v/v) (Leibly et al. 2012) 
 
Amino acid 
 
L-Arginine 
 
50 mM 
(Ho et al. 2003; 
Tsumoto et al. 2004) 
 
Osmolyte 
 
Trehalose 
 
150 mM 
 
(Leibly et al. 2012) 
  Sorbitol 200 mM (Leibly et al. 2012) 
 
Molecular chaperone 
 
α-cyclodextrin 
 
10 mM 
(Lanckriet and 
Middelberg 2004; 
Prashar et al. 2011; 
Serno et al. 2011) 
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Figure 3.4 Validation of buffer screening with wtVP1. Analysed with two parameters, Z-
average size (DLS) and the change in aggregation index (ΔAI), heat maps representing aggregation 
status give a snapshot of 40 buffer conditions employing various additives across a range of pH values 
as indicated in 0.5 pH unit increments.  
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Figure 3.5 Heat maps identifying optimal buffer conditions for the processing of modified 
capsomeres. Z-average size was normalised across all constructs to allow the comparison of 
constructs as well as the identification of optimised buffer conditions. 
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3.3.4 SEC using selected buffer conditions for capsomere recovery 
Several buffer conditions were analysed further with high-resolution SEC to determine whether they 
enable IT1 or DDIT1 capsomere recovery. Confirming the results of the screen, high resolution SEC 
on scaled down reaction volumes showed that promising conditions such as including the additives 
L-Arg and CHAPS at pH 8.5 could help in the recovery of DDIT1, whereas little to no soluble 
capsomere could be obtained from IT1 (Supplementary Figure 3.4). The most promising condition, 
50 mM L-Arg at pH 8.5 showed a major peak for DDIT1 between the aggregate and the GST peaks 
(Figure 3.6A) and SEC on this peak was scaled up as per the materials and methods section. The 
appearance of this peak indicated reduced aggregation and enabled recovery of soluble capsomeres. 
However, the capsomere peak was shifted to the right in comparison to wt capsomeres (Figure 3.2). 
This shift may be due to interaction of the charged amino acid inserts with the stationary phase or 
may be an indication of dissociation of the capsomeres into VP1 dimers. Sodium dedocylsulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) analysis (Figure 3.6B) showed that the peak 
consisted of isolated DDIT1 and to test this the fraction was examined by transmission electron 
microscopy (TEM), which showed the presence of pentameric capsomeres (Figure 3.6C). Given the 
purity of the capsomere peak, it is likely that the majority of species visible by TEM are capsomeres 
in varying orientations, with some in the ideal orientation for identification (arrowheads in Figure 
3.6C). However, some species may be capsomeres that are distorted or degraded by TEM grid 
preparation. Attempts to assemble the recovered DDIT1 capsomere in the standard assembly buffer, 
optimised for wtVP1, resulted in complete precipitation and loss of the protein. However, in the 
presence of L-Arg some spherical particles could be observed under TEM, indicating the formation 
of VLP-like structure (Figure 3.6D). These results show that the high-throughput solubility screen 
can successfully identify conditions for the recovery of MPyV capsomeres modified to present 
hydrophobic epitopes and initial assembly trials also indicated that these capsomeres are assembly 
competent.  
 
3.4 Discussion 
VLPs offer an interesting platform for Tc-epitope presentation because they can act as adjuvants by 
presenting PAMP and thus may initiate co-stimulatory signal required for Tc expansion (Murphy et 
al. 2008; Raghunandan 2011). In addition, VLPs present a manufacturing advantage over traditional 
live-attenuated or killed vaccines through the use of recombinant expression technologies that can 
significantly reduce cost (Chuan et al. 2014). In addition, they do not contain nucleic acid, thus 
reducing the risk of contamination with infectious agents (Josefsberg and Buckland 2012). Here we  
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Figure 3.6 Isolation of modified capsomere, DDIT1 using optimised buffer conditions. (A) 
SEC showed a capsomere peak (b) for DDIT1 following GST removal in the presence of 50 mM L-
Arginine, distinct from an aggregation peak (a) and GST peak (c). (B) SDS-PAGE gel analysis of 
SEC fractions, the products of thrombin digest and size of molecular weight standards are shown. 
Lanes are numbered by the corresponding SEC fraction volume (mL); M, molecular weight 
standards; a, b, and c correspond to peak fractions as indicated on the chromatogram (A). (C) The 
DDIT1 capsomere fraction was analysed by TEM showing the presence of capsomeres (black 
arrowheads point to examples). (D) The DDIT1 capsomere fraction was assembled in the presence 
of 50 mM L-Arginine and spherical entities resembling VLPs were observed.  
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have shown that capsomeres, the building block of MPyV VLPs, can accommodate hydrophobic Tc-
epitopes. We devised a high-throughput screen to identify buffer conditions for their soluble recovery 
and show that such modified capsomeres are assembly competent.  
Examination of the thrombin digest to remove GST tag from the IT1 construct indicated a slight 
increase in solubility during the initial stage of GST removal, followed by steadily increasing 
aggregation as the reaction progressed. There was also a slight reduction in the aggregation of wtVP1 
as GST was removed, which continues until 60 minutes into the reaction, after which the aggregation 
status stabilised. Increased protein concentration correlates proportionally to aggregation (Treuheit et 
al. 2002), as increased concentration reduces proximity of proteins in solution enhancing their 
interaction. In our system initial aggregation of affinity-purified capsomeres appears to involve the 
GST-tag itself, which can occasionally induce aggregation, often when fusion partners possess 
hydrophobic regions (Terpe 2003).  
IT1 is a well characterised Tc-epitope corresponding to amino acids 58-66 of the influenza M1 protein 
and its hydrophobicity stems from its localisation, buried within the globular M1 protein. The use of 
charged residue inserts, such as double aspartic acid, have been shown to help overcome aggregation 
due to hydrophobicity in vaccine protein engineering (Anggraeni 2014) and, indeed, we observed a 
considerable effect of the charged inserts in increasing the solubility of MPyV capsomeres displaying 
IT1. However, the addition of DD residues alone was not able to overcome this problem in standard 
buffer conditions. 
Optimisation of the buffer condition was attempted by adding a number of additives shown to prevent 
aggregation in previous studies. Buffer conditions were screened in a high-throughput manner and 
multiparametric analysis was used to assess the solubility of capsomeres as they were released from 
GST. The parameters used to assess solubility were validated with wtVP1 whose capsomere recovery 
pattern has been empirically established. The AI has been used to detect the formation of aggregates 
with respect to the total protein content (Esfandiary and Middaugh 2012), while the Z-average size 
measured by DLS has recently been shown to be inversely related to capsomere formation (Tekewe 
et al. 2015). When the buffer screen was applied to the four modified VP1 constructs, heat maps of 
the two parameters were in general agreement with each other and suggested that higher pH was more 
preferable for capsomere recovery. Differences between the two parameters for certain buffer 
conditions likely reflect the fact that AI detects both soluble and insoluble aggregates, whereas DLS 
measurements are made only after sample clarification. Therefore, the use of AI can provide a 
valuable check on the interpretation of favourable DLS results in cases where there are discrepancies 
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between the two. The detection of insoluble aggregates also explains the higher co-efficient of 
variation across the AI measurements compared to DLS measurements. 
The suitability of pH 9.0 for IT1 and IT123 and pH 8.5 for DDIT1 may be related to their iso-electric 
points (6.6, 7.1 and 5.6 respectively), as buffer conditions further away from the iso-electric point 
enhances protein solubility (Cohn 1920). However, a higher pH than 9.0 was not feasible for 
downstream processing due to chromatography media incompatibility. Among the additives tested in 
this study, the detergents CHAPS and triton X-100 as well as the positively charged amino acid L-
Arg, consistently enhanced the solubility of modified capsomeres. Non-ionic detergents have been 
shown to promote solubility of modified capsomeres (Tekewe et al. 2015), however, they can be 
difficult to remove completely. The commonly used zwitterionic detergent CHAPS is a relatively 
expensive additive although it proved to be very promising in the present study.  
Overall, the high-throughput screen successfully identified windows opportunity for the further 
processing of MPyV capsomeres as discussed below. The screen was able to provide information on 
the effect of construct design on capsomere solubility as well as the selection of buffer conditions 
suitable to prevent aggregation of modified capsomeres. Of the 400 data points from 200 reactions 
monitored, four DLS measurements failed and one of these corresponded to a failed 
spectrophotometric measurement. Therefore, due to the multiparametric analysis, no data was 
obtained for just one of the 200 samples, an error rate of 0.5%. The results of the screen were 
confirmed by the high resolution, low-throughput SEC, which showed that the use of L-Arg, and to 
some extent CHAPS, at pH 8.5 could be used to obtain soluble DDIT1 capsomeres. 
L-Arg is a promising additive for preparative processes because it is relatively inexpensive and easier 
to remove from the solution compared to other effective additives such as the detergents used in this 
study and is also safe for human use (Polycarpou et al. 2013; Yeo et al. 2013). L-Arg is known to be 
able to prevent aggregation caused by hydrophobic interactions (Tsumoto et al. 2004), by masking 
hydrophobic regions and reducing attractive intermolecular interactions (Ho et al. 2003). In silico 
modelling has shown that the guanidium group of L-Arg interacts with hydrophobic patches of 
protein while the polar carboxyl part of L-Arg forms a hydrophilic layer (Li et al. 2010). The 
combination of this surfactant-like behaviour and self-interactions leading to clusters of L-Arg around 
hydrophobic protein domains can provide colloidal stability to protein solutions. Maintaining the 
presence of L-Arg was also required to prevent aggregation and precipitation of DDIT1 capsomeres 
during in vitro assembly.  
Here we have developed an engineering approach and solubility screen to enable the recovery of 
recombinant VLP subunits carrying hydrophobic Tc-epitopes. Using a combination of light scattering 
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and spectrophotometry in a high-throughput manner, we were able to identify optimal buffer 
conditions for the processing of wt and modified MPyV capsomeres. In addition, we show that 
flanking charged amino acids could mitigate the negative impact on capsomere solubility imparted 
by some epitope inserts. Conditions identified by the screen could be confirmed to improve 
capsomere isolation for VP1 presenting engineered epitopes by SEC and electron microscopy showed 
that capsomeres were indeed purified and that they could be assembled into VLP structures. The 
colloidal stability of VLPs displaying hydrophobic epitopes is the subject of ongoing work and it will 
be interesting to compare the ability of L-Arg and CHAPS to permit effective assembly and maintain 
solubility of VLPs. We are also exploring the possibility of mixing modified and wt capsomeres to 
reduce the negative influence of hydrophobic inserts, although this must be balanced with the 
resulting reduced valency of the epitope. In future work we intend to test MPyV VLPs displaying Tc-
epitopes for their immunogenicity and their ability to stimulate cellular immunity. If this is successful, 
it will offer the possibility of developing this platform for other disease models that require cellular 
immunity for protection or for therapeutic vaccines against chronic diseases such as cancer. The work 
presented here provides a valuable approach in the development of processes to manufacture such 
vaccine candidates and those of other epitope presentation systems.  
 
3.5 Materials and Methods 
3.5.1 Insertion of cytotoxic T cell epitopes into MPyV VP1 
The coding sequence for MPyV VP1 (M34958) in pGEX-4T1 was generously provided by Professor 
Robert Garcea (University of Colorado, Colorado, USA) and Tc-epitopes were inserted into a surface-
exposed loop of VP1. Four constructs, containing either single (IT1) or multiple Tc-epitopes (IT1, 
IT2, IT3; See Table 3.1 for epitope sequences), with or without double aspartic acid inserts were 
generated by in vitro gene assembly and in vivo homologous recombination. See supplementary 
information for oligonucleotide sequences and detailed methods. The resulting constructs (Figure 
3.1) encoding the VP1 variants IT1, DDIT1, IT123 and DDIT123 fused to GST at the N-terminus 
were all confirmed by Sanger sequencing. 
3.5.2 Expression and Purification of MPyV VP1 capsomeres 
Plasmid of constructs were transformed into competent E. coli Rosetta (DE3) pLysS cells (Novagen, 
www.merckmillipore.com), and expressed as previously described (Chuan et al. 2008a) with slight 
modification. Briefly, following cell lysis and clarification, GST-tagged protein was purified with 
affinity chromatography, the GST tag removed with thrombin (GE Healthcare, 
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www.gehealthcare.com), followed by further purification of the cleaved product with y SEC to 
recover purified capsomeres (Chuan et al. 2008a; Lipin et al. 2008b). Running buffer for affinity 
chromatography (L-buffer) was composed of 200 mM NaCl, 40 mM Tris base, 1 mM EDTA 
disodium, 5% Glycerol, and 5 mM DTT at pH 8. Running buffer for SEC was either L-buffer, or 
buffer specific to the condition screened for digestion reaction. Standard SDS-PAGE was performed 
to analyse the quality of the protein. 
3.5.3 Buffer Condition Screening  
Concentration of GST-tagged protein fractions of each construct were measured with Bradford 
reagent (Thermoscientific, www.thermofisher.com), and adjusted to 4 mg/ml. This was then mixed 
with buffer solution in 1:1 ratio to a final protein concentration of 2 mg/ml, to which thrombin was 
added at a ratio of 1:25. Base components of the reaction buffer were 70 mM Tris-base, 150 mM 
NaCl, 0.6 mM EDTA, 5% Glycerol (v/v), and 5 mM DTT. In addition, the buffer solution also 
contained additives as listed in Table 3.2 and the pH of the buffer solutions were adjusted to give a 
range of final pH values from 7.0 to 9.0 in 0.5 pH unit increments such that each additive was tested 
at each pH. In addition, a control with no additive and a single combination of additives (L-Arg and 
CHAPS) were included resulting in 40 conditions. Buffer screening during the thrombin digest was 
carried out on UV-transparent 96-well plates (Corning, www.corning.com) in 100 µL reaction 
volume. 
3.5.4 Absorbance and turbidity 
To assess aggregation during GST tag removal, absorbance at 280 nm and turbidity at 350 nm were 
measured every 20 minutes over 2 h with 5 sec of shaking before each measurement using an 
Infinite200 Pro Plate Reader (Tecan, www.tecan.com). For solubility screening, absorbance and 
turbidity measurements were taken before and after the 2 h digest. These measurements were then 
translated into initial and final AI according to the following formula (Esfandiary and Middaugh 
2012): 
ܣܫ ൌ 100ݔ ൤ ܣ350ܣ280 െ ܣ350൨ ܧݍݑܽݐ݅݋݊	3.1 
3.5.5 Dynamic Light Scattering (DLS) 
Samples were clarified by centrifugation at 5000 g for 5 min and 25 μL was transferred in duplicate 
to 384-well polystyrene plates (Corning, www.corning.com). Scheduled analysis was performed 
using a DynaPro Plate Reader (Wyatt Technologies, www.wyatt.com) and DLS results were analysed 
with Dynamics software (Wyatt Technologies, www.wyatt.com). DLS was validated by measuring 
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mixtures of capsomeres and aggregates in different ratios to reflect possible particle distribution and 
concentration after cleavage. Using Z-average size, the primary statistic given by cumulants analysis, 
an inverse correlation was shown with increasing percentage of capsomeres (Tekewe et al. 2015). 
3.5.6 Size exclusion chromatography 
SEC was performed to detect and recover capsomeres after enzymatic GST tag removal. Digestion 
was carried out with selected buffer conditions in a total of 1 ml. SEC was performed on the reaction 
using a Superdex 200 10/300 GL column (GE Healthcare, www.gehealthcare.com) on an AKTA® 
Explorer 100 system (GE Healthcare, www.gehealthcare.com). The running buffer was matched to 
the digestion reaction and run at 0.5 ml/min. Where fractions were collected, the designated aggregate 
peak was collected in 1 ml fractions, putative capsomere peak and the GST peak were collected in 
250 μl fractions.   
3.5.7 In vitro VLP Assembly 
Modified DD IT1 capsomere recovered via SEC in buffer containing 50 mM L-Arginine (L-Arg) 
(>98%, Sigma-Aldrich, www.sigmaaldrich.com) at pH 8.5 was assembled by dialysis in standard 
assembly buffer containing 0.5 M (NH4)2SO4, 20 mM Tris-base, 5% glycerol (v/v), 1 mM CaCl2 at 
pH 7.4, with or without L-Arg at 50 mM. 
3.5.8 Electron Microscopy 
Samples were placed on 200-mesh carbon-coated copper grids and left to settle for 90 seconds. 
Following two washes in water, grids were negative stained with 2% Uranyl acetate for 60 seconds. 
TEM was carried out on a JEOL 1010 at 80 kV and images were cropped and adjusted for brightness 
using Adobe Photoshop (CS6; www.adobe.com).  
 
3.6 Supplementary Material 
The supplementary material contains Supplementary Figure 3.1 (SuppFigure1.pdf) showing the 
activity of thrombin in all buffer conditions, Supplementary Figure 3.2 (SuppFigure2.pdf) showing 
the aggregation status for the four different constructs, Supplementary Figure 3.3 
(SuppFigure3.pdf) showing the normalized final AI, and Supplementary Figure 3.4 
(SuppFigure4.pdf) showing high resolution SEC assessment of buffer screen hits for IT1 and DDIT1. 
In addition, there is also a Supplementary Methods Section (SuppMethods.pdf) detailing the 
cloning approach and containing a table of the oligonucleotides used. 
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Supplementary methods: Assembly and cloning of epitopes into MPyV VP1 
Four constructs containing either single (IT1) or three Tc-epitopes (IT1, IT2, IT3) together, with or 
without DD linker were inserted into the HI loop of MPyV VP1 by in vivo homologous 
recombination. Epitope sequences were assembled by annealing or polymerase cyclic assembly 
(PCA), optionally followed by amplification by PCR using end primers with the appropriate 
extensions for recombination. Oligonucleotides designed with optimal Escherichia coli codon usage 
(Suppelementary Table 3.1) using DNAWorks (http:// helixweb.nih.gov/dnaworks/).  
The constructs IT1 0010, DD IT1, and IT123 were assembled by annealing complementary 
oligonucleotides encoding the entire sequence and, in the case of IT1 and DD IT1, extensions for 
homologous recombination. Oligonucleotides were mixed at a final concentration of 8 µM each in 
annealing buffer (10 mM Tris pH 7.5, 50 mM NaCl, 1 mM EDTA), incubated at 95°C for 5 minutes, 
at 72°C for 30 minutes, and slowly brought to room temperature at 0.1° sec-1. DD IT123 was 
assembled by PCA, each oligonucleotide was mixed at a final concentration of 0.2 µM and the 
mixture was used as a template for Phusion polymerase (Finnzymes, Thermofisher Scientific, 
www.thermofisher.com) according to the manufacturer’s instructions. IT123 and DD IT123 
assembled by annealing and PCA, respectively, were PCR-amplified using end primers that 
introduced homologous recombination sequences at both ends (Hr primers; Supplementary Table 
3.1). Phusion polymerase was again used according to the manufacturer’s instructions with 1 µl of 
the assembled epitopes as the template. Fragments were gel-purified using Pure-LinkTM Quick Gel 
Extraction Kit (Life Technologies, www.lifetechnologies.com) according to manufacturer’s 
instructions. 
The pGEX-4T1 VP1 S1S4 (Middelberg et al., 2011) was linearized with AfeI (New England Biolabs, 
MA, USA) and treated with Calf intestinal Phosphatase (CIP, Thermofisher Scientific) according to 
manufacturer’s instructions. Epitope fragments were mixed with the linearized expression vector and 
used to transform OmniMAX 2T-1 (Life Technologies, www.lifetechnologies.com) by heat shock. 
Colonies were analysed by colony PCR and positive clones were confirmed by sanger sequencing.  
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Supplementary Table 3.1 Oligonucleotides used in epitope insertion. 
Construct  Method Oligonucleotide sequences 
 
IT1 
 
Annealing  
 
Sense: 
5’tggagagttacaagaagcggcattctgggctttgtgtttaccctgaaagcttatgatgtccat
cac3 
Antisense:’ 
5’gtgatggacatcataagctttcagggtaaacacaaagcccagaatgccgcttcttgtaact
ctcca3’ 
 
 
DD IT1 
 
Annealing 
 
Sense: 
5’tggagagttacaagaagcgatgatggcattctgggctttgtgtttaccctgaaagatgatgc
ttatgatgtccatcac3’ 
Antisense: 
5’gtgatggacatcataagcatcatctttcagggtaaacacaaagcccagaatgccatcatcg
cttcttgtaactctcca3’  
 
 
IT123  
 
Annealing 
and PCR 
 
Sense: 
5’ggcattctgggctttgtgtttaccctgaaactgctgaccgaagtggaaacctatgtgaaacg
tctgattcagaacagcattaccattaaa3’ 
Antisense:  
5’tttaatggtaatgctgttctgaatcagacgtttcacataggtttccacttcggtcagcagtttca
gggtaaacacaaagcccagaatgcc3’ 
Hr Forward: 
5’tggagagttacaagaagcggcattctgggctttgtgtt3’ 
Hr Reverse: 
5’gtgatggacatcataagctttaatggtaatgctgttctgaatc3’ 
 
 
DD IT123  
 
PCA and 
PCR 
 
PCA Forward 1: 
5’gatgatggcattctgggct3’ 
PCA Reverse 1: 
5’ttccacttcggtcagcagatcatctttcagggtaaacacaaagcccagaatgccatcatc3’ 
PCA Forward 2: 
5’tctgctgaccgaagtggaaacctatgtgaaggatgatcgtctgattcagaatagcattac3’ 
PCA Reverse 2: 
5’tttaatggtaatgctattctgaatcagacgat3’ 
Hr Forward: 
5’tggagagttacaagaagcgatgatggcattctgggc3’ 
Hr Reverse: 
5’gtgatggacatcataagctttaatggtaatgctattctgaatc3’ 
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Supplementary Figure 3.1 Confirmation of thrombin activity under the buffer conditions 
used in this study. The digestion reaction was performed on wtVP1 across a range of pH as indicated 
in the absence and presence of each of the additives. ND, non-digested GST-VP1 fusion. 
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Supplementary Figure 3.2 Aggregation status of each construct subject to the buffer screen. 
Colouring for both Z-average size (DLS) and the change in aggregation index (ΔAI) was generated 
for each construct individually. The range of values for each construct is given beside each heat map. 
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Supplementary Figure 3.3 Normalized aggregation index at the end of the tag removal 
reaction. Colouring was normalised across all constructs to allow the comparison of constructs as 
well as the identification of optimised buffer conditions. 
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Supplementary Figure 3.4 Assessment of screen hits by SEC. High-resolution SEC was 
conducted following tag removal reactions in selected buffer conditions for IT1 and DDIT1. 100 µl 
of reaction mixture was injected using an Agilent 1200 HPLC system and Wyatt DAWN EOS 
detector, aside from IT1 in Blank, which was run as described in materials and methods with a 1 ml 
reaction volume. Note that the accumulation of soluble aggregates of IT1 is improved relative to the 
standard pH 8.0 condition shown in Figure 3.2. 
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4 Encapsidation of GFP inside MPyV VLP 
via fusion with VP2C 
 
4.1 Abstract 
Optimised buffer condition and insert engineering enabled recovery of soluble capsomeres displaying 
a single Tc-epitope on the surface-exposed loop of VP1 protein. An alternative approach is needed to 
deliver more epitopes with MPyV VLPs. Here I explored the ability of MPyV VLP to encapsidate a 
foreign protein via fusion with the VP2 C-terminal region using GFP as a model protein. Preliminary 
results showed that truncation in the hydrophobic binding region of VP2C-GFP hinders their binding 
with wtVP1 capsomeres when mixed in vitro. To resolve this problem wtVP1 was co-expressed with 
VP2C-GFP and purified with Immobilised Metal Affinity Chromatography (IMAC) via a 6x 
Histidine (6His) tag at the C-terminus of VP2C-GFP. UV monitoring at A280 nm and A488 nm and 
SDS-PAGE showed successful co-purification of VP2C-GFP and wtVP1, indicating successful in 
vivo complex formation. Bound VP1:VP2C-GFP capsomere complex was separated from free VP2C-
GFP by SEC. The purified VP1:VP2C-GFP capsomere complex was assembly competent as 
demonstrated by AF4 and TEM. I further explored if the amount of encapsidated GFP could be 
controlled, and compared assembly mixtures of 100% wtVP1, 100% VP1:VP2C-GFP, and 50% 
VP1:VP2C-GFP capsomere complexes mixed with 50% wtVP1 capsomeres. Absorbance analysis 
showed that the amount of VP2C-GFP encapsidated at 50% concentration was half of that 
encapsidated at 100% concentration suggesting that encapsidation can be controlled. This approach 
is suitable, therefore, for encapsidating proteins of a foreign pathogen to deliver Tc-epitopes by 
MPyV VLPs.  
 
4.2 Introduction 
Capsomere aggregation due to Tc-epitope presentation at a surface-exposed loop of MPyV VP1 
necessitated the optimisation of buffer conditions (Abidin et al. 2015). Although this approach 
enables recovery of soluble and assembly competent modular capsomeres, Tc-epitope delivery is 
limited to a single epitope, while a Tc-based influenza vaccine conferring broad protection and 
coverage may benefit from multiepitope delivery (Berthoud et al. 2011; Brown and Kelso 2009). 
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Activation of Tc-epitopes is facilitated by parent protein degradation rather than protein 
conformational presentation at the surface (Yewdell et al. 2003). Thus an approach to engineer 
encapsidation of foreign protein inside the MPyV VLP was explored using GFP as a model. 
Encapsidation is achievable by utilising a segment of the C-terminus of VP2 protein. Research  has 
shown that a segment of the C-terminus of VP2 protein can bind to at least three VP1 subunits inside 
a capsomere (VP1 pentamer) cavity via a hydrophobic binding site (Figure 4.1) (Barouch and 
Harrison 1994; Chen et al. 1998). Fusion of GFP protein at the N-terminus of VP2 was attempted to 
encapsidate GFP inside the MPyV VLP. However, this approach resulted in externalisation of the 
GFP (Abbing et al. 2004; Boura et al. 2005; Pleckaityte et al. 2015).On the other hand, fusion at the 
C-terminus of the C-terminal binding fragment of VP2 (VP2C) of SV40 and HPyV allowed 
encapsidation of GFP inside MPyV VLPs (Inoue et al. 2008; Pleckaityte et al. 2015).  
Encapsidation of foreign protein via fusion with C-terminus of MPyV VP2C has not been tested, and 
I aim to apply this to the established MPyV VLP platform with E.coli as expression host at AIBN-
CBE (Chuan et al. 2008b). GFP was used as a model protein to enable monitoring and evaluation. In 
vitro mixing between wtVP1 capsomeres and free VP2C-GFP failed due to truncation in the 
hydrophobic binding region. To resolve this problem, wtVP1 was co-expressed with VP2C-GFP. 
VP2C was varied as 23, 31, and 51 aa fragments for optimisation and VP2C-GFP 31 aa gave the 
highest yield and considerable co-purification with VP1. VP1:VP2C-GFP capsomere complexes 
were assembly competent, and the amount of encapsidated VP2C-eGFP were controllable by co-
assembly with wtVP1 capsomeres in a defined molar ratio. 
 
4.3 Methods 
4.3.1 Cloning of free VP2C-GFP 
The pGEX-4T-1 plasmid was linearised with PCR, excluding the GST sequence, using primers in 
Table 4.1. The forward primer corresponds to the downstream section of the multiple cloning site 
(MCS) and the reverse primer corresponds to LacO gene site of the plasmid, immediately upstream 
of the GST sequence. VP2C-GFP was amplified from a synthetic construct containing the GFP gene 
with an upstream sequence encoding the 50 aa VP2C separated by a double GGGGS linker and a 
downstream 6His-tag. VP2C(50)GFP-6His, and the linearized plasmid were ligated by Gibson 
Assembly and the sequence was confirmed by Sanger sequencing. 
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Figure 4.1 Design of encapsidation within the MPyV VLP via VP2C fusion.  A protein model 
of engineered VP2C fused with GFP, aiming to encapsulate GFP inside MPyV VLP. 3D structure of 
VLP from VIPERdb (PDB 1SID) (A). GFP was fused at the the C-terminus of VP2C (266-302 aa 
segment of VP2) (B). The length variation of VP2C was designed based on literature. 
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Table 4.1  Oligonucleotides used in the cloning of free VP2C-GFP. 
Name Function Oligonucleotide sequence1 
pGEX-empty-F 
Linearise pGEX 
backbone 
5’CTGACGATCTGCCTCGCG3’ 
pGEX-empty-R 
Linearise pGEX 
backbone 
5’GAATACTGTTTCCTGTGTGAAATTG3’ 
VP2C-(pGEX)-F 
Amplify VP2C-
GFP 
5’ttcacacaggaaacagtattcatgAAGTTCTATCAGGCCCAGGTG3’
eGFP-(pGEX)-R 
Amplify VP2C-
GFP 
5’cgcgaggcagatcgtcagTCAGTGATGGTGATGGTGATGC3’ 
1 Upper case letters correspond to sequence the homology to the target sequence and lower case letters 
correspond to extensions with homology to vector. 
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4.3.2 Cloning of VP1:VP2C-GFP co-expression 
Fragments of VP1, the intergenic region of pETDuet-1, and VP2C-GFP-6His (three variations: 23aa, 
31aa, and 50aa) were created by PCR reaction with the primers listed in Table 4.2. These three 
fragments were joined to create the insert fragment via splice overlap extension (SOE).  Plasmid pET-
Duet1 was cut using XhoI and NcoI to remove the entire region from the first ribosome-binding site 
to the T7 terminator. The insert fragment and the linearised plasmid were joined via Gibson 
Assembly, and Sanger sequencing confirmed successful cloning.   
4.3.3 Expression 
Plasmid of wtVP1, free VP2C-GFP, and VP1:VP2C-GFP were transformed into competent E. coli 
Rosetta (DE3) pLysS cells (Novagen, www.merckmillipore.com), and expressed as previously 
described (Chuan et al. 2008a) with slight modifications: 1) free VP2C-GFP was induced with 0.2 
mM IPTG overnight at 20°C a; 2) VP1:VP2C-GFP was induced with 0.5 mM IPTG overnight at 
26°C.  
4.3.4  Affinity chromatography purification 
For VP1:VP2C-GFP and free VP2C-GFP constructs, thawed cell pellets were each resuspended in 
50 ml lysis buffer composed of 20 mM Tris, 500 mM NaCl, 5% glycerol, 1 mM DTT, 20 mM 
imidazole and complete protease inhibitor (PI) (Roche, lifescience.roche.com) at pH 8.0 for 
VP1:VP2C-GFP capsomere complex, or composed of 50 mM Na2HPO4 and 500 mM NaCl at pH 
7.5 for free VP2C-GFP. Resuspended pellets were lysed by sonication and the clarified supernatant 
was recovered. For IMAC purification of VP1:VP2C-GFP capsomere complex, an AKTA Pure (GE 
Healthcare Lifesciences, www.gelifesciences.com) was used to equilibrate a 5mL HisTrap HP (GE 
Healthcare Lifesciences) column with 1 column volume (CV, 5 ml) of MQW, 1 CV equilibrium 
buffer (lysis buffer without PI). 40 ml of clarified supernatant was then passed through the column, 
followed by washing with 6 CVs equilibrium buffer, and elution of bound material with 4 CVs of 
elution buffer (equilibrium buffer with 500 mM imidazole). All chromatography operations were 
conducted at 3 ml/min with the exception of the equilibration step, which was performed at 5 ml/min. 
Solution exiting the column was monitored inline at A280 nm and A480 nm and was collected as 
0.25 ml fractions using a built-in fractionator, once absorbance in the elution region showed elevation. 
Optimum elution peak fractions (as analysed by SDS-PAGE) were dialysed with capsomere 
compatible buffer (L-buffer) composed of 200 mM NaCl, 40 mM Tris base, 1 mM EDTA disodium, 
5% Glycerol, and 5 mM DTT at pH 8 at 4°C for 16 h protected from light. If not immediately dialysed, 
all protein solutions were stored at -80°C. For free VP2C-GFP, IMAC purification was performed as 
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Table 4.2 Oligonucleotides used in the cloning of VP1:VP2C-GFP co-expression vectors. 
Name Amplicon Oligonucleotide sequence1 
VP1-(Duet)-F VP1 5’ttaactttaagaaggagatatacATGGCCCCCAAAAGAAAAAGC3’ 
VP1-(adapter)-R VP1 5’atgcggccgTTAATTTCCAGGAAATACAGTCTTTGT3’ 
adapter-(VP1)-F 
pETDuet 
intergenic 
region 
5’ttcacacaggaaacagtattcatgAAGTTCTATCAGGCCCAGGTG3’
adapter-(VP2C23)-
R 
Intergenic 
region for 23aa 
VP2C 
5’ggtgggacatTGTATATCTCCTTCTTATACTTAACT3’ 
adapter-(VP2C31)-
R 
Intergenic 
region for 23aa 
VP2C 
5’tagaacttcatTGTATATCTCCTTCTTATACTTAACT3’ 
adapter-(VP2C50)-
R 
Intergenic 
region for 23aa 
VP2C 
5’catttcccatTGTATATCTCCTTCTTATACTTAACT3’ 
VP2C23-(adapter)-
F 
23aa VP2C-
GFP-6His 
5’gagatatacaatgTCCCACCAAAGAGTCACTCC3’ 
VP2C31-(adapter)-
F 
31aa VP2C-
GFP-6His 
5’ggagatatacaatgAAGTTCTATCAGGCCCAGGTG3’ 
VP2C50-(adapter)-
F 
50aa VP2C-
GFP-6His 
5’gagatatacaATGGGAAATGGTGGGCCTAC3’ 
GFPhis(Duet)-R 
VP2C-GFP-
6His 
5’gcggtttctttaccagacTCAGTGATGGTGATGGTGATGC3’ 
1 Upper case letters correspond to sequence the homology to the target sequence and lower case letters 
correspond to extensions with homology to vector or flanking inserts. 
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reported elsewhere (Li et al. 2016) with slight modification in lysis buffer (50 mM Na2HPO4, 500 
mM NaCl), equilibrium buffer (lysis buffer + 20 mM imidazole), and elution buffer (lysis buffer + 
500 mM imidazole). 
For wtVP1, purification was performed as previously described (Chuan et al. 2008a; Lipin et al. 
2008b) 
4.3.5 Size exclusion chromatography 
4.3.5.1 Capsomere SEC (S200) 
For VP1:VP2C-GFP, 1 ml of 1-3 mg/ml dialysed fractions were then injected through a Superdex 
200 GL 10/300 column (24 ml bed volume and 14.4 ml internal column volume) (GE Healthcare 
Lifesciences), equilibrated with L-buffer, at 0.5 ml/min. VP1:VP2C capsomere complex eluted 
between 10.8 ml to 13.8 ml, aggregates eluted between 7.5 ml to 10.3 ml, and free VP2C-GFP 
between 16 ml to 20 ml. 
For free VP2C-GFP, SEC  was performed after a mixture experiment with VP1 capsomeres (Section 
4.4.1) the same way as wtVP1 SEC as previously described (Chuan et al. 2008a; Lipin et al. 2008b).  
4.3.5.2 VLP SEC (S500) 
Assembled fractions (Section 4.3.7) were concentrated to >2 mg/ml and 80 µl was injected through 
an in-house Sephacryl 5/200 column (4 ml bed volume and 3.6 ml internal column volum), 
equilibrated with GL2 buffer (200 mM NaCl, 20 mM Tris, 5% glycerol, 1 mM CaCl2, at pH 7.4) at 
0.1 ml/min with standard wt VLP peak eluting between 2.6 ml to 3.1 ml. The method will be described 
in more detail in Chapter 5. 
4.3.6 N-terminal sequencing 
SDS-PAGE gel for an SEC run was blotted onto a PVDF membrane (Amersham GE Lifesciences) 
and band to be analysed excised from the membrane and sent for N-terminal sequencing. 
4.3.7 Dot blot 
Protein separated by SDS-PAGE were electroblotted onto nitrocellulose (Amersham GE 
Lifesciences). PBST with 5% skim milk was used as blocking solution, in-house anti-VP1 (1:4000) 
was used as a primary antibody, and HRP-conjugated goat anti-mouse antibody (Sigma-Aldrich, 
www.sigmaaldrich.com) as secondary antibody. Clarity Western ECL Blotting Substrate (Biorad, 
www.bio-rad.com) was used to visualise the bands on the membrane, and image acquisition was 
performed with Gel Doc XR System (Biorad).  
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4.3.8 Assembly  
Wild-type VP1 capsomeres and VP1:VP2C-GFP capsomere complex recovered via SEC in L-buffer 
at pH 8 were each assembled by dialysis with SnakeSkin Dialysis Tubing 10K MWCO 
(Thermofisher, www.thermofisher.com) in standard assembly buffer (GL1) containing 0.5 M 
(NH4)2SO4, 20 mM Tris-base, 5% glycerol (v/v), 1 mM CaCl2 at pH 7.4, at a concentration between 
0.55 – 0.65 mg/ml for 24 hours. This was followed by dialysis in GL2 for 16 hours. A mixture 
assembly experiment with both wtVP1 and VP1:VP2C-GFP capsomere complexes in 1:1 molar ratio 
was also carried out in the same manner. 
4.3.9 Dynamic Light Scattering 
Samples were clarified by centrifugation at 5000 g for 5 min,and 25 μl was transferred in duplicate 
to 384-well polystyrene plates (Corning, www.corning.com). Scheduled analysis was performed 
using a DynaPro Plate Reader (Wyatt Technologies, www.wyatt.com) and DLS results were analysed 
with Dynamics software (Wyatt Technologies). DLS measures light scattering fluctuations as a result 
of molecular diffusion and translates these fluctuations into diffusion coefficient via autocorrelation 
analysis. The diffusion coefficient can then be converted into hydrodynamic radius via Stokes-
Einstein relationship. There are several types of autocorrelation analysis, amongst them the cumulant 
and the regularisation analysis used in my research (Wyatt 2010). The cumulant analysis assumes the 
estimated particle size distribution to fit the Gaussian distribution, and thus calculates the 
hydrodynamic radius as the average of all particles in the solution (Koppel 1972). Regularisation 
analysis, on the other hand, does not assume any fitted particle size distribution, and thus estimates 
the radii and relative abundance of all species in the solution (Chu 2013; Provencher 1979). 
4.3.10 Electron Microscopy 
Samples were placed on 200-mesh carbon-coated copper grids and left to settle for 90 seconds. 
Following two washes in water, grids were negative stained with 2% Uranyl acetate for 60 seconds. 
TEM was carried out on a JEOL 1010 at 80 kV and images were cropped and adjusted for brightness 
using Adobe Photoshop (CS6; www.adobe.com).  
4.3.11 Asymmetrical Flow Field Flow Fractionation 
Asymmetrical Flow Field Flow Fractionation (AF4) was done as previously described (Chuan et al. 
2008a). Briefly, concentration of samples was adjusted to 1.2 mg/ml prior to analysis. Clarified 
supernatant (0.5 ml) was injected for each fractionation with an Eclipse 2 AF4 system (Wyatt 
Technology Corporation). AF4 of VLP samples was performed in GL2. The liquid flow rate out of 
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the channel was maintained at 0.75 mL min1 for all AF4 operations. All buffers used were degassed 
and filtered through a 0.1 mm inline-filter (Millipore, www.merckmilipore.com).  
4.4 Results  
Encapsidation of GFP inside the MPyV VLP was attempted by fusing with VP2C, which naturally 
binds to VP1 capsomeres. Fusion at the C-terminus of VP2C is expected to position GFP inside the 
cavity of the VLP (Inoue et al. 2008; Pleckaityte et al. 2015). This attempt was done by two 
approaches, the first is to bind VP2C-GFP and VP1 capsomeres in vitro, and the second is to facilitate 
binding of VP2C-GFP and VP1 capsomeres in vivo.  
4.4.1 VP2C-GFP failed to bind to VP1 when mixed in vitro 
A preliminary experiment showed that purification of free VP2C-GFP with a 6His-tag was successful 
under optimised condition (Kartikawijaya, 2014). However, SEC indicated that VP2C-GFP was not 
able to bind to VP1 when it was mixed with VP1 in standard buffer condition. If VP1 and VP2C-GFP 
bind, SDS-PAGE would show bands in the same lane on SDS-PAGE, and both A280 nm (protein 
monitoring) and A488 nm (GFP-specific monitoring) signals on the same peak in a chromatogram. 
However, both SDS-PAGE and the chromatogram showed that VP1 and VP2C-GFP appeared in 
different lanes and peaks respectively (Figure 4.2). Analysis by N-terminal sequencing showed that 
the truncation was located exactly at the hydrophobic site of VP2C corresponding to the binding site 
to VP1 capsomeres (Barouch and Harrison 1994; Chen et al. 1998) (Figure 4.2). Truncation at this 
hydrophobic site renders the recombinant VP2C-GFP unable to bind to VP1 capsomeres. 
4.4.2 Design of VP1 and VP2C-GFP co-expression 
Truncation of VP2C hydrophobic binding site may be caused by proteolysis during expression or cell 
lysis, as proteases target protein hydrophobic regions for protein degradation (Fredrickson et al. 
2013). VP1 capsomeres and VP2 naturally bind together in infected host cells during VLP formation, 
and imitation of this processs in expression host by recombinant co-expression may help to avoid 
proteolysis effect. High affinity between VP1 capsomeres and VP2C (Abbing et al. 2004; Barouch 
and Harrison 1994) allows binding to capsomeres in vivo, before proteolysis of VP2C, as the site 
would be enclosed within capsomere cavity.  
Co-expression of VP1 and VP2C-GFP was designed by cloning them into a pET-Duet1 plasmid 
(Figure 4.3A). Three variations of VP2C,  23 aa, 31 aa, and 50 aa, were designed based on a 
comparison between VP2 amino acid sequences of various polyomaviruses from the literature 
(Barouch and Harrison 1994; Chen et al. 1998). The comparison revealed an overlapping and 
conserved hydrophobic region at the C-terminal region of VP2 (VP2C), all or part of which is a  
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Figure 4.2 VP2C-eGFP expressed separately from VP1 failed to bind when mixed in vitro. 
SEC profile (A) showed that free VP2C-eGFP was purified separately from VP1 capsomeres after 
being mixed in standard condition. SDS-PAGE (B) with lanes corresponding to peak regions as 
indicated, confirms separate elution, and indicated truncation in VP2C-GFP. M is molecular weight 
standard. Arrows point to bands as indicated.  N-terminal sequencing (C) showed that truncation of 
VP2C-eGFP was located at the hydrophobic binding site. Arrow point to truncation site.  
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Figure 4.3 Design of VP2C-eGFP and VP1 co-expression. Design of pET-Duet1 plasmid (A) to 
facilitate co-expression of VP2C-eGFP and VP1 capsomere.  Detailed construct design for co-
expression (B). A 6His-tag (yellow) was placed at C-terminus of VP2C-eGFP. VP2C was engineered 
in three variations, 23 aa, 31 aa, and 50 aa. SDS-PAGE gel (C) of solubility testing of co-expressed 
constructs with arrows pointing to respective bands. 
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putative binding region to VP1 capsomeres. The constructs were designed to determine the shortest 
possible adapter which still allows encapsidation of a foreign protein. The 50 aa VP2C has been 
shown to permit this in plants (Catrice and Sainsbury 2015). GFP was fused at the C-terminus of 
VP2C and tagged with 6His. Both VP1 and VP2C-GFP were each preceded by a T7 promoter 
upstream, and a non-coding region was placed between the VP1 and VP2C-GFP coding regions. The 
non-coding region was designed to be out of frame between VP1 and VP2C-GFP (Figure 4.3 B). 
4.4.3 Expression and solubility test 
The constructs were expressed in E.coli and lysis was performed in the presence of  protease inhibitor.  
SDS-PAGE showed that fused protein of 50 aa VP2C construct had the highest total and soluble 
protein yield (Figure 4.3 C), which however was truncated based on the size of the bands, and thus 
was not pursued further. Soluble proteins of the 31 aa VP2C construct are both truncated and 
untruncated, but the latter was less soluble. This showed that the nature of untruncated protein is 
mostly insoluble, though this suggests that its presence in the soluble fraction may indicate complex 
formation. The 23 aa VP2C construct did not produce sufficient VP2C protein, even though VP1 
production was good, similar to other constructs. 
4.4.4 IMAC indicated successful binding between VP2C-GFP and VP1 
A 6His-tag was designed at the C-terminus of GFP which was fused to VP2C. Therefore, purification 
with an IMAC column would selectively purify VP2C-GFP which has a 6His-tag in it. The purified 
VP2C-GFP would come in two forms: free VP2C-GFP; and VP2C-GFP that bound to co-expressed 
VP1 capsomeres. Only VP1 that bound to VP2C-GFP would be co-purified, while free VP1 would 
not be co-purified and would be washed away from the column.  
The IMAC was run with two different wavelength detectors, which were A280 nm specific for 
proteins, and A488 nm specific for GFP. The chromatogram (Figure 4.4) showed a peak in both 
A280 nm and A488 nm in the purified eluted region and construct 31 aa VP2C had the highest yield. 
Construct 23 aa VP2C had a low yield and thus was not examined further (Figure 4.5). SDS-PAGE 
analysis showed that fractions of peak regions contain both bands of VP1 and VP2C-GFP and 
thickness of bands corresponded to height of peak in the chromatogram. The presence of both bands 
of VP1 and VP2C-GFP in the same fractions confirmed that VP2C-GFP was able to bind to VP1. 
The thicker band of VP2C-GFP indicated the co-purification of free VP2C-GFP that needed to be 
separated further by SEC. To confirm binding of VP1 to VP2C-GFP a dot blot was further carried  
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Figure 4.4 Purification of VP1:VP2C-eGFP 31 aa. Chromatogram of the IMAC purification (A) 
of the VP1:VP2C-eGFP 31 aa complex (zoomed in B) and SDS-PAGE with lanes corresponding to 
peak regions as indicated (C), showed that VP1 was co-purified with VP2C-GFP as confirmed with 
anti-VP1 dot blot. VP1:VP2C-eGFP 31 aa had the highest yield between the three tested constructs.  
Absorbance at 280 nm is shown in blue and absorbance at 488 nm is shown in green. M is molecular 
weight standard. Arrows point to bands as indicated. Elution fractions 31*aa and 31 aa as indicated 
were further analysed with SEC. 
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Figure 4.5 Purification of VP1:VP2C-eGFP 23 aa. Chromatogram of the IMAC purification (A) 
of the VP1:VP2C-eGFP 23 aa complex (zoomed in B) and SDS-PAGE with lanes corresponding to 
peak region as indicated (C), showed that VP1 was co-purified with VP2C-eGFP as confirmed with 
anti-VP1 dot blot. M is molecular weight standard. Absorbance at 280 nm is shown in blue and 
absorbance at 488 nm is shown in green. Arrows point to bands as indicated. 
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out with an anti-VP1 primary antibody, and confirmed that the fractions contained VP1. As only 
bound VP1 could be co-purified with VP2C-GFP, all the VP1 contained in the fractions are most 
likely bound to VP2C-GFP. A 70 kDa band was also present consistently in the elution fractions of 
all constructs.  
4.4.5 Isolation of VP1:VP2C-GFP interaction from free VP2C-GFP by 
size exclusion chromatography 
To separate VP2C-GFP bound to VP1 from free VP2C-GFP, SEC was performed on the collected 
IMAC elution peak fractions, preceded by dialysis in capsomere compatible L-buffer. Concerns about 
the 70 kDa band to interfere with assembly, led to the division of the fractions into two groups. The 
first group were IMAC fractions that contained less 70 kDa bands (three before last SDS-PAGE 
fractions for construct 31 aa (Figure 4.4)). The second group (denoted with a star) were IMAC 
fractions that contained not only more 70 kDa bands, but also more of the desired bands of VP1 and 
VP2C-GFP (third to sixth SDS-PAGE fractions for construct 31 aa (Figure 4.4)). Fractions of 
respective groups were mixed, dialysed, and run on SEC together.  
SEC of IMAC fractions of 31 aa (not starred) resulted in capsomere complex peak (elution: ~10 ml) 
and free VP2C-GFP peak (elution: ~ 16 ml) (data not shown). Capsomere complex peak had a small 
elevation in the A488 nm signal and contained VP1 as confirmed by SDS-PAGE, while a VP2C-GFP 
band could not be identified. On the contrary, free VP2C-GFP peak had a high A488 nm signal, thick 
VP2C-GFP bands, and no VP1 band. SEC of IMAC fractions of 31* aa resulted in capsomere 
complex peak (elution: ~ 10 ml) and free VP2C-GFP peak (elution: ~16 ml) (Figure 4.6). Although 
the A488 nm signal on capsomere complex peak was low in comparison to A280 nm signal, this peak 
not only contained VP1, but also contained visible VP2C-GFP band as confirmed by SDS-PAGE. 
Free VP2C-GFP peak for fractions 31* aa also had a high A488 nm signal, thick VP2C-GFP bands, 
and no VP1 band. Two overlapping bands at the VP2C-GFP region were even observed in free VP2C-
GFP peak, indicating that some of this protein was truncated as expected of free VP2C-GFP.  The 
~10 ml elution peak in both groups of fractions for both constructs are located near the elution volume 
known to be the capsomere region in wtVP1 (Abidin et al. 2015). Based on the chromatogram and 
SDS-PAGE, this peak is the desired peak that contains a VP1 capsomere bound to VP2C-GFP.  
4.4.6 Western blot to analyse purified SEC fractions 
To confirm the identity of expected bands, a western blot was run on the SEC fractions of the 31 aa 
construct in the capsomere complex peak region (~10 ml) (Figure 4.6C).  This showed anti-VP1 
stained bands in the region where VP1 was known to be located and GFP at approximately 30 kDa. 
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Figure 4.6 Purification of VP1:VP2C-GFP complex. Isolation of capsomeres by SEC (A) 
enabled separation of VP1:VP2C-eGFP complex (zoomed in B) from free VP2C-eGFP. SDS-PAGE 
with lanes corresponding to peak region, and western blot with anti-GFP and anti-VP1 antibodies on 
peak fraction marked with an asterisk identified VP1 and GFP bands (C). M is molecular weight 
standard and L is column load. Absorbance at 280 nm is shown in blue and absorbance at 488 nm is 
shown in green. 
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Both proteins also appeared as dimers. GFP is known to be a dimer (Malikova et al. 2011) and a 
double band appears at approximately 58 – 60 kDa. The dimer could also be due to interaction via 
the hydrophobic VP2C motifs as it persists under denaturing conditions. There was also an anti-
VP1stained band in the 90 kDa region, probably incompletely denatured VP1 in the form of dimers, 
which sometimes occurs on SDS-PAGE (Catrice and Sainsbury, 2015). The 70 kDa band was not 
identified by either antibody, indicating that this is a co-purified host protein contaminant. 
4.4.7 VP1:VP2C-GFP was able to assemble into VLP 
S200 fractions collected in previous step containing VP1:VP2C-GFP capsomere complex from the 
31* aa construct was assembled in assembly buffer. The complete formation of VLPs from 
VP1:VP2C-GFP capsomere complexes was observed by both AF4 and TEM (Figure 4.7 A and B), 
which showed that particles were externally identical. This indicated that the 70 kDa band did not 
interfere with assembly. AF4 chromatogram of VP1:VP2C-GFP assembled product indicated the 
presence and separation of a smaller particle in the mixture, possibly unassembled or disassembled 
capsomeres as previously observed elsewhere (Chuan et al. 2008a).  When the assembled product 
was run on S500,  a 70 kDa band did not appear in SYPRO Orange-stained SDS-PAGE gel (data not 
shown).  
4.4.8 Controlled GFP encapsidation was achievable by co-assembly 
with wt capsomeres 
To assess whether the amount of encapsidated protein could be controlled, three assembly 
experiments were carried out: 1) assembly of 100% wt capsomeres; 2) assembly of 100% VP1:VP2C-
GFP capsomere complex; 3) assembly of a mixture of wt capsomere and VP1:VP2C-GFP capsomere 
complex in 1:1 molar ratio (Figure 4.8). The assembled product was then run through a sephacryl-
based preparative S500 to enable separation and analysis of the VLPs developed as described in 
Chapter 5. The chromatogram of assembled 100% wt capsomeres showed complete VLP formation, 
as confirmed by DLS, with VLP elution peak at 2.8 mL (Figure 4.8A). Chromatogram of assembled 
100% capsomere complex showed an aggregate peak at 1.9 ml elution volume and VLP peak at 2.6 ml 
elution volume at 280 nm absorbance. An A488 nm absorbance corresponded to this curve displaying 
the same pattern (Figure 4.8B). Chromatogram of co-assembled VP1:VP2C-GFP capsomere 
complex with wt capsomeres in a 1:1 molar ratio showed an aggregate peak at 1.9 ml elution volume 
and VLP peak at 2.1 ml elution volume at A280 nm absorbance. Again, an A488 nm absorbance also 
corresponded to this curve displaying the same pattern (Figure 4.8C).   The A488 nm absorbance 
was also lower in 50% VP1:VP2C-GFP co- assembly than the 100% VP1:VP2C-GFP assembly. 
Absorbance analysis of collected SEC fractions showed that 100% VP1:VP2C-GFP assembly 
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Figure 4.7 VLP formation after assembly as confirmed by AF4 and TEM. Assembly of 
VP1:VP2C-eGFP complex SEC fractions in standard buffer conditions resulted in VLPs comparable 
to WT VLPs as confirmed by AF4 (A) and TEM (B). TEM scale bar is 300k. 
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Figure 4.8 Controlled encapsidation.  SEC chromatogram and TEM of 100% wt capsomere 
assembly reaction as a standard (A) were compared to that of 100% VP1:VP2C-eGFP (B) and an 
assembly mixture of wt and VP1:VP2C-eGFP capsomeres in 1:1 molar ratio (C). VLP peaks were 
observed in (B) and (C) even though aggregate peaks were also observed. Preparative SEC VLP peak 
fractions were observed under TEM, and VLP formation was observed. Absorbance at 488 nm in (C) 
was lower than in (B). Absorbance at 280 nm is shown in blue and absorbance at 488 nm is shown in 
green. TEM scale bar is 200k. 
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encapsidated 40 molecules of GFP, which indicated partial VP2C-GFP dissociation during assembly 
reaction. Absorbance analysis of collected SEC fractions showed that 50% VP1:VP2C-GFP co-
assembly encapsidated 20 molecules of GFP. This indicated that the amount of foreign protein 
encapsidation may be controlled by co-assembly with wtVP1 capsomeres based on a molar ratio. 
Resolution between aggregate peak and VLP peak is not ideal due to limitation in the S500 method. 
However, the chromatogram showed that particles of different sizes eluted at different times forming 
distinct, even though not fully separated, peaks. Although tailing of the aggregate peak within the 
VLP region is possible, DLS regularization analysis still measured the radius of the particles as 29 
nm for wt VLPs, 30 nm for 100% VP1:VP2C-GFP VLPs, and 35 nm for 50% VP1:VP2C-GFP VLPs. 
The measured VLP sizes are still within the range of reported VLP particle size (Abbing et al. 2004; 
Chuan et al. 2008a) and our validation of the DLS analysis.  
 
4.5 Discussion 
In this chapter, the approach to encapsidate foreign antigens inside the MPyV VLP was developed 
and optimised. The development and optimisation included molecular design and bioprocess 
modification to enable expression and recovery of VP1:VP2C-GFP capsomere complexes. 
Furthermore, the in vitro assembly competency of the complexes and the ability to control 
encapsidation of foreign molecules was evaluated. 
The first approach to mix free VP2C-GFP with wtVP1 in vitro to form a complex did not work due 
to truncation in the hydrophobic binding region of VP2C-GFP. Elimination of N-terminal region of 
VP2C in this project may have played a role in sterically exposing the hydrophobic binding region to 
proteolysis. This phenomenon was not observed when Abbing et al. (2004) mixed N-terminal region 
intact VP2-GFP with wtVP1, which resulted in successful VLP formation in vitro. 
Co-expression of VP2C-GFP and wtVP1 circumvented this problem probably due to the high affinity 
between those molecules. Rapid capsomere complex formation in vivo may have enclosed the 
hydrophobic binding site of VP2C inside the capsomere cavity and may have further protected it from 
proteolysis. VP1:VP2C-GFP capsomere complex formation was confirmed by IMAC, SEC, and their 
respective SDS-PAGE analysis. Construct 31 aa VP2C performed the best and was thus pursued 
further. Even though the VP2C-GFP band was very thick on IMAC SDS-PAGE gel, it was thinner 
than VP1 on the SDS-PAGE gel of capsomere complex peak of SEC fractions. This is because VP2C-
GFP is in a theoretical 1:5 molar ratio to VP1 in its bound form. Empirical calculation with absorbance 
data from UNICORN software results in a 1:7 molar ratio which is quite close to the theoretical ratio. 
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The difference between empirical ratio and theoretical ratio may be due to some part of the VP2C-
GFP being buried inside the capsomere cavity or partial unfolding of GFP. Correctly folded, stable 
GFP, is required for absorbance at A488 nm.  SEC has also enabled separation of bound VP2C-GFP 
from free VP2C-GFP that eluted later in free VP2C-GFP peak based on size difference. SDS-PAGE 
showed that some of free VP2C-GFP was truncated. Bands of truncated VP2C-GFP were not present 
in capsomere complex peak which indicated that only untruncated VP2C-GFP could bind to VP1. 
SDS-PAGE analysis of SEC fractions also showed co-purification of a 70 kDa band, co-stained with 
anti-GFP after subsequent western blotting, indicating association with VP2C-GFP. The complex 
involving VP2C-GFP in the 70 kDa band may contain an interacting chaperone as have been indicated 
in the literature (Liew et al. 2010). This species appears in two sizes in western blot, the smaller of 
which may be the truncated form of VP2C-GFP complex.  Even though the 70 kDa band was further 
shown not to interfere with assembly, the nature of the 70 kDa protein needs to be investigated further, 
for example by mass spectrometry.  
VP1:VP2C-GFP capsomere complex was recoverable in the bioprocessing methodology developed 
in this project. The recovered complexes were also assembly competent in vitro and yielded externally 
identical VLPs. This methodology differs with what has been demonstrated in the litereature in 
several ways. First is the use of a minimal 31 aa VP2C fragment with truncated N-terminal region 
and fusion at its C-terminal arm. Second is the use of co-expression in a prokaryotic host, which led 
to in vivo formation of VP1:VP2C-GFP capsomere complex rather than in vivo formation of VLPs as 
reported by Boura et al. (2005) and Inoue et al. (2008) in eukaryotic host. Recoverable VP1:VP2C-
GFP capsomere complex is advantageous as it eliminates the risk of genetic material inclusion. Third 
is the ability to assemble capsomere complexes in vitro, that not only avoids genetic material 
inclusion but also allows precise control over VLP modifications as explained in the next paragraph. 
This differs from in vitro assembly reported by Abbing et al. (2004) because they employed free VP2-
GFP and wtVP1 rather than capsomere complexes in their assembly reaction. In this project, the 
number of encapsidated molecules is slightly less than previously reported 64 encapsidated GFP 
molecules (Abbing et al. 2004; Schmidt et al. 2000). The dissociated free VP2C-GFP might play a 
significant role in aggregate formation. And more likely, the aggregate peak in the SEC analysis may 
be caused by sample concentration prior to chromatography application, as an AF4 analysis of 100% 
VP1:VP2C-GFP assembled product without sample concentration demonstrated low aggregate 
content (Figure 4.5). AF4 analysis also showed the assembly reaction of 100% VP1:VP2C-GFP did 
not result in 100% percent assembly unlike wt VP1 assembly, as free capsomeres were observed in 
the AF4 profile. These impurities could be removed with SEC500 VLP purification. 
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An approach to control the amount of encapsidated GFP was also pursued by mixing VP1:VP2C-
GFP capsomere complex with wtVP1 capsomere. Spectrophotometric analysis showed that the 
amount of encapsidated GFP was proportional to the ratio of co-assembled VP1:VP2C-GFP 
capsomere complex and wtVP1 capsomere. This does not only show that encapsidation was 
controllable, but also strongly indicates the ability to engineer capsomere composition of a mosaic 
VLP. 
 
4.6 Conclusion 
In this chapter, an in vivo interaction between wtVP1 capsomeres and a VP2C-GFP was established 
via molecularly designed and adjustable co-expression. Further expression and purification 
elucidated the optimum reduced VP2C fragment able to facilitate encapsidation of a foreign protein. 
In addition,  prokaryote-based upstream and chromatography-based downstream bioprocess 
development enabled purification of  the VP1:VP2C-GFP capsomere complex. . These VP1:VP2C-
GFP capsomere complexes were assembly competent in vitro, and the amount of encapsidated protein 
inside the MPyV VLPs appears to be controllable via a mixed assembly reaction, reported here for 
polyomavirus VLPs for the first time. The encapsidation methodology may then be applied to 
encapsidate foreign antigenic proteins to deliver Tc-epitope for vaccine development, and opens up 
many other possibilities for biomaterial advancement.  
92 
 
5 Cytotoxic T Cell Epitope-Based MPyV 
VLP Influenza Vaccine Development, 
Analysis, and Characterisation 
 
5.1 Abstract 
Influenza pandemic and epidemic, high mutation frequency of the virus, and problems related to 
vaccine production capacity and cost necessitate the development of next-generation vaccine 
candidates that are not only broadly cross-protective, but also efficient in terms of cost and production 
time. One of the ways to explore the solution to this problem is to develop influenza Tc-epitope-based 
vaccines with the MPyV VLP as a carrier. In this chapter, MPyV VLP vaccines carrying influenza 
Tc-epitopes either externally or internally were developed. An MPyV VLP carrying Tc-epitopes at a 
surface-exposed loop of VP1 subunit protein was further developed by optimising assembly by co-
assembling modified DDIT1 capsomeres with unmodified capsomeres to form stable mosaic VLPs. 
Furthermore, an MPyV VLP carrying Tc-epitopes internally was developed by encapsidating soluble 
subdomains of the M1 protein. To analyse and characterise the modified VLPs, a new semi-
preparative SEC method was developed and validated with wt VLPs. Capsomeres bound to M1-I 
subdomains (VP1:VP2C-M1-I) were successfully expressed and purified as indicated by SDS-PAGE 
and western blot. VLPs of VP1:VP2C-M1-I and mosaic DDIT were also successfully assembled and 
purified with the newly developed semi-preparative SEC method. Analysis and characterisation of 
elution fractions with DLS, SDS-PAGE, and TEM showed successful formation of the desired VLPs, 
both DDIT1 mosaic VLPs and M1-I encapsidating VLPs. 
 
5.2 Introduction 
So far in this research, development of a Tc-epitope-based influenza vaccine with MPyV VLP has 
been explored by two approaches: external presentation (Chapter 3) and internal encapsidation 
(Chapter 4). External presentation was achieved by insert engineering of DDIT1 at a VP1 surface-
exposed loop and devising a buffer screen to enable soluble and assembly competent capsomere 
recovery (Abidin et al. 2015). Even though the DDIT1 capsomeres were able to form VLPs, the 
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assembly reaction still required optimisation, for example by reducing the amount of hydrophobic 
epitopes on the surface of the VLPs to minimise aggregation and increase assembly efficiency. This 
may possibly be achieved by co-assembling DDIT1 capsomeres with unmodified VP1 to form more 
stable mosaic VLPs.  This approach to co-assemble modified and unmodified subunit proteins of a 
viral capsid has been demonstrated before with Qβ and CCMV particles resulting in successful 
formation of mosaic VLPs (Brown et al. 2009; Minten et al. 2010; Pokorski et al. 2011). Successful 
GFP encapsidation by MPyV VLP that has been demonstrated and optimised in Chapter 4 could 
then be applied to vaccine development by replacing GFP with an influenza protein. In this chapter 
(Chapter 5), the M1 protein  was selected for several reasons: 1) it contains epitopes IT1 and IT2 
used for external presentation in Chapter 3, and thus immunogenicity between externally and 
internally carried epitopes may be compared; 2) IT1 is also commonly used in the literature for 
influenza vaccine development because of its immunodominance (Berthoud et al. 2011; Deliyannis 
et al. 2006); 3) M1 is an internal influenza protein with a high degree of conservancy; and 4) the size 
of the soluble domain is relatively small so it would not overpopulate the VLP cavity. 
One important aspect in the development of vaccines by modifying MPyV VLPs is a method to 
analyse and characterise the modular particles to confirm the successful formation of desired 
particles. The current method for MPyV VLPs at AIBN-CBE employs asymmetric flow-field flow 
fractionation (AF4) which serves to measure  particle size and distribution (Chuan et al. 2008a). 
However, this method is only analytical and does not provide preparative samples required for SDS-
PAGE and TEM. SDS-PAGE is important to show the presence of engineered subunit components 
of the modified VLPs, and TEM is important to visualise the formation of intact VLPs. Therefore, a 
new semi-preparative method for analysis and characterisation with the following desired traits 
needed to be developed: 1) able to isolate different assembly reaction species; 2) efficient in terms of 
time; 3) efficient in terms of sample consumption; and 4) allows fraction collection to enable further 
analysis and characterisation (for example for SDS-PAGE and TEM); and 4) cost effective.  
Preparative protein purification may be achieved with SEC. This technique has been widely used for 
several purposes including buffer exchange; separation and purification based on particle size; MWD 
determination; automated analysis with different detectors such as UV, light scattering, and 
conductivity; manual analysis such as SDS-PAGE and TEM; and large scale production of purified 
proteins (Hagel and Janson 1992) . SEC medium works as a molecular sieve to separate particles 
based on their size. Larger particles are less exposed to pores in the media in comparison to smaller 
particles, and thus elute earlier than smaller particles (Hagel 2011). Various media are available 
commercially to separate particles of different sizes, such as Superose, Superdex, and Sephacryl. The 
medium suitable to separate MPyV VLP is Sephacryl S500 HR as its fractionation range for proteins 
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is 10 – 105 kDa while MPyV VLP size is ~16 x 103 kDa (GE-Healthcare 2010b; Rayment et al. 1982). 
Commercially available prepacked S500 columns are designed for production of a large volume of 
samples, and not for analysis and characterisation of small sample volumes. Therefore, a new semi-
preparative SEC method to analyse and characterise VLPs needed to be developed. 
In this last part of my research, an SEC-based method to analyse and characterise modified MPyV 
VLPs was developed by assessing the column efficiency of an in-house packed Sephacryl S500 
column, reflected in their h and As. After the optimum flow rate range was determined, the column 
was validated with wt MPyV VLPs in combination with DLS, SDS-PAGE, and TEM. The column 
was first used to confirm the assembly of MPyV VLPs encapsidating GFP, as described in Chapter 
4. The method was then applied to analyse and characterise modified MPyV VLP based vaccines 
explained as follows. MPyV VLP encapsidating the M1-I soluble subdomain of influenza was 
developed according to the previously optimised and adjusted method (Chapter 4). Meanwhile, 
capsomeres with externally presented DDIT1 were co-assembled in optimised assembly buffer to 
form mosaic particles. The successful formation of MPyV VLPs which carry antigens either 
externally or internally was confirmed using the semi-preparative SEC method.  
 
5.3 Materials and methods 
5.3.1 Column packing 
Packing of a Tricorn 5/200 Empty High Performance column (GE Healthcare, 
www.gelifesciences.com) was done according to manufacturer’s instructions. Sephacryl S500 High 
Resolution medium (GE Healthcare Lifesciences) was poured into the empty column in one 
continuous motion avoiding the formation of bubbles. The column was then packed at 2.3 ml/min for 
an hour, and then packed at 1 ml/min for two hours until the bed height was constant. 
5.3.2 Column efficiency testing 
Column efficiency was tested by injecting 2% acetone (8 µl) into the column, run at various flow 
rates in MQW (GE Healthcare Lifesciences). N (Equation 2.1), HETP (Equation 2.2), h (Equation 
2.3) and As (Equation 2.4) were measured,  where dp was 50 µm and L was 20 cm. Values of h and 
As were plotted against different flow rates to determine the optimum flow rate for the column. 
5.3.3 Cloning of VP1:VP2C-M1-I and VP1:VP2C-M1-II 
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Cloning of VP1:VP2C-M1-I and VP1:VP2C-M1-II constructs was done by replacing GFP in 
VP1:VP2C-GFP (Figure 4.3) with either M1-I or M1-II (Figure 5.1) using Gibson Assembly as 
described in Chapter 4. The pET-Duet construct containing VP2C(31)GFP was linearised by PCR, 
excluding the GFP sequence, and the M1 domains were amplified using the primers listed in table 
5.1.  
5.3.4 Expression 
pET-Duet 1 plasmid containing either VP1:VP2C-M1-I or VP1:VP2C-M1-II constructs were 
transformed into competent E. coli Rosetta (DE3) pLysS cells (Novagen, www.merckmillipore.com), 
and expressed as previously described in Chapter 4 with a 0.5 mM IPTG induction. 
5.3.5 Affinity chromatography purification 
For VP1:VP2C-M1-I and VP1:VP2C-M1-II, thawed cell pellets were each resuspendend in 50 ml 
lysis buffer composed of 20 mM Tris, 500 mM NaCl, 5% glycerol, 1 mM DTT, 20 mM imidazole 
and complete  of protease inhibitors (PI) (Roche, www.lifescience.roche.com) at pH 8.0. 
Resuspended pellets were lysed by sonication and clarified supernatant was recovered. For IMAC 
purification, an AKTA Pure (GE Healthcare Lifesciences) was used to equilibrate a 5mL HisTrap HP 
(GE Healthcare Lifesciences) column with 1 column volume (CV, 4 ml) of MQW, 1 CV equilibrium 
buffer (lysis buffer without PI). 40 ml of clarified supernatant was then passed through the column, 
followed by washing with 6 CVs equlibrium buffer, and elution of bound material with 4 CVs of 
elution buffer (equilibrium buffer with 500 mM imidazole). All chromatography operations were 
conducted at 3 ml/min with the exception of the equilibration step, which was conducted at 5 ml/min. 
Solution exiting the column was monitored inline at 280 nm and was collected as 0.25 ml fractions 
using a built-in fractionator, once absorbance in the elution region showed elevation. Optimum 
elution peak fractions (as analysed by SDS-PAGE) were dialysed with capsomere compatible buffer 
(L-buffer) composed of 200 mM NaCl, 40 mM Tris base, 1 mM EDTA disodium, 5% Glycerol, and 
5 mM DTT at pH 8 at 4 °C for 16 h. If not immediately dialysed, all protein solutions were stored at 
-80 °C.  
For wtVP1, purification was performed as previously described (Chuan et al. 2008a; Lipin et al. 
2008b). For DDIT1 capsomere, purification was performed as previously described (Abidin et al. 
2015). 
5.3.6 Size exclusion chromatography 
5.3.6.1 Capsomere SEC (S200) 
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Table 5.1 Oligonucleotides used in the cloning of VP1:VP2C-M1-I and VP1:VP2C-M1-II. 
Name Function Oligonucleotide sequence1 
His-Tag-F 
Linearise pETDuet-
VP1 backbone 
5’CATCACCATCACCATCACTGAG3’ 
G4S-R 
Linearise pETDuet-
VP1 backbone 
5’AGAACCGCCACCTCCAGAAC3’ 
M1-(VP2C)-F2 Amplify M1 5’tctggaggtggcggttctAGTCTTCTAACCGAGGTCGA3’ 
M1b1-(His)-R Amplify M1-I 5’gtgatggtgatggtgatgTCCTCGCTCACTGGGCA3’ 
M1b2-(His)-R Amplify M1-II 5’gtgatggtgatggtgatgATGCTGGGAGTCAGCAATCT3’ 
1 Upper case letters correspond to sequence the homology to the target sequence and lower case letters 
correspond to extensions with homology to vector or flanking inserts. 
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Figure 5.1 VP2C-M1 constructs. Two constructs were designed for encapsidation of M1 soluble 
subdomains inside MPyV VLP. The first is VP1:VP2C-M1-I containing a shorter subdomain (light 
blue) (A) and VP1:VP2C-M1-II containing an additional subdomain (dark blue) (B). The influenza 
proteins were fused to C-terminus of VP2C 31 aa (grey and red regions) and were tagged with 6His 
(yellow) at their C-terminus. 
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For VP1:VP2C-M1-I and VP1:VP2C-M1-II, 1 ml of 1-3 mg/ml dialysed fractions were then injected 
through a Superdex 200 GL 10/300 column (24 ml bed volume and 14.4 ml internal column volume) 
(GE Healthcare Lifesciences) equilibrated with L-buffer at 0.5 ml/min with AKTA Explorer 100 (GE 
Healthcare Lifesciences) 
S200 for wtVP1 capsomeres was performed in L-buffer as previously described (Chuan et al. 2008a; 
Lipin et al. 2008b), while S200 for DDIT1 capsomeres was run with the addition of 50 mM L-Arg in 
L-buffer as previously described (Abidin et al. 2015). 
5.3.6.2 VLP SEC (S500) 
Assembled fractions (Section 5.3.8) in a concentration of >2 mg/ml and 80 µl were injected through 
an in-house Sephacryl S500 5/200 column (4 ml bed volume and 3.6 ml internal column volume) 
equilibrated with GL2 buffer (200 mM NaCl, 20 mM Tris, 5% glycerol, 1 mM CaCl2, at pH 7.4) for 
VP1:VP2C-M1-I, and with GL2 with 50 mM L-Arg for DDIT1 mosaic particles, at 0.1 ml/min. 
5.3.7 Western blot 
 Proteins separated by SDS-PAGE were electroblotted onto nitrocellulose (Amersham GE 
Lifesciences). PBST with 5% skim milk was used as blocking solution, in-house anti-VP1 (1:4000) 
and anti-6His (Thermofisher, www.thermofisher.com) were used as primary antibodies, and HRP-
conjugated goat anti-mouse (Sigma-Aldrich, www.sigmaaldrich.com) as secondary antibody. Clarity 
Western ECL Blotting Substrate (Bio-Rad, www.bio-rad.com) was used to visualise the bands on the 
membrane, and  image acquisition was performed with Gel Doc XR System (Bio-Rad).  
5.3.8 Assembly  
5.3.8.1 Standard wtVP1 assembly 
Capsomeres of wtVP1 were assembled as described elsewhere (Abidin et al. 2015). 
5.3.8.2 VP1:VP2C-M1-I assembly 
VP1:VP2C-M1-I capsomeres recovered via SEC in L-buffer at pH 8 were each assembled by dialysis 
in standard assembly buffer (GL1) containing 0.5 M (NH4)2SO4, 20 mM Tris-base, 5% glycerol (v/v), 
1 mM CaCl2 at pH 7.4 for 24 hours. This was followed by dialysis in GL2 for 16 hours.  
5.3.8.3 Mosaic DDIT1 assembly 
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A mosaic assembly experiment by mixing DDIT1 and wtVP1 capsomeres, at a 1:4 molar ratio was 
also carried out by dialysis as in Section 5.3.7.2 in modified buffer conditions by adding 50 mM L-
Arg in the assembly buffers (GL1 and GL2). 
5.3.9 Dynamic light scattering 
Samples were clarified by centrifugation at 5000 g for 5 min and 25 μl was transferred in duplicates 
to 384-well polystyrene plates (Corning, www.corning.com). Scheduled analysis was performed 
using a DynaPro Plate Reader (Wyatt Technologies, www.wyatt.com) and DLS results were analysed 
with Dynamics software (Wyatt Technologies). DLS measures light scattering fluctuations as a result 
of molecular diffusion and translates these fluctuations into diffusion coefficient via autocorrelation 
analysis. The diffusion coefficient can then be converted into hydrodynamic radius via Stokes-
Einstein relationship. There are several types of autocorrelation analysis, amongst them the cumulant 
and the regularisation analysis used in my research (Wyatt 2010). The cumulant analysis assumes the 
estimated particle size distribution to fit the Gaussian distribution, and thus calculates the 
hydrodynamic radius as the average of all particles in the solution (Koppel 1972). Regularisation 
analysis on the other hand does not assume any fitted particle size distribution, and thus estimates the 
radii and relative abundance of all species in the solution (Chu 2013; Provencher 1979). 
5.3.10 Electron microscopy 
Samples were placed on 200-mesh carbon-coated copper grids and left to settle for 90 seconds. 
Following two washes in water, grids were negative stained with 2% Uranyl acetate for 60 seconds. 
TEM was carried out on a JEOL 1010 at 80 kV and images were cropped and adjusted for brightness 
using Adobe Photoshop (CS6; www.adobe.com).  
 
5.4 Results 
5.4.1 Optimisation of a new S500 column 
An in-house Sephacryl-based S500 5/200 column was packed and optimised to develop semi-
preparative SEC method for VLP samples to enable their further analysis and characterisation. The 
column efficiency was tested based on h and As (Table 5.2), within a flow rate range from 
0.05 ml/min to 0.15 ml/min in 0.025 ml/min intervals in a total of five measurements. A good column 
efficiency is indicated by h<3 (particle diameter = 50 µm) and As between 0.8 and 1.3 for Sephacryl 
(GE-Healthcare 2010b). As can be seen in Figure 5.2, h was above 3 for all flow rates tested. The 
value of h ranged between 5.4 and 6.5 and increased along with increasing flow rate until the flow  
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Table 5.2 Calculation of variables for column efficiency testing. 
Flow 
rate 
(ml/min) 
Ve1 
(ml) 
Wh2 
(ml) 
N3 Plates/m4
HETP5 
(cm) 
h6 a7 b8 As9 
0.05 4.01 0.345 745.5 3727.6 0.027 5.4 0.34 0.3 0.87 
0.075 4.16 0.374 682.2 3411.1 0.029 5.9 0.38 0.34 0.89 
0.1 4.18 0.383 659.7 3298.4 0.030 6.1 0.41 0.33 0.81 
0.125 4.23 0.401 615.0 3075.0 0.032 6.5 0.42 0.34 0.81 
0.15 4.26 0.394 648.8 3244.0 0.031 6.2 0.47 0.33 0.71 
1Ve is peak elution volume. 
2Wh is peak width at half peak height. 
3N is number of theoretical plates in the column, calculated according to Equation 2.1. 
4Plates/m is the number of theoretical plates per meter, where length of column (L) is 20 cm. 
5HETP is height equivalent of a theoretical plate, calculated according to Equation 2.2. 
6h is reduced plate height, calculated according to Equation 2.3. 
7a is forward peak part width at 10% peak height. 
8b is rear peak part width at 10% peak height. 
9As is asymmetry, calculated according to Equation 2.4. 
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Figure 5.2 Column efficiency test. The efficiency of the column was tested by running acetone 
solution on the column in five different flow rates, one of which (0.1 ml/min) is depicted here (A). 
Data collected from these runs were used to measure h and As, which indicate the efficiency of the 
column (B). . Optimum flow rate fell between 0.075 and 0.1 ml/min. 
 
 
102 
 
rate reached 0.125 ml/min after which the value of h decreased. The ideal h value could not be 
achieved due to the system volume. As of the column ranged between 0.71 and 0.89 with a decreasing 
pattern along an increasing flow rate. Based on empirical h and As value and the time it took to run a 
sample in a column with a total column volume of 4 ml, the optimum flow rate for the column was 
between 0.075 ml/min and 0.1 ml/min. Therefore, 0.1 ml/min was used for the rest of this chapter, as 
it was closest to the intersection of the h and As curves.  
5.4.2 Column validation with wt MPyV VLPs  
The column was validated by running wt MPyV VLPs. The chromatogram showed a single VLP peak 
at 2.85 ml elution volume within an acceptable symmetry (Figure 5.3A). DLS analysis of collected 
elution fractions showed 100% VLP-size particles within the peak region with radius slightly 
decreasing along the elution volume, as expected. VLP particle radius at the peak region was 29.6 nm 
and polydispersity was 3.8% based on regularisation analysis. SDS-PAGE gel confirmed that the 
fractions contain VP1 corresponding to the peak region (Figure 5.2B), and TEM confirmed they were 
in the form of VLPs (Figure 5.3C).   
5.4.3 Design of encapsidated influenza M1 protein construct 
A Tc-epitope-based influenza vaccine via internal encapsidation by MPyV VLPs was developed. 
Previous encapsidation optimisation with GFP as the model protein in Chapter 4 was applied to 
encapsidate the soluble domain of influenza M1 protein. The soluble domain of M1 protein used in 
this research was the N-terminal region of M1 (2-159) (more in Section 2.3.5). The first subdomain, 
M1-I (2-73), contains IT1 and IT2 that have been presented externally as described in Chapter 3. 
The second subdomain, (74-159), contains a self-interacting domain, and M1-II consists of both first 
subdomain (M1-I) and the second. Both M1-I and M1-II were fused to VP2C 31 aa in place of GFP 
(Figure 5.1). Similar to the VP2C-GFP 31 aa construct on Chapter 4, either M-I or M-II were fused 
to the C-terminus of VP2C and a 6His-tag was engineered in the C-terminal end of the inserted protein 
to enable IMAC purification. The 6His-tag allows the purification of free VP2C-M1-I or VP2C-M1-
II as well as VP1:VP2C-M1-I and VP1:VP2C-M1-II complexes. Only VP1 forming a complex with 
the VP2C fusion proteins can be purified with IMAC. 
5.4.4 IMAC purification of VP1:VP2C-M1-I indicated successful 
binding with VP1 
VP1:VP2C-M1-I was purified with IMAC (Figure 5.4A & B) with conditions optimised in Chapter 
4. Elution fractions were collected and analysed with SDS-PAGE. The gel showed that VP1 was co- 
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Figure 5.3 wtVP1 VLP was tested with S500 5/200 column. The S500 5/200 column was 
evaluated for its ability to isolate wtVP1 VLPs by semi-preparative SEC (A) for validation by DLS, 
SDS-PAGE (B), and TEM (C). Absorbance is at 280 nm and TEM scale bar is 100 nm. Lanes b of 
SDS-PAGE corresponds to VLP peak on the chromatogram as indicated. M is molecular weight 
standard. Lo is loading sample, Arrow points to wtVP1 subunit. 
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Figure 5.4 IMAC of VP1:VP2C-M1-I. Pellets were sonicated and VP1:VP2C-M1-I was purified 
with IMAC. Absorbance is at 280 nm (A). The elution peak was zoomed to indicate collected 
fractions (B). SDS-PAGE with lanes corresponding to peak regions as indicated, showed that the co-
purification of VP1 suggests the presence of VP2C-M1 even though it is not clear on the SDS-PAGE 
gel (C). M is the molecular weight standard. Arrows point to bands as indicated. 
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eluted with VP2C-M1-I even though the band of the latter was not clearly visible on the gel (Figure 
5.4C). Peak elution fractions of IMAC purification were further purified with SEC and resulted in 
three major peaks: a) aggregate peak (8.7 ml); b) capsomere complex peak (11.7 ml); and c) free 
VP2C-M1-I peak (16 ml) (Figure 5.5A). SDS-PAGE analysis of peak fractions showed that peak a 
contained VP1, VP2C-M1-I, and contaminating proteins; peak b contained VP1, VP2C-M1-I, and a 
70 kDa band, and peak c contained what may be dimers of free VP2C-M1-I (Figure 5.5B). The 
VP2C-M1-I band is a faint band due to its small size. Co-elution of VP1 and VP2C-M1-I in peak b 
indicated successful formation of VP1:VP2C-M1-I capsomere complex.  
Western blot of these fractions with anti-VP1 (Figure 5.5C) also confirmed the presence of VP1 
especially in peaks a and b. Other non-specific bands were also stained. Anti-6His blotting (Figure 
5.5D) showed staining in the VP1 region which may indicate that the complex was not fully denatured 
or that there were some cross-reactivity with VP1. The aggregate peak also contained anti-6His ~30 
kDa and ~15 kDa putative VP2C-M1-I bands, the former may be a dimer of the latter. Of the two, 
only the ~15 kDa band was found in peak b, while only the ~30 kDa band was found in peak c.  
5.4.5 VP2C-M1-II oligomerisation complicates complex purification 
The VP1:VP2C-M1-II construct was also expressed in small scale and purified in optimised 
condition. IMAC elution peak (Figure 5.6A) and S200 of this peak resulted in multiple peaks (Figure 
5.6B). Multiple peaks may be caused by oligomerisation due to a self-interacting region in the M1-II 
domain (Zhang et al. 2012), and thus complicated the purification. Due to this, and because M1-I 
contains both IT1 and IT2, this construct was not pursued further. 
5.4.6 Development, analysis, and characterisation of M1-I-based VLPs 
as vaccines 
The VP1:VP2C-M1-I capsomere complex harvested in Section 5.4.3 was assembled in standard wt 
buffer conditions into VLPs, concentrated, and then injected into S500 SEC column. The 
chromatogram profile showed two peaks: a) aggregate peak at 2 ml; and b) VLP peak at 2.8 ml. Peak 
fractions and other regions as indicated in Figure 5.7A were collected and analysed with SDS-PAGE 
and characterised by DLS and TEM. SDS-PAGE analysis showed the presence of VP1 in peaks a and 
b (Figure 5.7B). DLS characterisation was done with both cumulant and regularisation analysis. 
Cumulant analysis showed a large cumulant radius in peak a, and the size of the cumulant radius of 
this peak decreased with higher elution volume. Although the cumulant radius in the VLP region 
(peak b) decreased significantly in comparison to the aggregate region, it did not decrease into the 
reported radius for VLPs (73 nm instead of 27nm - 35 nm) indicating incomplete separation from the 
106 
 
 
 
Figure 5.5 S200 of VP1:VP2C-M1-I. IMAC purified fractions were further purified with S200 to 
separate modified capsomeres from aggregates and free VP2C-M1-I (A). The fractions were run on 
SDS-PAGE with lanes corresponding to peak regions as indicated, which showed the content of each 
peak (B). Western blot using anti-VP1 (C) and anti-6His (D) showed that VP2C-M1-I may appear as 
dimers in both aggregate and free forms, but only in monomer  when binding to VP1. Absorbance is 
at 280 nm. Arrows point to bands as indicated. 
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Figure 5.6 S200 of VP1:VP2C-M1-II. Pellets were sonicated and VP1:VP2C-M1-II was purified 
with IMAC (A). IMAC fractions were further purified with S200 (B) and the chromatogram showed 
multiple peaks. 
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Figure 5.7 S500 of VP1:VP2C-M1-I. Assembled VP1:VP2C-M1-I was purified by semi-
preparative SEC and showed aggregate and VLP peaks (A).  SDS-PAGE with lanes corresponding 
to peak regions as indicated, showed the presence of VP1 (B), and TEM showed formation of VLPs 
(C). Absorbance is at 280 nm and TEM scale bar is 200 nm. M is molecular weight standard. Arrow 
points to bands as indicated. 
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aggregates. Regularisation analysis confirmed this by showing different particle species in peak b, 
including aggregates and VLPs, with the aggregate ratio decreasing with increasing elution volume 
and the VLP ratio increasing on the contrary (data not shown). According to regularisation analysis, 
the VLP particle radius was 27.7 nm and the formation of VLPs in fractions derived from peak b was 
confirmed by TEM (Figure 5.7C). 
5.4.7 Development, analysis, and characterisation of DDIT1-based 
VLPs as vaccines 
To enhance VLP formation and reduce hydrophobic effects, DDIT1 capsomeres derived from 
Chapter 3 were co-assembled with unmodified VP1 capsomeres at a 1:4 molar ratio. Assembly was 
performed in an optimised assembly buffer containing 50 mM L-Arg to maintain the solubility of 
DDIT1 during the formation of mosaic VLPs. This assembled mixture was concentrated (>2 mg/ml) 
and injected into S500 column for analysis. Similar to VP1:VP2C-M1-I VLPs, the chromatogram 
showed two peaks: a) an aggregate peak at 2 ml; and b) a VLP peak at 2.7 ml (Figure 5.8A). Peak 
fractions were collected for further analysis with SDS-PAGE and characterisation with DLS and 
TEM. SYPRO Orange-stained SDS-PAGE gels showed the presence of two adjacent bands in the 
VP1 region, the upper band thinner than the lower band. The upper band corresponds to the DDIT1-
inserted modular capsomere because it was slightly larger in size than the wtVP1 capsomeres. The 
thinner band also reflects its lower molar concentration in comparison to wtVP1. The lower band 
corresponds to wtVP1 capsomeres (Figure 5.8B). According to densitometry analysis, the ratio 
between modular and wt capsomeres on peak b is 1:2.32. The presence of these two bands in the VLP 
region and the stabilising effect of co-assembled wt capsomeres strongly indicated that mosaic VLPs 
had been successfully assembled. Cumulant analysis of the fractions by DLS showed a similar pattern 
to VP1:VP2C-M1-I, and according to regularisation analysis the VLP particle radius is 26 nm. 
Formation of intact VLP was again confirmed by TEM (Figure 5.8C). 
 
5.5 Discussion 
In this project, a semi-preparative SEC for VLP purification, analysis, and characterisation was 
developed and optimised. The MPyV VLP encapsidation platform optimised in Chapter 4 was used 
to encapsidate influenza M1 protein for vaccine development, and a DDIT1-based VLP from 
Chapter 3 was improved. Using the developed semi-preparative SEC method these vaccines were 
then analysed and characterised.  
The semi-preparative SEC utilised a 5/200 Tricorn column with a 4 ml total volume using Sephacryl 
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Figure 5.8 S500 of mosaic VP1 S1S4 DD IT1. Assembled mosaic VLPs of VP1 S1S4 DDIT1 and 
wt was purified by semi-preparative exclusion chromatography (A) and showed aggregate (a) and 
VLP peaks (b). Analysis of fractions with SDS-PAGE and SYPRO Orange staining showed that VLP 
and aggregates contained both VP1 S1S4 DD IT1 and wtVP1 capsomeres (B). Successful mosaic 
particle formation was confirmed by TEM (C). Absorbance is at 280 nm and TEM scale bar is 200 
nm. Arrows point to bands as indicated. 
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S500 HR as a medium. This column was selected to shorten analysis time with the least amount of 
sample possible. Commercially available Sephacryl-based column (Hi-Prep 16/60 Sephacryl S500 
HR) requires 4 hours for one sample run, and a higher amount of protein in a larger volume was 
required. This was not practical for an expression scale that aimed to analyse and characterise formed 
VLPs prior to large-scale production. A prepacked Tricorn 5/200 S500 column with Sephacryl S500 
was not commercially available, and so the column was packed in-house and its column efficiency 
tested before use.  The external volume, defined as the tubing volume from the point of sample 
application to column inlet and from the column outlet to the UV detector should theoretically be 3% 
of the total column volume for optimum column efficiency (GE-Healthcare 2010a; Hagel 2011). 
However, as the volume of the optimised Tricorn 5/200 S500 column in this project is only 4 ml, a 
3% external column volume (120 µl) could not be achieved, even by using the AKTA Pure 25 system 
with the shortest tubing possible. This was reflected in measured h plotted against increasing flow 
rates (Figure 5.1) that were all above 3, while an efficient column would have h < 3. Thus, efficiency 
analysis for this column was more focused on the As and the performance with known samples, such 
as VLPs. Considering both h and As as depicted in Figure 5.2 and all other non-adjustable factors, 
column efficiency was best at flow rates of 0.075 ml/min – 0.1 ml/min. With a 0.1 ml/min flow rate, 
a sample could be run within 40 min, which was selected as optimal. Increasing the flow rate would 
compromise column efficiency, while decreasing the flow rate would lengthen purification time.  
Validation of the column with wtVP1 VLPs showed that the VLP peak was within acceptable 
symmetry (Figure 5.3). DLS cumulant and regularisation analysis of eluted fractions also 
demonstrated that particles in the VLP region were 100% VLPs (monodispersed) and eluted with 
slightly decreasing size along the peak volume as expected. DLS measurement before and after the 
VLP peak was not consistent, and this may be due to the nature of light scattering measurement, 
which is compromised when sample concentration is too low. Column optimisation and validation 
results give a good level of confidence that it would be a useful tool for a semi-preparative SEC to 
analyse and characterise VLPs. The method is not time consuming and the injected sample volume 
required is relatively small (80 µl), which allows concentration of protein solutions harvested from a 
standard laboratory expression scale. A report on concurrently developed interlaced size exclusion 
ultra-high performance liquid chromatography (iSE-UHPLC) (Ladd Effio et al. 2016) and a 
Captocore-based column to purify VLPs (Lagoutte et al. 2016) have recently been reported. However, 
while the iSEC-UHPLC has a faster run time, it was only analytical and not preparative. Moreover, 
the ability of the Captocore-based column to separate VLPs from aggregates was not clearly 
demonstrated. 
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One of the modification strategies to develop MPyVLP based vaccine is to encapsidate antigenic 
protein inside the VLP. Encapsidation technology had been optimised in Chapter 4 and this was then 
applied to encapsidate the influenza M1 protein. The M1 protein is a transmembrane protein and thus 
contains a hydrophobic region (Zhang et al. 2012). To avoid aggregation, only the soluble domain of 
this protein was fused to VP2C, which came in two variations, VP2C-M1-I and VP2C-M1-II. The 
M1-I domain contains several epitopes (Figure 1.2) comprising several HLA supertypes such as A2, 
A3, B44, and B12 (Adar et al. 2009; Alexander et al. 2010; Assarsson et al. 2008; Babon et al. 2009; 
Liu et al. 2013; Reemers et al. 2012), which would be good for broader cross-protection (Brown and 
Kelso 2009) and wider population coverage (Sette and Sidney 1998). VP1:VP2C-M1-II was not 
pursued further due to complication in purification related to the presence of the previously reported 
self-interacting domain (Figure 5.6)(Zhang et al. 2012). VP1 band was more clearly visible than the 
VP2C-M1-I on SDS-PAGE when clarified supernatant was purified with IMAC (Figure 5.4), but the 
presence of VP1 indicated co-purification of VP2C-M1-I as only VP1 bound to VP2C-M1-I could be 
eluted from an IMAC column. Faint bands of VP2C-M1-I were visible on SDS-PAGE and anti-6His 
stained western blot of S200 (Figure 5.5). This confirmed that the VP1:VP2C-M1-I capsomere 
complex was formed. Analysis of SEC fractions of VP1:VP2C-M1-I implied that VP2C-M1-I existed 
as a dimer in free form, and this may be due to the presence of the hydrophobic IT1 epitope at the C-
terminal region of M1-I which may have facilitated dimerisation by hydrophobic interaction. The 
presence of the 70 kDa band in peak b, the putative capsomere peak, but not in the aggregate peak of 
the SEC chromatogram may indicate that the 70 kDa protein was necessary for formation of a soluble 
VP1:VP2C-M1-I capsomere complex and that without it aggregation may occur. Western blot of SEC 
fractions may indicate that when bound to VP1, VP2C-M1-I is monomeric, but otherwise dimeric 
when unbound. This dimerisation may also have resulted in aggregation as both forms were detected 
in the aggregate peak. 
Characterisation of the eluted peak fractions of assembled VP1:VP2C-M1-I was done with DLS 
cumulant and regularisation analysis. Cumulant radius is the average radius of total particles in the 
solution, so the measurement is influenced by the size of different species in the solution, including 
aggregates. The number and size of aggregated particles in the putative VLP peak may be a lot less 
than to those in the first peak, but the size of the particles may be enough to mask the presence of 
correctly sized VLPs in this peak and resulted in increased overall cumulant radius. The regularisation 
analysis was able to detect and measure the size of VLPs, the presence of which, was confirmed by 
TEM. These results indicated initial success in the development, analysis, and characterisation of an 
MPyV VLP-based carrier carrying M1-I subdomain. 
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The results presented in Chapter 4 suggested that mosaic particles could be assembled from mixed 
capsomere assembly reactions. Mosaic particle formation by co-assembly of DDIT1 capsomeres with 
wtVP1 capsomeres in optimised buffer condition was confirmed by TEM through observation of 
clearly visible VLPs and in a higher density (Figure 5.8C) than assembly solution of DDIT1 
capsomeres alone (Figure 3.6D) as has been demonstrated in Chapter 3. SDS-PAGE gel showed the 
simultaneous presence of DDIT1 and wtVP1 which also strongly indicated the formation of mosaic 
particles. However, we cannot be certain that the VLPs consist of mixed capsomeres, only that the 
ensemble of VLPs does. DLS measurement showed a similar pattern to that of VP1:VP2C-M1-I VLPs 
and the radius was also not far from normal wtVP1, which is expected with the addition of a single 
epitope. These results also indicated initial success in the development, analysis, and characterisation 
of an MPyV VLP-based carrier carrying IT1 epitope at a surface-exposed loop of VP1. 
Aggregation in the vaccine formulation may be caused by several factors, including self-interaction 
between recombinant proteins due to hydrophobic interaction, and VP2C-M1-I dissociation which 
initiates aggregate nucleation. Aggregation may also occur during concentration of the VLP sample. 
Tailing of the aggregate peak in the VLP region as indicated by cumulant analysis suggests further 
optimisation of the semi-preparative SEC method. The currently developed method is enough for 
analysis and characterisation, but would be less suitable for vaccine purification as aggregates need 
to be fully separated from the vaccine. Optimisation strategies may include an increase in column 
length, or lower flow rates. Increasing the column length and column volume would increase the 
tolerated external volume and sample volume and thus would lead to a more accurately estimated 
value of h. 
5.6 Conclusion 
Here I have demonstrated initial success in the development of an MPyV VLP-based influenza 
vaccine, carrying Tc-epitopes either externally or internally. A semi-preparative SEC method to 
analyse and characterise the VLPs was also developed and was within acceptable efficiency. Further 
vaccine development may be done by combining external and internal epitope presentation in one 
particle. Developed vaccines still need to be produced in sufficient quantities to test their 
immunogenicity and protection against influenza virus in humanised mice. The encapsidation 
platform may also be further developed into an enzyme, a drug, and an imaging component carrier. 
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6 Conclusion and Future Direction 
 
6.1 Summary of research findings 
Limitations in current influenza vaccines, including high updating frequency, slow production time, 
and high production cost, necessitates the development of next-generation influenza vaccine that is 
broadly cross-protective and efficient in terms of time and cost of production. A microbially produced 
modular MPyV-based vaccine is a promising approach to overcome these limitations. Influenza 
candidate vaccines based on this platform have been developed to raise humoral immunity against 
both variable (H190) and relatively conserved (M2e) influenza antigens. The development of 
influenza vaccine candidates based on this platform to raise cellular immunity has not been explored. 
Targeting cellular immunity may exploit antigens of the more conserved internal influenza proteins, 
and may thus confer broader cross-protection and reduce vaccine updating frequency. 
My research project aims to explore the potential of the MPyV VLP platform to carry identified 
influenza Tc-epitopes both externally via surface-exposed loops, and internally via encapsidation. 
The MPyV VLP can enter mammalian cells, can be processed by the MHC Class I pathway, and can 
activate dendritic cells. These characteristics are necessary requirements to stimulate cellular 
immunity. Antigenic Tc-epitopes to stimulate cellular immunity come in the form of nonameric 
peptide, and thus may be inserted into surface-exposed loop or encapsidated as soluble protein domain 
within the MPyV VLP platform. However, bioengineering challenges posed by the hydrophobic 
nature of Tc-epitopes need to be properly addressed.  
The experimental work discussed in this thesis was designed to explore four key aspects in the 
application of MPyV VLP as a carrier for influenza Tc-epitopes:  
1) External Tc-epitope presentation – This preliminary study evaluated the robustness of MPyV 
VLP to carry identified influenza Tc-epitopes via insertion into surface-exposed loop of the 
VP1 subunit. Insert engineering and buffer optimisation through multiparametric screening to 
overcome hydrophobicity-related aggregation was highlighted in Chapter 3. 
2) Optimisation of encapsidation – Prior to influenza antigen encapsidation, the molecular design 
and bioprocess of the established MPyV VLP platform was optimised to encapsidate the 
model protein GFP. Optimisation in expression, purification, and assembly was monitored 
and evaluated as highlighted in Chapter 4.  
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3) Tc-epitope-based MPyV VLP candidate vaccines – Candidate vaccines carrying influenza Tc-
epitope in the form of chimeric MPyV VLP were optimised. Capsomeres externally carrying 
Tc-epitope were co-assembled with unmodified capsomeres to optimise VLP formation. 
Encapsidation approach was applied to soluble domain of influenza M1 to carry the antigen 
internally. Development of these candidate vaccines, and their analysis and characterisation 
were highlighted in Chapter 5. 
4) A method to characterise and analyse VLPs – For Mosaic VLPs to be analysed and 
characterised a semi-preparative SEC method was developed for this purpose as highlighted 
in Chapter 5. 
The following sections summarise key findings of this project obtained from experimental work. 
6.1.1 External Tc-epitope presentation 
Three identified Tc-epitopes, IT1, IT2, and IT3 were inserted into VP1 surface-exposed loop in four 
variations which are IT1, DDIT1, IT123, and DDIT123. Standard expression and purification 
indicated that capsomeres aggregated during tag-removal and were not recoverable when purified 
afterwards, most likely due to the hydrophobic nature of the Tc-epitopes. Two strategies were applied 
to overcome hydrophobicity-related aggregation. Firstly, charged amino acids (DD) flanking the 
epitopes were engineered to reduce surface hydrophobicity. Secondly, a high-throughput 
multiparametric buffer screen was implemented employing spectrophotometric (Esfandiary and 
Middaugh 2012) and light scattering (Mohr et al. 2013) parameters to measure aggregation. Forty 
buffer conditions were evaluated in a 96-wells plate miniaturised tag removal reaction. The buffer 
conditions tested included varying pH (7-9 in 0.5 increments) together with a selection of additives 
(Arakawa et al. 2007; Lanckriet and Middelberg 2004; Leibly et al. 2012).  
Results showed that in the case of a single epitope (IT1), a combination of flanking charged amino 
acid (DD), the presence of L-Arg or detergents as additives, as well as a high pH, were able to improve 
capsomere recovery and reduce aggregation. This, however, was not true for multiple epitope inserts. 
These results underline the fact that successful buffer optimisation and insert engineering depends on 
the nature of individual inserts, and optimisation should be tailored according to insert characteristics. 
It also suggests that the number of Tc-epitopes that could be inserted into surface-exposed loop is 
limited.  
L-Arg was further used as additive to recover DDIT1 capsomeres for assembly, due to the 
biocompatibility and inexpensiveness of the additive. This additive is widely used in the literature to 
overcome protein aggregation (Arakawa et al. 2007; Tsumoto et al. 2004). Assembly of modified 
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capsomeres was also only possible in the presence of L-Arg and was not observed in standard 
assembly buffer in the absence of L-Arg. However, VLP yield was very low and a different strategy 
had to be employed to reduce hydrophobicity that might have interfered with assembly. One such 
strategy was the co-assembly of modified capsomeres displaying hydrophobic epitopes with 
unmodified capsomeres to reduce surface hydrophobicity. This strategy was pursued in Chapter 5.  
6.1.2 Optimisation of encapsidation 
Another approach to circumvent VLP surface hydrophobicity is by encapsidating influenza antigen 
inside the MPyV VLP. Tc-epitope proteasomal processing is intracellular, and unlike recognition of 
antibody-based antigens, Tc-epitopes may be carried inside the cavity of the VLP. This approach 
allows the carriage of multiple Tc-epitopes within a protein or soluble domain. The delivery of 
multiple epitopes may enhance protection against heterologous strains and extend vaccine population 
coverage due to a more variable HLA specificity. Prior to encapsidation of influenza antigen, 
encapsidation with the MPyV VLP platform needed to be optimised in every step of the bioprocess 
including genetic manipulation, expression, purification, and assembly. To achieve this, 
encapsidation of GFP as a model foreign protein to facilitate monitoring and evaluation was explored 
in Chapter 4. 
Encapsidation of foreign protein is possible by fusing the protein of interest with the MPyV VP2 
minor coat protein. VP2 binds to the inner cavity of one VP1 capsomere via a hydrophobic binding 
region close to the VP2 C-terminal end. Foreign protein fusion either at the N-terminal or C-terminal 
ends of polyomaviral VP2 have been reported in the literature (Abbing et al. 2004; Boura et al. 2005; 
Inoue et al. 2008). In my research, GFP was fused to the C-terminus of VP2. For efficient 
encapsidation, a VP2C segment was specially designed. The VP2C segment was designed in three 
variations which consisted either of 23, 31, or 50 amino acids (aa). These constructs retain the 
hydrophobic binding site of VP2, but most of the N-terminal amino acids upstream of the 
hydrophobic binding site were truncated, and a small part of the C-terminal amino acids were also 
eliminated. GFP was fused to the C-terminus of VP2C and was tagged with 6His to enable 
purification. Unlike previous reports where GFP was fused to the N-terminus of MPyV VP2 (Abbing 
et al. 2004; Boura et al. 2005), in my research GFP was fused to C-terminus of VP2C based on the 
findings of Inoue et al. (2008) with SV40 and Pleckaityte et al. (2015) with HPyV, that suggested a 
complete encapsidation with C-terminal fusion. 
When free VP2C-GFP was mixed in vitro with VP1 capsomeres, no binding between them occurred. 
Unsuccessful binding was due to truncation at the hydrophobic binding site of VP2C-GFP, probably 
by proteolytic activity. Truncation was not observed when Abbing et al. (2004) mixed GFP-VP2 with 
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VP1 capsomeres, where binding and subsequent encapsidation occurred successfully. Intact 
hydrophobic binding site in their experiment might be due to GFP fusion to the N-terminal end of 
VP2 whereby the preservation of the N-terminal sequence, as well as GFP fusion to the N-terminus, 
may have sterically protected the hydrophobic binding site from proteolytic activity in Abbing et al. 
(2004). The elimination of most of the N-terminal sequence and GFP fusion to the C-terminus of 
VP2C in my constructs may have exposed the hydrophobic binding site, rendering it accessible to 
proteases. 
Taking into account the high binding affinity between VP1 capsomeres and VP2, and that their 
binding occurs naturally in the natural host cell, I decided to emulate this reaction in vivo by co-
expressing VP1 and VP2C-GFP inside the host cell. It was expected that the binding would occur 
rapidly in vivo, protecting the hydrophobic binding site of VP2 inside the cavity of the capsomere 
from protease activity. A 6His-tag was engineered downstream of the GFP to enable IMAC 
purification, and SDS-PAGE of IMAC fractions indicated co-purification of VP2C-GFP and VP1. 
Co-purification of VP1 with 6His-tagged VP2C-GFP indicated successful VP1:VP2C-GFP 
capsomere complex formation in vivo, as only VP1 bound to VP2C-GFP could be selectively purified 
with IMAC. Further purification with SEC enabled the isolation of VP1:VP2C-GFP capsomere 
complex from free VP2C-GFP and aggregates. Of the three constructs tested, VP1:VP2C-GFP 23 aa 
had a low expression and solubility level while VP1:VP2C-GFP 50 aa was truncated and had a low 
VP1:VP2C-GFP capsomere complex yield after purification. Therefore, only VP1:VP2C-GFP 31 aa 
was pursued further as it had significant expression and solubility level and relatively high 
VP1:VP2C-GFP capsomere complex yield after purification.  
Purified VP1:VP2C-GFP capsomere complex were then assembled in standard assembly buffer and 
subsequent AF4, as well as TEM and SEC analysis, confirmed that VLP with GFP encapsidated 
inside were formed. The approach in my research differed from what was previously reported in the 
literature in several ways. Firstly, VP1 and VP2C-GFP were co-expressed in E.coli and purified as a 
VP1:VP2C-GFP capsomere complex. Both Boura et al. (2005) and Inoue et al. (2008) co-expressed 
VP1 and VP2-GFP in insect cells and thus assembly occurred in vivo and the product was purified 
VLPs instead of a VP1:VP2-GFP capsomere complex. Secondly, in my research, purified 
VP1:VP2C-GFP capsomere complex were assembled in vitro in standard assembly buffer condition 
established in AIBN-CBE, and MPyV VLP with GFP encapsidated were successfully formed. 
Abbing et al. (2004) also performed assembly in vitro, but their assembly employed free capsomeres 
and excessive free VP2-GFP, where removal of remaining free VP2-GFP was done after VLP was 
formed. 
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The advantage of the approach in my research is that the amount of encapsidated GFP inside the VLP 
could be controlled by in vitro co-assembly of VP1:VP2C capsomere complex with unmodified VP1 
capsomeres. Controlled assembly could not have been achieved by simply assembling free 
capsomeres and free VP2-GFP alone. Controlled assembly was demonstrated when an assembly of 
100% VP1:VP2C capsomere complex, a co-assembly of 1:1 molar ratio of VP1:VP2C-GFP 
capsomere complex and unmodified VP1 capsomeres, and an assembly of 100% unmodified VP1 
capsomeres were compared. Spectrophotometric analysis revealed that 100% VP1:VP2C-GFP 
capsomere complex assembly resulted in encapsidation of 40 functional GFP molecules while 50% 
co-assembly resulted in encapsidation of on average approximately half the amount of GFP molecules 
per VLP.  
Thus, these experiments elucidated the ability to engineer controlled encapsidation of foreign protein 
inside the cavity of MPyV VLPs within the established platform developed at AIBN-CBE. This 
bioengineering milestone was achieved by additional adjustment, optimisation, and modification of 
the genetic manipulation, expression, purification, and assembly steps of the established platform. 
Having established the methodology for controlled foreign protein encapsidation, its application to 
encapsidate foreign antigenic proteins to stimulate cellular immunity was subsequently approached. 
Developing a MPyV VLP vaccine candidate with influenza protein soluble domains encapsidated 
inside was pursued in Chapter 5.  
6.1.3 Tc-epitope-based MPyV VLP candidate vaccines 
Building on the previous experiments, Tc-epitope-based MPyV VLP candidate vaccines were 
developed in Chapter 5. Two types of candidate vaccines were developed: 1) candidate vaccine that 
display identified influenza Tc-epitopes on surface-exposed loop; 2) candidate vaccine that 
encapsidate influenza antigen in the form of protein soluble domain with multiple overlapping Tc-
epitopes within.  
As had been summarised in Section 6.1.1, capsomeres displaying a Tc-epitope (DDIT1) on the 
surface were recoverable after insert engineering and buffer optimisation via multiparametric buffer 
screen. However, when the capsomeres were assembled in optimised assembly buffer, VLP yield was 
low. This low yield may be due to VLP surface hydrophobicity caused by surface-exposed 
hydrophobic Tc-epitopes, which may interfere with VLP formation. To improve yield, an approach 
to reduce surface hydrophobicity was applied by co-assembly of DDIT1 capsomeres with unmodified 
VP1 capsomeres in optimised assembly buffer. This optimised assembly buffer retained L-Arg as 
additive. SEC of the assembly reaction showed two major peaks, an aggregate peak and a VLP peak. 
DLS analysis indicated the formation of VLPs in the VLP peak, even though the VLPs were not 
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completely separated from aggregates. The presence of bands of the modified and unmodified 
capsomeres in the VLP peak on SDS-PAGE, as well as a more densely populated VLPs shown by 
TEM analysis in comparison to VLP formation in Chapter 3, strongly indicated the formation of 
mosaic particles able to circumvent surface hydrophobicity, aiding in the formation of VLPs.  
However, it should be noted that this result does not conclusively confirm that the VLPs consisted of 
mixed capsomeres, it only shows that the ensemble of VLPs did. 
The encapsidation methodology developed in Chapter 4 and summarised in Section 6.1.2 was 
applied to encapsidate influenza protein inside the MPyV VLP. The M1 protein was selected for this 
purpose for several reasons. Firstly, M1 protein is a relatively conserved internal protein and thus the 
Tc-epitopes it contains have a higher probability to be broadly cross-protective. Secondly, the M1 
protein is the most abundant protein in the influenza virus (Lamb and Krug 2001) and thus increases 
the likelihood of Tc-epitope presentation by infected cells, necessary for Tc recognition. Thirdly, the 
M1 protein, especially its N-terminal soluble domain, contains IT1. IT1 is used as surface-exposed 
Tc-epitope insert for the other candidate vaccine in my research project as described in previous 
paragraph, and thus immunogenicity and protection of externally displayed and internally 
encapsidated IT1 may be compared in the future. In addition, IT1 (amino acid sequence on Table 
3.1) is an immunodominant Tc-epitope widely used in the literature to test immunogenicity and 
protection of influenza vaccine candidates.  
Two variants of soluble M1 domain were tested. The first was M1-I which is the first N-terminal 
helical domain containing IT1 and IT2. The second was M1-II which the full soluble N-terminal 
domain including M1-I and a self-interacting region. SEC purification of M1-II revealed unidentified 
peaks suggestive of interactions between M1 domains so it was not pursued further. SEC purification 
of M1-I revealed distinct peaks of aggregates, VP1:VP2C-M1-I capsomere complex, and free VP2C-
M1-I. Western blot analysis of these peaks with anti-VP1 and anti-6His indicated the formation of 
VP1:VP2C-M1-I capsomere complex at the expected peak, and that in free form, VP2C-M1-I tended 
to form dimers. Interestingly, SDS-PAGE analysis of these fractions indicated that the 70 kDa 
putative chaperone might be necessary for complex formation, and its absence might have led to 
aggregation. The 70 kDa chaperone DnaK is known to associate with capsomeres in vivo and except 
in the presence of ATP can block assembly, which can be seen as controlled encapsidation, in vitro 
(Chromy et al. 2003). These results together showed that successful capsomere complex formation, 
purification, as well as subsequent VLP formation depends on the nature of the foreign protein fused 
to VP2C. And thus, bioengineering of each fusion protein needs to be adjusted accordingly. 
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Purified VP1:VP2C-M1-I capsomere complex were further assembled in standard buffer condition. 
SEC fraction of assembly reaction was then analysed and characterised with SDS-PAGE, DLS, and 
TEM. Similar to VP1:VP2C-GFP VLPs, SEC profile revealed aggregate and VLP peaks and their 
analysis with TEM confirmed VLP formation with small amount of aggregates in the VLP peak 
fractions. DLS regularisation analysis measured a smaller VLP radius (26 nm) in comparison to that 
of VP1:VP2C-GFP (30 nm). The size difference was not unexpected as GFP is larger in size that M1-
I, and size of encapsidated particles can affect VLP size (Lipin et al. 2008a). Interestingly, the 
presence of the putative chaperone did not block assembly of this construct despite the absence of 
ATP in the assembly buffer. Furthermore, SEC showed that it was not associated with the assembled 
VLPs.   
In this section, candidate vaccines carrying influenza Tc-epitopes either externally on surface-
exposed loop or internally via encapsidation of M1 subdomain was developed. Both approaches to 
carry Tc-epitopes either externally or internally have their advantages and disadvantages. The 
advantage of external Tc-epitope presentation include simple genetic manipulation which only 
involves the VP1 protein. If hydrophobicity-related aggregation could be circumvented by insert 
engineering and buffer optimisation, a recently developed salting-out precipitation method to recover 
stable capsomeres (Wibowo et al. 2015) may be applied. The use of salting-out precipitation method 
could omit previous purification methods involving sophisticated equipment that may be less 
applicable in developing countries. However, surface-exposed loop display does not facilitate the 
presentation of multiple Tc-epitopes which limits broader cross-protection and wider population 
coverage. This problem may be circumvented by co-expressing VP1 displaying different Tc-epitopes 
resulting in mosaic capsomeres (Tekewe et al. 2016), or the development of mosaic VLPs composed 
of capsomeres displaying different Tc-epitopes.  
The advantages of internal encapsidation of Tc-epitopes include the ability to carry multiple Tc-
epitopes and the prevention of hydrophobicity-related aggregation due to antigen encapsidation inside 
the VLP. The ability to carry multiple Tc-epitopes may allow a broader crossprotection and a wider 
population coverage of the vaccine candidate. However, the encapsidation strategy involves VP1 
binding with fused VP2 and thus requires a more complex downstream processing, which at the 
current stage may still need to rely on sophisticated protein purification equipment.  
Whether the surface display of antigens is more favourable for proteasomal access in comparison to 
encapsidation of antigens still needs to be evaluated further. External antigen display, as well as 
engineered linker sequence to facilitate proteosomal degradation, may enhance Tc-epitope 
processing. However, Tc-epitope located inside a subunit protein may have the advantage of 
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emulating natural Tc-epitope processing and protection of the antigen from premature or non-specific 
degradation. 
These experiments aim to develop Tc-epitope-based influenza vaccine using two approaches, either 
by external or internal presentation of influenza antigens. Optimisation of those approaches included 
the formation of mosaic particles and the encapsidation of M1-I soluble domain. Both methods 
resulted in VLP formation in considerable yield, as shown by analysis and characterisation of SEC 
fractions of the assembly reactions. A new SEC method with Sephacryl S500 HR media to analyse 
and characterise the VLPs was developed and validated in Chapter 5, as summarised in Section 
6.1.4. 
6.1.4 SEC-S500 to analyse and characterise VLPs 
A method to analyse and characterise purified VLPs developed in my research, after separation from 
aggregates, was needed for several reasons. Firstly, to confirm successful encapsidation of GFP 
protein inside the MPyV VLP and to quantitate GFP content during controlled assembly via 
spectrophotometric measurement. Secondly, to confirm the formation of mosaic particles, which 
required recovery of purified VLP fractions to run on SDS-PAGE gels. Finally, to visualise the VLPs 
via TEM and characterise them based on hydrodynamic radius, where preparative samples of purified 
VLPs were also needed.  
The VLP purification in my research is aimed only for analysis and characterisation, instead of 
production and formulation. Commercially available column for SEC commonly used to purify 
VLPs, such as the Hi-Prep 16/60 Sephacryl S500 HR, was not suitable for relatively small laboratory 
scale VLP preparation. In addition, one sample required 4 hours to run with this column, and fractions 
were distributed in a large total peak volume. A large total volume of peak fractions reduced fraction 
protein concentration and rendered them insufficient for analysis and characterisation. Therefore, a 
new SEC method employing Sephacryl S500 HR media in a column with custom dimension (20 cm 
in height and 0.25 cm in radius) was developed. The total volume of this column was 4 ml and thus 
may allow shorter run time and smaller sample volume. Column efficiency testing was performed at 
flow rates ranging between 0.05 ml/min to 0.15 ml/min. Ideal h value should be equal to or less than 
3, however, this was not achievable due to unmodifiable external column volume. The As, however, 
was within acceptable range and indicated good column efficiency. Based on both h and As, optimum 
flow rate was between 0.075 ml/min and 0.l ml/min.  
The S500 column was validated with wt VLPs. The chromatogram profile showed a major VLP peak 
at 3 ml, and depending on the purity of the samples, a minor aggregate peak appeared at 2 ml. The 
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VLP peak was within acceptable symmetry, close to Gaussian distribution, which not only suggests 
the suitability of the method to purify VLPs, but also confirms the efficiency of the column. Light 
scattering analysis showed that hydrodynamic radius of the VLP peak was consistent within the 26 
nm to 32 nm range, with decreasing radius along increasing elution volume as expected. The validated 
method was then applied to analyse and characterise VLPs of VP1:VP2C-GFP, VP1:VP2C-M1-I, 
and DDIT1 mosaic particles as summarised in Section 6.1.2 and Section 6.1.3. 
The semi-preparative SEC-S500 method to analyse and characterise VLPs by collection of purified 
fractions differed from the iSE-UHPLC developed at around the same time by Ladd Effio et al. 
(2016). While the iSE-UHPLC enabled chromatographic analysis within minutes, the method was 
analytical and does not provide collectable VLP fractions. Another method by Lagoutte et al. (2016) 
employed the recently developed Captocore-based column to purify VLPs, however, it was not clear 
if it was able to separate aggregates or not. Thus, the semi-preparative SEC-S500 method has several 
advantages over those two methods. However, it needs to be optimised further to improve resolution 
for the purpose of VLP formulation and administration. 
 
6.2 Future Direction 
Awareness of the importance of broadly cross-protective vaccine to limit disease spread during 
influenza epidemic and pandemic, has led to the development of candidate vaccines to stimulate 
cellular immunity. These candidate vaccines aim to deliver Tc-epitopes from conserved influenza 
proteins, and different carriers have been explored for this purpose. These carriers include 
lipopeptides, liposomes, virosomes, subunit protein carriers, VLPs, and attenuated viral vectors. 
However, these carriers face significant setbacks such as the use of mammalian or insect cells as 
expression host which may add to cost and time of production, the lack of industrial scale production 
platform, or the administration of potentially infectious material.  
My research aims to explore the ability of MPyV VLP to carry influenza Tc-epitopes and address 
bioengineering challenges associated with epitope hydrophobicity. The MPyV VLP has an 
established and scalable microbial platform that could reduce cost and time of production. The MPyV 
VLP is also able to enter dendritic cells of different cell types and enter the MHC Class I pathway 
necessary for Tc activation. The MPyV VLP employs the viral coat proteins of MPyV and is thus 
non-infectious. The MPyV VLP is also relatively easy to genetically manipulate, facilitating flexible 
bioengineering design. This platform has been developed to include external Tc-epitope presentation, 
and internal Tc-epitope encapsidation in my research project. The research outcomes collectively 
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show the potential of the MPyV VLP to carry influenza Tc-epitopes. The realisation of the MPyV 
VLP as Tc-epitope-based influenza vaccine, however, requires further study in four main aspects: 
1) Further development of the Tc-epitope-based candidate influenza vaccine. In my research 
project, bioengineering challenges associated with epitope hydrophobicity and encapsidation 
of foreign antigenic proteins have been addressed. However, further research needs to be 
carried out to evaluate the immunological potential of the candidate vaccines: 
a. Immunological testing – The candidate vaccines need to be tested for immunogenicity 
and protection in humanised transgenic mice. The humanised transgenic mice should 
express HLAs relevant for the Tc-epitope displayed in the candidate vaccine. The 
HLA specific for externally displayed Tc-epitopes in the vaccine developed in my 
project is the HLA A*0201.  
b. Immunological comparison between externally and internally delivered Tc-epitopes – 
The immunogenicity and protection between candidate vaccine displaying Tc-
epitopes in surface-exposed loop and candidate vaccine encapsidating multiple Tc-
epitopes in the form of M1 soluble domain need to be compared. This comparison will 
give insight into which approach is more effective in raising cellular immunity for 
further research. The outcome of this evaluation will not only be applicable for 
influenza, but also for other diseases such as cancer and HIV.  
c. Mannosylation – VLPs are considered relevant for cellular immunity stimulation due 
to their PAMP. Nevertheless, in case MPyV VLP alone only elicit weak cellular 
immunity, VLP mannosylation (Al-Barwani et al. 2014) could be explored to enhance 
dendritic cell activation. 
2) Vaccine bioengineering advancement. Candidate vaccine development using the MPyV VLP 
platform could further be advanced with the following approaches: 
a. Further investigation of surface-exposed loop insertion with DDIT2 and DDIT3 – As 
insertion of a single epitope with flanking charged amino acid in optimised buffer 
condition resulted in successful capsomere recovery for IT1, this could be also applied 
to other epitopes such as IT2 and IT3. The recovered recombinant capsomeres could 
then be co-assembled with wt capsomeres or capsomeres containing other epitopes to 
form VLPs displaying different epitopes on the surface. Another option is to co-
express VP1 proteins displaying different individual epitopes each with flanking 
charged amino acid to form mosaic capsomeres. 
b. Combination of externally and internally presented epitopes - Co-assembly between 
capsomeres displaying antigens on the surface and VP1:VP2C capsomere complex 
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with fused foreign protein may be explored. The VLP formed may target both the 
humoral and cellular immunity. The surface-exposed antigen could be designed to 
target antibody production and the encapsidated antigen could be designed to target 
Tc activation. 
c. External antigen presentation by N-terminal fusion to VP2 – Pleckaityte et al. (2015) 
have shown that foreign protein fusion to the N-terminus of VP2 resulted in external 
presentation of the fusion protein due to protrusion of the fusion protein through the 
upper opening of the capsomere into external space. This approach could be explored 
as it may permit external presentation of larger size proteins instead of just a string of 
peptides. 
d. Encapsidation of other influenza internal proteins – Other internal proteins of 
influenza such as NP, PB1, PB2, and PA are also conserved and contain various Tc-
epitopes of different HLA specificities. Encapsidation of these proteins or their soluble 
domains may enhance immunity and broader cross-protection, and is, therefore, worth 
to explore further. 
3) Encapsidation bioprocess optimisation. A bioengineering milestone had been achieved in my 
research by establishing the methodology for in vitro foreign protein encapsidation within 
MPyV VLP. However, more improvement is needed in the process development, which 
include: 
a. Optimisation of expression parameters – This includes IPTG concentration, induction 
time, temperature, and agitation speed, tailored specific to the construct at hand. 
b. Optimisation of purification of capsomere complex and VLPs to increase yield and 
reduce aggregation – For example, protein concentration prior to S500 may play a role 
in the aggregate formation and thus alternative ways may be explored to overcome 
this problem. Endotoxin removal and subsequent vaccine formulation and 
administration would require the removal of aggregates and other contaminants to 
achieve a high VLP purity.  
c. Simulation and subsequent establishment of large-scale production – The laboratory 
scale bioprocess of foreign protein encapsidation differs in several aspects from the 
already established approach for external display of foreign antigens. Thus, the foreign 
protein encapsidation approach needs to be adjusted for large-scale upstream and 
downstream processing. 
4) Mixture assembly optimisation. Despite the controlled average GFP content following mixed 
assembly and the strong indication that mosaic particles were made with DDIT1 capsomeres 
mixed with wt capsomeres, it is still not conclusive whether mosaic particles containing 
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different capsomeres were really formed. The data just goes so far as to say that the ensemble 
of VLPs consisted of mixed capsomeres, but not the VLPs themselves. To confirm that mosaic 
particles can be formed via a mixture assembly, the following evaluation method may be 
performed: 
a.  Fluorescence resonance energy transfer (FRET) - FRET method utilises the ability of 
a pair of fluorophores with overlapping spectra to transfer the resonance energy from 
the donor to the acceptor fluorophore when they are within close proximity. FRET 
occurs when the emission wavelength of the donor fluorophore sufficiently overlaps 
with the excitation spectra of the acceptor fluorophore such that the acceptor is excited 
by light emitted from the donor and it can be detected by either increased emission by 
the receptor or reduced emission by the donor, depending on the extent of spectral 
separation between the fluorophores. The energy transfer occurs over a certain 
distance known as the Förster radius, usually from 1 to 10 nm, thus it is frequently 
used to detect protein-protein interactions (Aoki et al. 2013). If a mixture of 
VP1:VP2C-GFP and VP1:VP2C-mRuby capsomere complexes (Bajar et al. 2016) are 
co-assembled, and recovered VLPs exhibit FRET, then the close proximity of the 
different encapsidated fluorescent proteins, which would reflect successful mosaic 
VLP formation via mixture assembly, can be confirmed.  
5) Delivery vehicle beyond influenza vaccine candidate. The approaches used in my research, as 
well as methods to validate them could be utilised beyond influenza vaccine development, 
such as: 
a. Application for cancer and HIV candidate vaccines - Tc-epitope carriage by the MPyV 
VLP platform both externally and internally developed in my research may be applied 
to deliver antigens for other pathogens or non-pathogenic diseases such as HIV and 
cancer.  
b. Delivery of other types of proteins – The encapsidation methodology may be 
implemented to deliver other proteins such as enzymes, drugs, imaging tool, 
intracellular analysis agents, or theranostic entities. Encapsidation may be required to 
maintain intact protein before entry into the target cell. The MPyV VLP pathway 
inside target cells needs to be further elucidated to provide beneficial information for 
more robust engineering of the MPyV VLP platform. 
 
6.3 Concluding Remarks 
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The advancement of immuno-informatics does not only allow the prediction of Tc-epitopes of 
different proteins but also provides a database of identified Tc-epitopes along with information about 
their conservancy and tested immunogenicity. Recent progress in rapid genomic and proteomic 
sequencing of emergent pathogenic strains aids in reverse-genetics to apply recombinant technology 
in candidate vaccine bioengineering. Both immuno-informatics and reverse-genetics support the 
development of next-generation vaccines based on modular synthetic VLPs to stimulate the cellular 
immunity. Extensive research on MPyV VLPs results in a wealth of information that allows the 
establishment of a flexible vaccine platform. Microbial production with this platform allows faster 
and cheaper production and promotes vaccine affordability and timely availability in developed and 
developing countries.  
In my research, flexible protein design and bioprocess modification of the established MPyV VLP 
platform was implemented for internal and external carriage of hydrophobic influenza antigens. This 
resulted in two candidate vaccines, one which presents influenza Tc-epitope on the surface of the 
MPyV VLP, and the other which encapsidates multiple overlapping Tc-epitopes in the form of protein 
soluble domain inside the VLP. However, the candidate vaccines still require immunological 
evaluation. Nevertheless, the high-throughput multiparametric buffer screen developed here could be 
applied to optimise buffer for other hydrophobic modularised antigens. Furthermore, the 
encapsidation methodology provides an adjustable molecular design and an adjustable bioprocess to 
encapsidate antigens of other pathogens, and also of other protein tools beyond vaccination purposes. 
Further development in the rational design of modular synthetic VLPs and their immunological 
evaluation may draw us closer to the realisation of timely, safe, affordable, and effective influenza 
vaccines. 
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